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Abstract
Hydrogen sulphide (H2S) is a naturally occurring gas and originally the primary focus o f 
research was to investigate its toxicity. In 1989 a physiological role of H2S was 
proposed after endogenous levels were detected in the rat brain and normal human 
post-mortem tissue. This discovery has led to an explosion of interest in H2S as a 
biological mediator. Identification of H2S synthesising enzymes in the cardiovascular 
system has led to a number of studies examining specific regulatory actions of H2S. 
The hypothesis underlying the studies in this thesis was that H2S synthesising enzymes 
exist in the myocardium and the resulting H2S provides cardioprotection against 
ischaemia-reperfusion injury. This was investigated using a broad range of 
experimental techniques including Langendorff isolated perfused rat heart models, 
biochemical H2S stimulation and detection assays, PCR, and Western blotting. The 
principal findings can be summarised as follows:
1. Rat myocardium has the potential to express both CSE and CBS H2S 
synthesising enzymes, due to the confirmed detection of mRNA.
2. Furthermore it was possible to exogenously stimulate the CSE enzyme, with its 
substrate L-cysteine, to produce H2S gas which limited infarct size during 
regional ischaemia-reperfusion.
3. Endogenous H2S levels were up-regulated during ischaemia-reperfusion, 
consistent with an endogenous protective role within the myocardium.
4. Simple and complex H2S/thiol containing compounds produced 
cardioprotection during regional ischaemia-reperfusion, with a mechanism 
that involves PI3k and Akt activation, implicating recruitment of downstream 
kinases within the RISK pathway.
The studies presented have provided a significant advancement in understanding the 
involvement of H2S in cardioprotection during ischaemia-reperfusion. It has also 
raised questions such as the exact mechanism of action of H2S donor/thiol containing 
compounds and highlighted the need for more robust H2S donors. The scope for H2S 
as an endogenous mediator also stems beyond that of cardioprotection, as the range 
of body systems and cell types are continually expanding.
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Chapter 1 Part I
1.1 Coronary heart disease
Cardiovascular disease accounts for 198,000 deaths per year in the UK and is the 
leading cause of premature death. Coronary heart disease and stroke are the main 
forms of cardiovascular disease, accounting for 48% and 28% of cardiovascular deaths 
respectively (Allender et a l, 2008). An additional 31,000 deaths occur from other 
forms of heart disease. In 2006 there were 126,000 deaths from heart disease in the 
UK. Death rates for coronary heart disease have been falling in the UK since the late 
1970s, and for people under the age of 75, they have fallen by 40% in the last 10 years 
(Allender et a l, 2008). However, the rates in the UK are still amongst the highest in 
Western Europe. In the UK currently 2.7 million people have coronary artery disease 
(Allender et a l, 2008).
Cardiovascular disease is a global burden on healthcare resources worldwide and 
results in 15 million deaths per year. Coronary heart disease is also the leading cause 
of death worldwide, with the death of 3.8 million men and 3.4 million women each 
year (Yellon etal., 2007). Current findings from World Heath Organisation predict that 
as far as 2030, cardiovascular disease will remain the leading cause of mortality in the 
world (Mathers et al., 2006).
The economic burden of coronary heart disease in the UK is very high, with the cost of 
healthcare at over £1.7 billion a year. The majority of the costs of coronary artery 
disease fall outside of healthcare and result from illness and death in those of working 
age and the economic effects on families who are caring for them (BHF, 2006). Whilst 
significant medical advances have been made in trying to reduce the mortality rates 
from coronary heart disease, new strategies and drug targets are still required.
An acute myocardial infarction (AMI), commonly referred to as a heart attack, is the 
single largest cause of mortality from coronary artery disease and accounts for 17 
million deaths worldwide (Reeve et a l, 2005). An AMI occurs when there is a sudden 
impairment of the oxygen rich blood supply to a portion of the heart relative to its
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metabolic demands, resulting in muscle death and subsequent heart failure. The most 
common cause of an AMI is the rupture of an unstable atheroma plaque resulting 
from coronary artery disease, which impairs the blood flow to the heart via the 
coronary artery (Kumar et al., 2002). The mainstay of current therapeutic 
intervention is the restoration of blood flow to the heart, termed reperfusion, as 
rapidly as possible by removal of the blockage. The most commonly used techniques 
are throbolytic therapy or primary percutaneous intervention (Yellon et al., 2007). 
Unfortunately, as will be discussed in detail later, restoration of blood flow to the 
heart also carries a paradoxical risk of producing further damage (Yellon et al., 2007). 
The rate of early death following an acute myocardial infarction is 10%, and the 
incidence of cardiac failure is 25% (Keeley et al., 2003). More recently, greater 
emphasis is being placed on trying to prevent the occurrence of AMI through lifestyle 
changes such as encouraging diets lower in saturated fats and more active lifestyles 
(Hu et al., 2002). Until such preventative measures are widely accepted into society, 
therapeutic interventions to limit the damage caused by AMI and the restoration of 
blood flow are required. Due to the worldwide incidence of AMI, research in this field 
is rapidly expanding through the use of experimental animal models to identify new 
targets which can be exploited at the time of reperfusion to limit the extent of further 
damage.
1.2 Myocardial infarction
1.2.1 Coronary artery disease
As mentioned previously an AMI most commonly occurs due to the rupture of 
unstable atherosclerotic plaques formed in coronary arteries (Kumar et al., 2002). 
Coronary atherosclerosis arises from a complex interplay of inflammatory process 
caused by the accumulation of lipid, macrophages, and smooth muscle in the intimal 
plaques of large and medium sized coronary arteries. Atherosclerotic lesions are 
asymmetrical thickenings of the intima, the innermost layer of the artery. They are 
composed of cells, connective tissue, lipids, and debris (Stary et al., 1995). Blood- 
borne inflammatory and immune cells compose an important part of the atheroma, 
with the remainder being composed of vascular endothelial and smooth muscle cells.
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An accumulation of lipid-laden cells, mainly comprised of macrophages and T-cells, 
beneath the endothelium transforms the atheroma into a fatty streak (Stary et al.,
1994). The centre of the atheroma is composed of foam cells and extracellular lipid 
droplets which form a core region. This is surrounded by a cap of smooth muscle cells 
and a collagen rich matrix. Infiltration of T-cells, macrophages, and mast cells into the 
lesion occurs in the shoulder region where the atheroma expands (Stary et al., 1995). 
Activation and production of inflammatory cytokines has been observed in the 
immune cells (Kovanen et al., 1995). Ruptures of the plaque occur when the fibrous 
cap of the plaque is thin and partly destroyed (Falk et al., 1995). The abundance of 
activated immune cells results in the production of inflammatory mediators and 
proteolytic enzymes that weaken the cap and activate the cells in the core (van der 
Wal et al., 1994). This creates an unstable plaque that is liable to rupture, inducing a 
thrombus and resulting in an AMI.
1.2.2 Mechanisms o f myocardial injury
Relative to its oxygen needs, the heart is one of the most poorly perfused tissues in 
the body (Giordano, 2005). The heart is unable to extract oxygen and nutrients from 
blood within the atria and ventricles, and therefore relies on the coronary arteries as 
its own blood supply (Tune et al., 2004). Under normal aerobic conditions the 
majority of cardiac energy is derived from fatty acids which provides between 60 -  
90% of the energy for A TP  synthesis (Bing, 1955). Carbohydrate metabolism only 
accounts for 10-40% of the energy generated in a healthy adult human heart at rest 
(Bing, 1955). A  defining characteristic of ischaemia is that the oxygen supply is 
insufficient to support oxidative phosphorylation (Hearse, 1994). Therefore a sudden 
occlusion of a major branch of the coronary artery results in a rapid shift to anaerobic 
glycolysis, accompanied by an increase in myocardial glucose uptake and glycogen 
breakdown (Stanley et al., 1997). A  reduction in A TP  inhibits the N a +/K +-A T P a s e , 
resulting in increased intracellular concentrations of sodium and chloride ions, which 
causes cell swelling. Transport systems in the sarcolemma and sacoplasmic reticulum 
become disrupted, producing an increase in cytosolic calcium. The resulting increase 
in calcium causes activation of proteases and alterations in contractile proteins. In the 
mitochondria pyruvate is not readily oxidised and lactate is produced, resulting in a
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fall in intracellular pH, a reduction in contractile function, and a greater ATP 
requirement to maintain calcium homeostasis (Stanley, 2001).
1.2.3 Pathophysiology o f AMI
Irreversible cell injury in AMI occurs after 20 minutes of total, no-flow ischaemia as a 
result of tissue necrosis. Ultra-structural changes occur within 10 minutes of the 
onset of ischaemia (Jennings et al., 1974). The injury may be reversible with prompt 
reperfusion as long as the sarcolemma remains intact (Herdson et al., 1965). After 20 
minutes of ischaemia there is severe disruption of the sarcolemma as a result of 
osmotic swelling and phospholipase activation, causing a loss of the barrier function. 
Prolonged periods of ischaemia result in myocardial necrosis. The extent and rate of 
necrosis are determined by the duration and severity of ischaemia, the size of the 
myocardial bed-at-risk, and the amount of collateral blood flow available shortly after 
coronary occlusion (Fozzard et al., 1991) (summarised in figure 1.1).
Irreversibly injured myocytes contain shrunken nuclei with marked chromatin 
margination. Irreversible ischaemic injury is characterised by the disruption and cell 
death of the sarcoplasmic reticulum. An increase in the cytosolic concentrations of 
calcium and mitochondrial impairment cause phospholipase activation and the 
release of phospholipids and free fatty acids, which are incorporated within the cell 
and damaged from reactive oxygen species. The cleavage of anchoring of cytoskeletal 
proteins and increases in cell membrane permeability, cause physical disruption and 
cell death (Jennings et al., 1974).
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Figure 1.1 A summary o f the biochemical and ionic changes that occur during myocardial ischaemia. If ischaemia occurs fo r a sufficient 
duration, it results in alterations in metabolism and ion fluxes, resulting in irreversible cell injury. Adapted from Ferdinandy et a I. (2007).
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1.2.4 Wavefront propagation o f injury:
As with all experimental studies of human diseases, animal models are initially used to 
investigate the condition further. Typically rats, rabbits and dogs are used to model 
AMI, since this is the most humanely and economically viable option. However, this 
can pose difficulties with translating the results from animals to humans, since 
severity and size of infarct can vary between species. The major determinants of final 
infarct size are the size of the area at risk (Reimer et al., 1979), the extent of collateral 
flow or residual blood flow (Reimer et al., 1979), temperature (Miki et al., 1998), and 
the haemodynamic situation during ischaemia in particular heart rate (Schulz et al.,
1995). Initial studies investigating the wavefront propagation of injury were 
conducted in canine hearts. This was a useful model since humans and dogs are 
physiologically very similar. In particular both hearts contain collateral vessels, which 
act as an alternative blood supply to regions of the heart after the main source is 
impaired and allow the flow of blood to be restored to an adjacent artery or further 
down the same artery, to allow bypassing of a blockage. It was observed that necrosis 
begins in the subendocardial region of the myocardium and progresses as a wave 
front of necrosis into the mid-myocardium and sub-epicardium with increasing 
duration of coronary occlusions and with increasing severity of ischaemia (Reimer et 
al., 1979; Reimer et al., 1977) (summarised in figure 1.2). In humans coronary artery 
occlusions lasting fewer than 6 hours produce subendocardial infarcts, in which the 
infarct is smaller than the area at risk. When the coronary occlusion period exceeds 6 
hours, the resulting infarcts encompass the entire area at risk. However, greater 
difficulties become apparent when comparing the results between small rodents and 
other non-collateralised species to humans. In small rodents with a high heart rate 
and low collateral flow, models of regional ischaemia 30 minutes typically produce a 
35% infarct. This is obviously far more rapid in onset than in humans, and in patients, 
3 hours of coronary occlusion have shown no detectable infarction (Dixon et al., 
2002). These findings suggest that the physiology of the two species differs, with a 
major contributing factor perhaps being the existence of collateral vessels in humans 
which serve as a protective mechanism (Downey et al., 2006). However, despite the 
difference in the duration of onset of ischaemic damage, animal models are still 
widely employed for investigating AMI, as the underlying pathophysiology is the same.
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Therefore this allows data from animal models to be used with confidence and the 
results translated into humans. The other advantage of a more rapid onset of damage 
in small rodents such as rats, is that experiments can be conducted over shorter time 
periods and data obtained more quickly.
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Figure 1.2 Transverse sections through infarcted heart tissue demonstrating the Wavefront phenomenon o f cell death as described by 
Reimer and Jennings (Reimer et a!., 1977). The infarct initiates in the subendocardium, due to the least collateral flow, and progresses 
across to the epicardium.
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1.3 Reperfusion
Reperfusion is restoration of blood flow to the myocardium and is the only effective 
method of overcoming ischaemia. Reperfusion cannot occur in the absence of 
ischaemia. Paradoxically reperfusion is associated with both beneficial and 
deleterious components. Reperfusion is beneficial because it restores the oxygen and 
metabolic substrate supply, allows washout of accumulated metabolites, it may halt 
the process of necrosis, and is required for the recovery of reversibly injured myocytes 
(Baxter, 1998). The more quickly reperfusion is performed the less the extent of 
irreversible injury and the severity of post-infarction remodelling, which also effects 
the development of chronic cardiac failure and death (Simoons et a i, 1997). Failure of 
rapid reperfusion increases the likelihood that even if a patient survives an AMI, they 
could sustain a large infarct and be at a higher risk of morbidity and mortality 
associated with chronic cardiac failure. Intervention should therefore aim to 
maximise the speed and effectiveness of reperfusion and reduce the rate of 
irreversible cell injury during ischaemia or reperfusion.
Reperfusion can be deleterious because it can cause myocardial stunning (Braunwald 
et a i, 1982), the no-reflow phenomenon (Krug et a i, 1966), reperfusion arrhythmias 
(Manning et a i, 1984) and lethal cell injury to occur (summarised in figure 1.3). 
Myocardial stunning is used to describe the mechanical dysfunction of the heart after 
reperfusion despite the absence of irreversible damage and a restoration of blood 
flow (Braunwald et a i, 1982). This is usually a short lived effect from which the heart 
fully recovers. The no-reflow phenomenon refers to the impeded flow through the 
micro-vasculature after opening of the previously infarcted coronary artery (Krug et 
a i, 1966). Reperfusion arrhythmias are potentially harmful but can be effectively 
controlled with therapeutic intervention (Manning et a i, 1984). The most severe 
consequence of reperfusion is lethal reperfusion injury, which causes the death of 
previously viable myocytes at reperfusion, and will be discussed in greater detail 
below.
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Figure 1.3 The balance of beneficial and deleterious components o f reperfusion. The beneficial effects include restoration of oxygen and 
metabolic substrate supply and washout o f accumulated proteins. The deleterious effects include generation of oxygen free radicals, 
calcium overload and damage o f previously reversibly injured tissue. Adapted from Baxter (1998).
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1.3.1 Lethal reperfusion injury
Initially it was viewed that cell death occurred during ischaemia due to the lack of ATP, 
which could not be produced by oxidative phosphorylation due to the anaerobic 
ischaemic environment (Ferdinandy et at., 2007). Therefore in an attempt to salvage 
the myocardium, reperfusion must be performed to reintroduce oxygen to protect 
both the uninjured and reversibly injured cells. The original hypothesis posed 
regarding reperfusion was that cells died that were already irreversibly damaged by 
ischaemia, and therefore reperfusion did not exacerbate damage (Ferdinandy et o/., 
2007).
However, a phenomenon called reperfusion-induced injury was proposed in 1960 by 
Jennings et al. (1960) who described the histological features of reperfused canine 
hearts, which included cell swelling, contracture of myofibrils, disruption of the 
sarcolemma, and the appearance of intramitochondrial calcium phosphate particles. 
As result of these observations it has been proposed that reperfusion of the ischaemic 
myocardium carries a paradoxical risk in that it has the potential to cause further 
irreversible cell injury to cardiac myocytes that were viable before reperfusion (Piper 
et al., 1998). However, the additional injury is largely dependent on the duration and 
severity of the preceding ischaemia. The extent of reperfusion injury is highly debated 
and it is argued that reperfusion has the potential to further exacerbate the cellular 
injury sustained during the ischaemic period (Kloner, 1993), whilst others suggest that 
oxidative stress and abrupt metabolic changes that occur during reperfusion initiate 
injury independent of ischaemia (Vanden Hoek et al., 1996), suggesting that lethal 
reperfusion injury could be an independent mediator of cell death from ischaemic 
injury. The greatest evidence for the existence of lethal reperfusion injury was 
provided by Yellon et al. (1999) who demonstrated a reduction in myocardial infarct 
size if an intervention was used during the initial stages of reperfusion.
The greatest difficulty with trying to measure lethal reperfusion injury is that it is not 
possible to accurately assess in situ the progress of necrosis during the transition from 
myocardial ischaemia to reperfusion (Piper et al., 1998). Lethal reperfusion injury 
occurs as a result of the rapid restoration of oxygen, as well as factors such as
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endothelial damage, platelet aggregation and neutrophil adhesion and activation. It 
can also be caused by massive calcium overloading of the metabolically impaired 
myocytes with damaged sarcolemma (Maxwell et al., 1997) and the rapid restoration 
of physiological pH. If reperfusion occurs within 2 to 3 hours of the onset of 
ischaemia, the amount of salvage greatly exceeds the amount of irreversible 
reperfusion injury (Buja, 2005). The additional damage to the myocardium caused by 
lethal reperfusion injury often detracts from the potential benefit of reperfusion 
compared to an un-reperfused heart.
There is also increasing evidence to suggest that myocardial infarct size can increase in 
relation to the duration of reperfusion. This suggests the possibility of a wavefront of 
myocardial reperfusion injury caused by apoptosis and inflammation (Zhao et al., 
2 0 0 0 a), which could be reduced by a late intervention of antiapoptotic and anti­
inflammatory agents (Doukas etal., 2006).
1.3.2 Proposed mediators of lethal reperfusion injury
Several potential mediators of lethal reperfusion injury have been proposed and will 
be discussed briefly. The oxygen paradox suggests that the generation of reactive 
oxygen species (ROS) at reperfusion produces damage to the myocardium to a greater 
extent than ischaemia alone (Hearse et al., 1973). However, there is the lack of 
consistent experimental evidence to support this theory. The calcium paradox 
suggests that sarcolemmal-membrane damage and oxidative stress induced damage 
to the sarcoplasmic reticulum, results in an abrupt increase in calcium due to the 
inability to regulate the intracellular concentration. Intracellular and mitochondrial 
calcium overload occur, resulting in hypercontracture of cardiac cells (Bolli et al.,
2004). Again, inconclusive experimental evidence surrounds this theory. The pH 
paradox proposes that the rapid restoration of physiological pH contributes to lethal 
reperfusion injury (Lemasters et al., 1996), but clinical studies delaying the restoration 
of physiological pH have been ineffective (Avkiran et al., 2002). The accumulation of 
inflammatory mediators at reperfusion into the infarct zone and subsequent 
migration into the myocardial tissue, with the release of degradative enzymes and 
ROS is another proposed mechanism of lethal reperfusion injury (Vinten-Johansen,
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2004). Clinical trials have shown some promise with an 11% reduction in infarct size 
following use of an anti-inflammatory agent, adenosine, at reperfusion (Ross et al.,
2005). However, in addition to these paradoxes, the mitochondrial permeability 
transition pore (mPTP) has been proposed as a key mediator of reperfusion injury, for 
the reasons discussed below. However, mTP is probably not exclusively the causative 
factor of lethal reperfusion, and intra-cellular calcium over-load and ROS generation 
(Opie, 1989) are probably contributing factors too.
1.3.3 Role of the mitochondrial permeability transition pore in reperfusion injury
Greater understanding of the role of the mitochondria in determining cell fate during 
and after cellular stresses, has led to the discovery that reperfusion favours opening of 
the mPTP, a pore on the mitochondrial inner and outer membrane which when open 
results in cell death due to uncoupling of oxidative phosphorylation and loss of 
membrane potential (Halestrap et al., 2003). The idea that the mPTP may play a role 
in cardiac reperfusion injury is not a new concept and was first proposed by Crompton 
et al. in 1987 (Crompton et al., 1987).
Opening of the mPTP at reperfusion occurs due to the favourable environmental 
conditions. The rapid restoration of oxygen at reperfusion causes re-activation of the 
mitochondria and electron transport chain, resulting in a significant production of ROS 
and further ROS in a ROS-induced-ROS release (Griffiths et al., 1995). Reactive 
nitrogen species (RNS), for example peroxynitrite (ONOO ), are also generated from 
the presence of nitric oxide. These reactive species causes oxidative damage to 
cellular structures such as the sarcoplasmic reticulum, resulting in calcium release. 
ATP production is restored allowing activation of the sodium/calcium (Na+/Ca2+) 
exchanger, resulting in calcium overload. The combined effect of calcium 
accumulating in the mitochondrial matrix, along with ROS and RNS, and the increase 
in pH due to hydrogen ions being washed out, provides favourable conditions for the 
formation and opening of the mitochondrial permeability transition pore. Allowing 
the mPTP to open during the first few moments of reperfusion, results in cell death via 
necrosis due to the uncoupling of oxidative phosphorylation and collapse of the
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mitochondrial membrane potential, resulting in mitochondrial swelling and a 
sustained lack of ATP production (Hausenloy etal., 2003).
Crompton et al. (1988) demonstrated that inhibition of opening of the mPTP with 
cyclosporine A induced cardioprotection. Further investigation by Halestrap's 
laboratory (Griffiths et a i, 1995) showed that the mPTP remained closed during 
ischaemia and only opened during the initial stages of reperfusion. Infarct size 
limitation with mPTP inhibitors at reperfusion provided further evidence for inhibiting 
opening of the pore to produce cardioprotection (Hausenloy et al., 2003). If the pore 
is kept in a closed state it protects the myocardium against reperfusion injury 
(Hausenloy et al., 2002). However, it has been shown that inhibiting opening of the 
pore is ineffective if it occurs after the initial few minutes of reperfusion, suggesting a 
critical time period for inducing cardioprotection (Hausenloy et al., 2003). There 
appears to be substantial evidence to support the role of mPTP opening at reperfusion 
induces ischaemia-reperfusion injury (Halestrap et al., 2000b) and that to enable 
complete recovery from ischaemia-reperfusion the mitochondria must return to full 
functioning and the mPTP be kept in closed state.
Following on from studies in animals that demonstrated a 50% reduction in infarct size 
when inhibiting mPTP opening at reperfusion (Hausenloy et al., 2003), has led to 
proof-of-concept clinical trials to be undertaken. These trials discussed in more detail 
below (section 1.7.2), will hopefully confirm the results shown in animal models, and 
assist with clarification of the mediator role of the mPTP in lethal reperfusion injury.
1.3.4 Composition o f the mPTP
The exact composition of the mPTP still remains unclear, although several 
components have been identified which appear essential for its function. These 
include the voltage dependent anion channel (VDAC), adenine nucleotide translocator 
(ANT) and cyclophilin-D (CYP-D) (Halestrap et al., 2004). CYP-D knock-out mice 
showed an increased resistance to mPTP opening and infarct size limitation compared 
to wild type mice (Baines et al., 2005; Nakagawa et al., 2005). However, the clinical 
use of cyclosporine A as a cardioprotective agent is limited by concerns about its
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dosing and side effects (Hausenloy et al., 2008). This may limit the drug to a single 
intravenous bolus that could be administered to patients undergoing myocardial 
reperfusion after an AMI or in patients receiving coronary artery bypass angioplasty 
surgery, or angioplasty.
1.4 Modes of cell death
Originally it was proposed that there were four main types of cell death, oncosis, 
necrosis, apoptosis, and autophagy involved in both the maintenance of normal 
cardiac homeostasis and in the development of cardiac and vascular diseases (Buja, 
2005). It appears that multiple modes of cell death can participate simultaneously in 
various pathological processes (Kostin, 2005). Environmental factors play a large part 
in determining which process of cell death occurs, in particular the availability of ATP 
to drive active processes such as apoptosis. However, since Majno et al. (1995) 
reviewed the modes of cell death, the Society for Toxicologic Pathologists 
recommended that the term necrosis should only be used to describe the changes 
that occur after cell death, regardless of the pathway by which the cell originally died 
(Levin et al., 1999). The modifiers "apoptotic" or "oncotic" should be used to specify 
the predominant cell death pathway.
1.4.1 Oncosis
Oncosis is non-programmed form of cell death characterised by swelling, disruption of 
the sarcolemma and the mitochondria, chromatin clumping, blebbing and removal of 
cells by inflammatory mediators (Majno et al., 1995). It is a passive response to 
external noxious stimuli (Majno et al., 1995) such as ischaemia-reperfusion and 
hyoxia.
1.4.2 Apoptosis
Apoptosis is an ATP dependent conserved form of self-destruction, resulting in cell 
and nuclear shrinkage and fragmentation without external inflammation (Kerr et al., 
1972). It is characterised by preservation of mitochondrial and sarcolemmal integrity, 
nuclear chromatin condensation, removal of debris by macrophages or neighbouring
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cells (Majno et al., 1995), nuclear fragmentation, blebbing, and phosphatidylserine 
exposure on the cell surface of the plasma membrane (Zamzami et al., 1996). 
Apoptosis can be stimulated by both a receptor mediated (extrinsic) and a 
mitochondrial (intrinsic) pathway in acute and chronic cardiac disease (Borutaite et al., 
2003a). Both pathways are operative in cardiomyoctes. One of the main 
characteristics of apoptosis is the cleavage of chromosomal DNA into nucleosomal 
units. The activation of a specific class of proteases called the caspases (cytsolic 
apartate residue-specific cysteine proteases) are required for this process because 
they activate DNases, inhibit DNA repair enzymes, and cause the break down of 
structural proteins in the nucleus (Kroemer et al., 2007). Most cell death in 
vertebrates occurs via the mitochondrial pathway (Green et al., 2004). Formation of 
the mPTP causes the release of cytochrome c, which is a key mediator of caspase 
activation, highlighting the critical role the formation of the mPTP plays in apoptosis 
(Scaffidi et al., 1998).
1.4.3 Necrosis
Necrosis is a degradative process that follows the onset of irreversible injury via 
oncosis and apoptotic forms of cell death (Majno et al., 1995). Cells die from necrosis 
when they cannot maintain adequate ATP levels, in contrast to apoptosis which 
requires ATP to activate the caspase cascade (Weiss et al., 2003). Necrotic cells gain 
volume which leads to rupture of the plasma membrane and the unorganised 
dismantling of swollen organelles (Kroemer et al., 2007). Necrosis lacks a specific 
biochemical marker and can only be detected by electron microscopy. It is also 
considered harmful because it is also often associated with local inflammation, which 
can lead to tumour growth (Vakkila et al., 2004).
1.4.4 Modes of cell death during ischaemia-reperfusion
The primary pathological expression of coronary artery disease is myocardial cell 
injury resulting from AMI (Skyschally et al., 2008). Injury can range from a small insult 
with no permanent damage, to a large insult resulting in alteration of cardiac function 
and ultimately cell death (Skyschally et al., 2008). The duration and severity of
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ischaemia appears to be the key factor in the resulting insult. An ischaemic insult 
causing cardiac myocytes to become irreversibly injured will result in cell death. The 
modes of cell death elicited during ischaemia-reperfusion will now be addressed.
Ischaemia causes progressive ultrastructural and functional damage to the 
mitochondria as the duration and intensity increases (Lesnefsky et al., 1997). Since 
cardiac myocytes are highly aerobic cells, the mitochondria are vital to cell survival as 
they are the primary source of ATP production via oxidative phosphorylation (Solaini 
et al., 2005). Since the ischaemic environment is highly anaerobic (Dobson et al.,
2002), oxidative phosphorylation cannot occur and there is the rapid depletion of ATP 
during the initial stages of ischaemia (Javadov et al., 2007). Initially glycolysis can be 
used to maintain ATP levels, but this is short lived due to a rise in H+ which prevents 
glycolytic enzyme activity (Solaini et al., 2005) and also causes the mPTP to remain 
closed (Javadov et al., 2007). This suggests that oncosis and subsequent necrosis 
would be the favoured route of cell death during ischaemia, since they are passive 
processes.
Evidence investigating the role of oncosis during ischaemia in the absence of 
reperfusion is limited, but several studies suggest a role. Takemura et al. (1997) 
showed that apoptosis was absent in rabbit hearts after coronary occlusion, through 
the use of immunogold dUTP nick-end labelling (TUNEL) staining and electron 
microscopy, whilst a study by Ohno et al. (1998) suggests that apoptosis does not play 
a role in myocardial infarction. Ischaemia induced in human myocardial cells also 
demonstrated fragmentation indicative of the occurrence of oncosis (Itoh et al.,
1995).
However, despite oncosis/necrosis being a logical route of cell death, there is much 
experimental to suggest a role of apoptosis during ischaemia. Borutaite at al. (2003b) 
used TUNEL positive staining to demonstrate that apoptosis occurred during 60 
minutes of global ischaemia in the absence of reperfusion. They did however only 
show that 2 % of myocytes underwent apoptosis, and went on to demonstrate that a 
far greater number of apoptotic cells were present during reperfusion. These findings
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suggest that apoptosis may be initiated during ischaemia, but cannot actually occur to 
completion until reperfusion when ATP levels are restored. There are in fact very few 
studies that support a role of apoptosis during ischaemia alone (Fliss et al., 1996). 
Since apoptosis is an ATP dependent process it may explain why it is more likely to 
occur at reperfusion when there is a restoration of ATP production (Leist et al., 1997). 
In studies investigating ischaemia following by reperfusion, there is a greater 
incidence of apoptosis reported, suggesting that reperfusion accelerates the apoptotic 
death process initiated during ischaemia (Fliss et al., 1996; Freude et al., 2000; 
Gottlieb et al., 1994; Scarabelli et al., 1999).
Opening of the mPTP at reperfusion has been implicated to produce a switch from 
reversible to irreversible cell injury (Halestrap et al., 2004). Mitochondrial dysfunction 
has been shown to affect cell viability in several ways. It causes a loss of ATP 
synthesis, increases ATP hydrolysis, impairs ionic homeostasis, causes the production 
of ROS, and the release of pro-apoptotic proteins (Kroemer et al., 1998). These are all 
factors involved in irreversible damage, suggesting that the mitochondria are involved 
in apoptosis and necrosis. There appears to be growing evidence to suggest that the 
level of mitochondrial damage and duration of opening of the mPTP at reperfusion 
determines the fate of cardiac myocytes (Crompton, 1999). Brief opening of a limited 
number of pores will produce far less damage than a generalised prolonged opening, 
which will result in cessation of ATP production and cell death via necrosis. An 
intermediary stage may exist whereby transient and localised opening of mPTP allows 
apoptotic proteins, such as cytochrome C, to be released initiating the apoptotic 
cascade (Halestrap et al., 2000a). There is also strong evidence to suggest that the 
necrotic centre of an infarct is surrounded by a peripheral ring of apoptosis (Takemura 
et al., 2004) perhaps where mitochondrial damage was less severe and apoptosis 
could occur. Early studies by Crompton et al. (1987; 1988) suggest a role of necrosis 
during ischaemia-reperfusion mediated by opening of the mPTP.
Apoptosis has also been reported to only occur during reperfusion, or to become the 
dominant form of cell death after reperfusion (Gottlieb et al., 1994; Zhao et al., 
2000b). Zhao et al. (2001b) demonstrated that necrotic cell death peaked after 24
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hours of reperfusion and apoptotic cell death increased up to 72 hours of reperfusion, 
presumably once the oxidative phosphorylation was fully restored. Other studies 
have shown that inhibition of the apoptotic signalling cascade during reperfusion is 
able to attenuate the apoptotic and necrotic components of cell death, suggesting 
that apoptosis can evolve into necrotic cell death (Zhao et al., 2003c). Inhibition of 
apoptosis at reperfusion has also been shown to improve contractile function of 
ischaemic canine hearts (Zhao et al., 2003c).
An interesting study by McCully et al. (2004) compared the relative contribution of 
apoptosis and necrosis to myocardial ischaemia-reperfusion injury. They reported 
through the use of TUNEL positive staining, tetrazolium staining, and caspase activity, 
that during global ischaemia lasting up to 30 minutes in isolated rabbit hearts, 
necrosis contributed significantly more to infarct than apoptosis. Apoptosis was also 
shown to be significantly decreased by inhibition of caspases, which are an essential 
component of apoptosis, during early reperfusion. However, surprisingly this did not 
lead to an improvement in the immediate post-ischaemic functional recovery.
Scarabelli et al. (1999) were the first to quantify apoptosis in cardiac myocytes using 
TUNEL positive and counter staining. They showed that apoptosis predominantly 
affects endothelial cells during early reperfusion and that these cells undergo 
apoptosis before cardiac myocytes. These findings are highly important because they 
suggest that soluble factors may be released from the injured vascular cells which 
diffuse into the myocardium during reperfusion, contributing to cell death. This 
suggests that apoptosis could occur in cardiac myocytes during reperfusion despite 
opening of the mPTP. Knock-out mouse models lacking various apoptotic components 
have shown between a 50 and 65% reduction in infarct size, providing further 
evidence for a role of apoptosis in cell death in ischaemia-reperfusion (Garg et al., 
2003; Takashi eta!., 2000).
Whilst reviewing the literature about the role of apoptosis in ischaemia-reperfusion 
injury, it appears that there is much evidence to support its role. However, a large 
number of studies measure apoptotic mediators as opposed to using staining
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techniques to observe the hallmark effects of apoptosis. This implies that whilst 
apoptotic mediators may be released, whether they actually initiate apoptosis is 
questionable. Interestingly, apoptotic cell death can be shifted to a more necrotic 
phenotype by the removal of essential caspase activators such as APAF-1 (Golstein et 
a i, 2005). This suggests that during ischaemia-reperfusion whilst the release of some 
apoptotic mediators may occur, other key components may not be released shifting 
apoptosis towards a necrotic death pathway. With this in mind it appears that 
oncosis/necrosis is a far more likely form of cell death during ischaemia and the early 
stages of reperfusion, than apoptosis. Whilst apoptosis initiated during the early 
stages of ischaemia or even reperfusion, may contribute to cell death during the later 
stages of reperfusion after the restoration of oxidative phosphorylation, providing ATP 
to drive the process. However, what remains clear is that there is still great 
uncertainty surrounding the relative contributions of apoptosis and necrosis to cell 
death, and whether the two processes are related.
1.5 Cardioprotection
Cardioprotection refers to the prevention of stress-induced myocardial injury. This 
term has been used to describe the protection against ischaemia-reperfusion induced 
myocardial injury. Cardioprotection at reperfusion is an important clinical target 
because the onset of AMI cannot be predicted. This means that therapeutic 
intervention can only occur once AMI is initiated during the final moments of 
ischaemia and initial stages of reperfusion. Since both ischaemia and reperfusion 
have been reported to cause injury to the heart, with reperfusion possibly extenuating 
that caused during ischaemia, limiting the overall damage to the myocardium is of 
great importance to preserve its structural integrity and maintain maximum function.
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1.5.1 Historical background to the reperfusion injury salvage kinase (RISK) pathway
1.5.1.1 Anti-apoptotic effects ofPI3K and Akt
It has long been recognised that activation of the protein and lipid kinase cascade 
phosphoinositide 3-kinase (PI3K) and its downstream effector serine-threonine kinase 
(Akt), produces a potent stimulus for cell proliferation, growth and survival in many 
systems of the body (Matsui et a i, 2003). Activation of PI3K subsequently causes 
phosphorylation of membrane phosphatidylinositol 4,5-bisphosphate, producing 
phosphatidylinositol 3,4,5-triphosphate (PIP3), some of which is converted to 
phosphatidylinositol 3,4-trisphosphate (PIP2) by an inositol phosphate (Damen et a i,
1996). PIP2 and PIP3 accumulate in the cell membrane and recruit Akt and PDK1 to 
the cell membrane, resulting in phosphorylation and activation of Akt 
(Vanhaesebroeck et a i, 2000). Perhaps the most interesting feature of PI3K and Akt 
activation in the context of cardiomyocytes is the antiapoptotic effect. Insulin-like 
growth factor (IGF1) has been shown to activate PI3K (Kulik et a i, 1997) and Akt, and 
activation of PI3K is essential for the anti-apoptotic effects of IGF1 (Matsui et a i, 
1999). Most importantly it has been demonstrated that acute activation of PI3K or 
Akt is sufficient to inhibit cardiomyocyte apoptosis (Matsui et a i, 1999). Adenoviral 
gene transfer of constitutively active Akt to the heart has been shown to cause a 
significant reduction in cardiomyocyte apoptosis and infarct size in vivo (Matsui et al., 
2001). Interestingly inhibition of Akt activity with a dominant negative construct has 
been shown to accelerate hypoxia-induced dysfunction of cardiomyocytes (Matsui et 
al., 2001). These findings provide evidence that acute activation of Akt provides both 
cardioprotection and improved function of cardiomyocytes (Matsui et al., 2003). PI3K 
is thought to play a critical role in organ size and development (Leevers et a i, 1996) 
and transgenic cardiac over-expression of either the constitutively active or dominant 
negative forms has demonstrated its role in the modulation of cardiomyocyte growth 
(Shioi et a i, 2000). Transgenic over-expression of activated Akt in the heart has been 
shown to induce hypertrophy (Matsui et a i, 2002) suggesting it may mediate the 
effects of cardiac growth. Taken together these findings demonstrate that PI3K and 
Akt are important pro-survival kinases in the myocardium and acute activation 
produces cardioprotection due to their anti-apoptotic function.
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Extending the pro-survival effects of PI3K and Akt in the myocardium, in particular the 
finding that constitutively expressed PI3K and Akt limits hypoxia-reoxygenation 
induced apoptosis, led to the proposal of the reperfusion injury salvage kinase (RISK) 
pathway in the late 1990's. This concept stems from the hypothesis that apoptotic 
cell death was contributing to lethal reperfusion injury, and the existence of the pro­
survival anti-apoptotic protein kinases Akt and Erkl/2, which when specifically 
activated at the time of reperfusion produced cardioprotection (Yellon et al., 1999). 
Many subsequent studies have supported this hypothesis and have shown the 
involvement of anti-apoptotic effectors downstream of Akt including phosphorylation 
of proapoptotic proteins, such as BAX and BAD, the inhibition of caspase 3 activation, 
and the phosphorylation and activation of p70s6K. p70s6K acts to inhibit BAD and 
also activates Bcl-2 a proapoptotic protein (Harada et al., 2001), although as 
previously explained, the quantitative contribution of apoptosis to the overall cell 
death in AMI may be limited.
There is now a continually expanding list of pharmacological agents that have been 
shown to activate the RISK pathway to induce cardioprotection. Further investigation 
into the RISK pathway has revealed that is can be primed for activation prior to 
reperfusion (preconditioning) and also at reperfusion (postconditioning). Also the 
identification of cardioprotective kinases involved in the RISK pathway is continually 
expanding and now includes protein kinase C (PKC), protein kinase G (PKG), 
phosphoprotein 70 kDa ribosomal protein S6  kinase (p70s6K), and Glycogen synthase 
kinase 3 beta (GSK-3J3).
1.5.1.2 Role o f inhibition o f the mitochondrial permeability transition pore (mPTP) in 
cardioprotection
The original hypothesis that activation of the RISK pathway produced cardioprotection 
by the recruitment of anti-apoptotic pathways has been extended further since the 
discovery that activation of the RISK pathway also causes cardioprotection by the 
inhibition of the mitochondrial permeability transition pore (mPTP) opening 
(Juhaszova et al., 2004). As already mentioned, the mPTP is a non-selective 
conductance pore of the mitochondrial inner membrane (Griffiths et al., 1995).
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Opening of the mPTP channel at reperfusion has been shown to mediate cell death in 
the first few minutes of reperfusion (Hausenloy et al., 2002). However, if the pore is 
kept in a closed state this induces cardioprotection. Once it had been established that 
there was a link between activating the RISK pathway and inhibition of the mPTP to 
induce cardioprotection, exactly how these two components were linked was 
investigated.
Prevention of mPTP opening occurs as a downstream event of the RISK pathway 
components discussed previously. Specifically activation of PKG via cGMP, which in 
turn activates PKC-e, causes opening of the ATP-dependent mitochondrial 
permeability potassium channel (K At p )  (Costa et al., 2005). Opening of the channel 
results in the production of reactive oxygen species (ROS) (Andrukhiv et al., 2006) 
which perform two functions. The first is to activate protein kinases in the cytosol 
such as Akt, Erkl/2, p38 mitogen activated protein kinases, and PKC. This relays the 
cardioprotective signal to protect the myocardium after a prolonged ischaemic 
episode (Yellon et al., 2003). The second role of the ROS is to inhibit the opening of 
the mitochondrial permeability transition pore (mPTP) (Costa et al., 2006) at 
reperfusion. Therefore activation of the RISK pathway specifically during the first few 
minutes of reperfusion is believed to be cardioprotective by attenuating reperfusion 
induced cell death via anti-apoptotic mechanisms. This suggests the pro-survival 
kinase cascades would be a suitable target to manipulate and upregulate during early 
reperfusion in order to limit reperfusion induced cell death. A summary of the kinases 
and proposed mechanism involving inhibition of mPTP opening at reperfusion is 
shown in figure 1.4.
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Figure 1.4 The RISK pathway consists o f the pre-ischaemic "Trigger phase" which primes the pathway prior to ischaemia. At reperfusion 
the "Mediator pathway" is activated, comprised o f pro-survival kinases which prevent opening of the mPTP and induces cardioprotection. 
Adapted from Costa et al. (2008)
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1.5,13 Activators o f the RISK pathway
The RISK pathway is activated in response to a wide range of receptors, including 
growth factors and G-protein coupled receptor ligands. Examples of growth factors 
are transforming growth factor-pi, insulin and corticotrophin-1 (Hausenloy et al., 
2007). Some of the G-protein coupled receptor ligands that activate the RISK pathway 
include adenosine, bradykinin (Bell et al., 2003b) and adrenomedullin (Hamid et al., 
2005). There is also a third group of mediators that activate the pathway via other 
receptors and these include the natiuretic peptides (ANP)/B-type natriuretic peptide 
(BNP) (D'Souza et al., 2003), oestrogens (Patten et al., 2004) and erythropoietin 
(Bullard et al., 2005). It has also been shown that it is possible to activate the RISK 
pathway through non-receptor mediated activation with agents such as volatile 
anesthetics (Schlack etal., 1998) and HMG-CoA reductase inhibitors ("statins") (Bell et 
al., 2003a).
1.5.1.4 Regulation o f RISK pathway activation
Activation of the RISK pathway must occur immediately at the onset of reperfusion to 
induce cardioprotection. This time point is critical because during the initial few 
minutes of reperfusion the mPTP opens due to the generation of ROS, an increase in 
mitochondrial calcium and the restoration of normal pH (Griffiths et al., 1995). 
Pharmacological inhibition of the mPTP after the first few minutes of reperfusion has 
been shown to be ineffective at inducing cardioprotection (Hausenloy etal., 2003)
Whilst it has been clearly demonstrated that the RISK pathway plays an important role 
in protecting the myocardium against ischaemia reperfusion injury, over-activation 
results in hypertrophy and malignancy (Franke et al., 2003). Phosphatase and tensin 
homolog deleted on chromosome ten (PTEN) is a ubiquitous phosphatase that acts to 
protect cells against the long term activation of the PI3K/Akt (Hlobilkova et al., 2003), 
the major upstream components of the RISK pathway. PTEN acts a lipid phosphatase 
(Leslie et al., 2004), causing the reversal of the phosphorylation of the second 
messenger phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3), which would normally act downstream to activate 3- 
phosphoinositide-dependent kinase 1 (PDK-1) and subsequently Akt activation
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(Mocanu et al., 2007) (as shown in figure 1.4). Recently it has been shown that PTEN 
is down regulated after 15 minutes of ischaemia and 30 minutes of reperfusion in an 
isolated rat heart model (Cai et al., 2005). Whilst this study used a relatively mild 
ischaemic episode, it does highlight the potential for acute down-regulation of PTEN, 
to increase RISK pathway activation and enhance endogenous cardioprotection.
1.5.1.5 Detrimental protein kinases
Although the RISK pathway consists of a cascade of pro-survival kinases, there are also 
deleterious components. For example Rho-kinase (ROCK) has been shown to be 
activated by ischaemia-reperfusion. Its mode of action is to regulate the RISK pathway 
and overactivation causes cardiovascular damage by inhibiting the RISK pathway 
(Noma et al., 2006). Hamid et al. (2007) demonstrated that inhibition of ROCK, 
specifically at the time of reperfusion, produced cardioprotection through an 
Akt/eNOS-dependent mechanism. These findings suggest that ROCK activation at 
reperfusion may be deleterious through suppression of the RISK pathway.
1.6 Activating the RISK pathway to induce cardioprotection
The RISK pathway and subsequent cardioprotection can be activated by two 
cardioprotective algorithms: ischaemic preconditioning (IPC) and ischaemic
postconditioning (IPOST). Both involve one or more short bursts of ischaemia- 
reperfusion either prior to a prolonged ischaemic episode, IPC, or at the beginning of 
reperfusion, IPOST, to induce a reduction in damage to the myocardium. More 
recently it has been shown that pre and post-conditioning utilise many of the same 
kinases of the RISK pathway, and that both mechanisms of cardioprotective cause 
inhibition of mPTP opening at reperfusion. This finding has provided increased 
potential cardioprotective targets, as the knowledge of the RISK pathway and its 
components are expanded. The concepts of IPC and IPOST will now be addressed and 
the potential cardioprotective mechanisms that cause activation of the RISK pathway 
will be discussed and explored.
27
Chapter 1 General Introduction
1.6.1 Ischaemic preconditioning
The most Interesting feature of the RISK pathway is that various components such as 
Akt and Erkl/2 p38 MAPK can be primed for activation prior to a prolonged ischaemic 
period, to induce cardioprotection at reperfusion. This is achieved by ischaemic 
preconditioning (IPC), a cardioprotective phenomenon produced by sub-lethal short 
periods of coronary occlusion and reperfusion prior to a prolonged ischaemic event. It 
was first described by Murry et al. (1986) who demonstrated that infarct size could be 
reduced in anaesthetised dogs subjected to four, 5 minute periods of left anterior 
descending coronary artery occlusion, with 5 minutes periods of reperfusion between, 
prior to 40 minutes of occlusion of the same artery. The cardioprotective effect 
observed was independent of changes in transmural myocardial blood flow and it was 
proposed that the effect was as a result of a rapid metabolic adaptation of the 
ischaemic myocardium. Ischaemic preconditioning has been shown to be reliably 
reproducible in a variety of species using varying protocols, resulting in its acceptance 
as the "gold standard" for cardioprotection. "Classical" preconditioning, as just 
described, is a short lived transient effect and is lost if the interval between 
preconditioning and prolonged ischaemic episode is greater than 60 minutes. A 
second window of protection exists between 24 and 72 hours of the preconditioning 
stimulus (Kuzuya et al., 1993). This was designated the title "late phase 
preconditioning" to distinguish it from "classical" preconditioning.
1.6.1.1 Mechanism o f action o f ischaemic preconditioning
It is thought that during IPC there is the generation of endogenous autacoid ligands, 
such as adenosine (from breakdown of ATP), bradykinin, opioids, prostacyclin, NO, 
reactive oxygen species and TNF-a (Gross et al., 2006). These endogenous ligands 
accumulate during the preconditioning stimulus and bind to their respective GPCRs to 
trigger the preconditioned state by activating PKC. Adenosine couples directly to PKC 
through the phospholipases. The EGF receptor (EGFR) couples muscarinic and opioid 
receptors to PI3K (Critz et al., 2005). EGF receptor transactivation requires 
metalloproteinase (MMP) cleavage from its membrane bound precursor pro-heparin- 
binding EGF (HB-EGF) (Krieg et al., 2004). This then gives rises to activation of a 
complex pathway that includes PI3K, Akt, NO synthase, guanylyl cyclase, PKG, opening
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of mitochondrial K At p  channels, activation of PKC by redox signalling, and ultimately 
results in inhibition of the mPTP opening at reperfusion (see figure 1.4) (Davidson et 
al., 2006; Gross et al., 2006; Hausenloy et al., 2002; Hausenloy et al., 2005a; 
Hausenloy et al., 2004; Javadov et al., 2003; Lecour et al., 2005; Matsumoto-lda et al., 
2006; Solenkova et al., 2006). It is unknown if bradykinin signals through an EGF 
receptor or whether it activates a different metalloproteinase to activate PI3K and the 
subsequent downstream effectors (Critz et al., 2005). The signalling events that occur 
during IPC are therefore considered of importance at reperfusion.
The exact mechanism of RISK pathway recruitment at reperfusion is unclear, but 
several mechanisms have been proposed. A possible mechanism of protection 
induced by IPC is that kinase activation, initiated by ischaemic preconditioning, needs 
to be sustained into reperfusion to induce cardioprotection. It has been shown that 
Akt activation needs to be continued for the initial 50-60 minutes of reperfusion 
(Solenkova et al., 2006). However, whether activation of kinases can be maintained 
during ischaemia is questionable. Interestingly at reperfusion adenosine receptors 
must be repopulated for IPC to protect the heart, this is presumed to be through an 
A 2b receptor (Solenkova et al., 2006). The threshold for activation of these low affinity 
receptors is lowered by PKC activation, allowing endogenous adenosine released 
during ischaemia to be protective during ischaemia. Recently Urn et al. (2007) 
proposed that during the ischaemic preconditioning stimulus there may be non- 
pathological opening of the mPTP, inducing a mild form of mitochondrial stress, which 
acts as a trigger for adaptation. Therefore the mPTP could be acting as a mediator of 
cardioprotection prior to ischaemia.
1.6.1.2 Clinical intervention with ischaemic-preconditioning
The potential of IPC as a clinical cardioprotective strategy has yet to be fulfilled 
because of the unpredictable nature of AMI and the need for intervention prior to an 
ischaemic episode (Hausenloy et al., 2008). However, in scheduled surgical 
interventions such as elective coronary artery bypass graft, or in unstable angina 
which often precedes AMI, the ischaemic episode can be predicted and this 
cardioprotective strategy could be of greater clinical benefit.
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1.6.2 Pharmacological preconditioning
Ischaemic preconditioning can also be mimicked by perfusing the heart with drugs in 
the place of brief ischaemic episodes, and is termed pharmacological preconditioning. 
Pharmacological preconditioning has been observed with many agents including 
acetylcholine (Critz et al., 2005), bradykinin (Critz et al., 2005), opioids (Peart et al.,
2005), and volatile anaesthetics (Bienengraeber et al., 2005). Pharmacological 
preconditioning is thought to occur via a similar mechanism to IPC.
1.6.3 Differences in kinase recruitment between iPC and pharmacological IPC
Despite ischaemic preconditioning and pharmacological preconditioning producing 
ultimately the same cardioprotective effect through activation of the RISK pathway 
and inhibition of the mPTP, there appear to be some differences between the 
recruited components of the RISK pathway. For example ischaemic preconditioning 
appears to activate p38 and Erkl/2 at reperfusion, whilst pharmacological 
preconditioning with isoflurane only causes activation of Erkl/2 (da Silva et al., 2004). 
In addition TNF-a appears to activate STAT-3 to induce cardioprotection and not 
through the conventional activation of the RISK pathway via Akt and Erkl/2 activation. 
These findings imply that there are potentially multiple kinases that may become 
activated during ischaemic preconditioning, but which all appear to converge on 
causing inhibition of the mPTP opening at reperfusion. Flow all of these kinases 
interact and the exact mechanism of action is currently unknown.
1.7 Ischaemic postconditioning
Ischaemic postconditioning (IPOST) was first reported in 2003 by Zhao et al. (2003b) 
who reported that three, 30 second intermittent periods of left coronary artery 
occlusion at the onset of reperfusion, after a 60 minute occlusion period, caused 
significant infarct limitation in dog hearts (44%), comparable to that seen by IPC 
(40%).
IPOST was an extremely important discovery for several reasons. Firstly it is clinically 
relevant to patients who sustain an AMI because it is a therapeutic intervention that
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can be applied at reperfusion (Hausenloy et al., 2008). Secondly, it increased the 
research interest in cardioprotective intervention at reperfusion (Vinten-Johansen et 
al., 2005). Thirdly, there was finally convincing evidence for reperfusion injury being a 
distinct entity (Yellon et al., 2006). Interestingly, ischaemic pre- and postconditioning 
are not additive (Tsang et al., 2004), despite there being a significant similarity in the 
kinases activated by both interventions (Hausenloy etal., 2005b).
1.7.1 Mechanism of action
Several studies investigating the mechanism of action of ischaemic-postconditioning 
have demonstrated a reduction in oxidative stress (Sun et al., 2005), mitochondrial 
calcium accumulation (Sun et al., 2005), improved endothelial function (Zhao et al., 
2003b) and reduced inflammation (Zhao et al., 2003b). Ischaemic postconditioning 
has also been shown to confer cardioprotection through the inhibition of mPTP 
opening (Argaud et al., 2005; Bopassa et al., 2006), in a similar fashion to ischaemic 
preconditioning. The involvement of the RISK pathway in pharmacological 
postconditioning was first demonstrated in 2002 by Schulman et al. (2002), by 
demonstrating that administration of urocortin at the time of reperfusion protected 
the intact heart from reperfusion injury both in vitro and in vivo, thorough the up- 
regulation of the Erkl/2-dependent signalling pathway. They proposed that the 
hearts possessed a pro-survival reperfusion injury salvage kinase pathway that had the 
potential to be exploited by pharmacological agents to protect the myocardium 
against lethal reperfusion injury. Subsequently from these findings the concept 
extended beyond the classical RISK pathway (P13k/Akt and ERK) to include other pro­
survival kinases such as PKG, PKC-e, ps70S6K and GSK-30.
A recent publication by Skyschally et al. (2009) questioned the activation of the RISK 
pathway in postconditioning in an in vivo pig study. They observed an increase in RISK 
pathway protein phosphorylation at reperfusion in both postconditioned and normally 
reperfused hearts, despite a reduction in infarct size. In addition inhibition of PI3K 
with wortmanin did not block the cardioprotective effect of postconditioning.
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There still remains some controversy about the use of ischaemic postconditioning as a 
cardioprotective strategy, as several research groups have reported the inability to 
reproduce data (Dow et al., 2007; Schwartz et al., 2006). It has been suggested that 
ischaemic postconditioning is only effective if the preceding ischaemic period does not 
exceed 45 minutes in rodents (Tang et al., 2006b). Postconditioning is clearly a more 
recent discovery and investigation into the mechanism of action and application of 
this potential cardioprotective strategy are still evolving.
1.7.2 Clinical intervention with ischaemic-postconditioning
There have been several small scale clinical trials conducted to investigate the 
potential cardioprotective effect of ischaemic postconditioning. This involves using an 
invasive technique in which several cycles of low pressure coronary angioplasty 
balloon inflation and deflations are performed in the coronary artery immediately 
following functional reperfusion. It has been demonstrated that ischaemic- 
postconditioning is cardioprotective in patients undergoing primary percutaneous 
coronary intervention for Ml, measured by a reduction in infarct size, attenuated ST 
segment elevation, and improved coronary blood flow and myocardial reperfusion 
(Laskey, 2005; Ma et al., 2006; Staat et al., 2005). A recent study by Thibault et al. 
(2008) showed that IPOST produced a persistent reduction in infarct size and 
improved long-term functional recovery in patients with acute myocardial infarction. 
These findings provide much promise for a post-ischaemic cardioprotective 
intervention.
1.7.3 Differences in kinase recruitment between iPC and IPOST
Various studies investigating the key components of the cardioprotective signalling 
pathways have provided convincing evidence to show that most, if not all, of those 
involved in early reperfusion in the post-conditioned heart are the same as those 
observed during the trigger phase of IPC (Penna et al., 2006a; Penna et al., 2006b; 
Tsang et al., 2004; Yang et al., 2005b; Yang et al., 2004). Perhaps the most profound 
evidence is the observation that combining IPC and IPOST resulted in no additional 
cardioprotection (Yang et al., 2004). However, connexin-43 has recently been shown
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to be an essential feature of IPC, but not required for IPOST (Heusch et al., 2006; 
Schulz et al., 2007).
Chapter 1 Part II
1.8 Endogenous gaseous mediators
Since the discovery that gases can be endogenously produced by living cells, gaseous 
mediators have received increasing interest over the past two decades as biological 
mediators. Gases have a special advantage as biologically active mediators because 
being small molecules they can infiltrate the 3-dimensional structure of receptors, 
enzymes and channels and alter their chemical structure to affect biological function 
(Tang et al., 2006a). Nitric oxide (NO) and carbon monoxide (CO) have previously 
been identified as gaseous mediators (Cao et al., 2001; Furchgott et al., 1980; Wang, 
1998). Hydrogen sulphide (H2S) is commonly recognised and described as a gas with 
an offensive odour of rotten eggs (Petersen, 1977). The toxicology of H2S has received 
the greatest attention in the biological literature, dating from the 1713 treatise De 
Morbis Artificum Diatriba (Treatise On the Diseases of Workers) by the Italian 
physician Bernardino Ramazzini (Lambert et al., 2006) who described the irritant and 
toxic effects of the gas in occupational exposure. A physiological role of H2S in 
mammalian tissues was first proposed in 1989 when endogenous levels were detected 
in the rat brain (Warenycia et al., 1989) and normal human post-mortem tissues 
(Goodwin et al., 1989). Since this discovery H2S has received increasing interest and is 
now regarded along with CO and NO as an endogenous gaseous mediator produced 
by regulated pathways and exerting discrete physiological actions (Wang, 2002). The 
recent discovery of endogenous sulphur dioxide (S02) (Du et al., 2008), demonstrates 
just one of many potential endogenous gaseous mediators that are yet to be 
discovered.
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1.8.1 Classification criteria for a gaseous mediator:
The following criteria have been proposed for a substance to qualify as a gaseous 
mediator (Wang, 2003):
1. It is a small molecules of gas
2. It is freely permeable to membranes. As a result their effects do not rely on 
cognate membrane receptors, and they have endocrine, paracrine and 
autocrine effects
3. It is endogenously and enzymatically generated and regulated
4. It has well defined and specific functions at physiologically relevant 
concentrations
5. Its cellular effects may or may not be mediated by second messengers, but 
should have specific targets
H2S appears to satisfy these criteria, justifying its classification as a gaseous mediator.
1.9 Biochemistry of H2S
1.9.1 Biosynthesis of H2S
H2S is a reactive thiol with strong reducing activities. It is produced predominantly by 
the tissue-specific enzymes that regulate the metabolic pathways for sulphur- 
containing amino acids, principally methionine. The two key enzymes are 
cystathionine-P-synthase (CBS) or cystathionine-y-lyase (CSE). Both are pyroxidal-5'- 
phosphate-dependent (P-5'-P) enzymes, that use L-cysteine, derived from the dietary 
amino acid methionine, as their principal substrate (Hosoki et al., 1997). Catabolism 
of methionine-derived homocysteine to L-cysteine occurs in cardiovascular cells and 
tissues as well as in the liver (Chen et al., 1999) through the transsulfuration pathway 
which is initiated by CBS (as summarised in Figure 1.5). This catalyses a p-replacement 
exchange reaction between the hydroxyl group of serine and the thiolate of 
homocysteine to form cystathionine which is converted to L-cysteine and a- 
ketobutyrate by CSE (Chen et al., 1999). L-cysteine then forms the endogenous 
substrate for H2S production. A third H2S synthesizing enzyme, 3-
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mercaptosulfurtransferase (MST), also exists (Tang et al., 2006a). The initial stage of 
H2S production involving MST involves the conversion of L-cysteine to 3- 
mercaptopyruvate by cysteine aminotransferase (Stipanuk etal., 1982).
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Figure 1.5 The primary enzymatic route o f H2S production uses the tissue specific 
enzymes cystathionine-y-lyase (CSE) and cystathionine-/3-synthase (CBS) using L- 
cysteine as substrate. In mitochondria cysteine can be converted to 3- 
mercaptopyruvate forming the substrate fo r H2S production using mercaptopyruvate 
sulphur transferase (MPST) enzyme. MAT = methionine adenosyltransferase, GNMT = 
glycine N-methyltransferase, CDO = cysteine deoxygenase, CSD = cysteine 
dehydrogenase, AAT = aspartate aminotransferase, TSR = thiosulphate sulphur, TSST = 
thiosulphate sulphur transferase, SO = sulphite oxidase, GSH = glutathione, TSMT = 
thiol-S-methyltransferase, S0 = elemental sulphur.
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1.9.2 Localisation and expression of H g  synthesising enzymes
There is strong evidence to suggest that the cardiovascular system is an endogenous 
source of H2S generation (Hosoki et al., 1997). This evidence includes both the 
expression of H2S-generating enzymes CBS, CSE and MST within the vasculature and 
heart, and the detection of H2S within these tissues.
CBS activity has been reported in rat liver, pancreas and kidney, in human brain and 
liver, and in mouse pancreas, liver, kidney and brain (Hosoki et al., 1997). CBS is most 
abundantly expressed in the CNS (Moore et al., 2003). The low abundance or absence 
of CBS in rat vasculature tissue has been reported (Zhao et al., 2002). However, CBS 
expression in human umbilical vein endothelial cells has been shown to be elevated 
when they are cultured in the presence of high concentrations of homocysteine. In 
contrast, expression of CSE is reported to be highest in cardiovascular tissues, and is 
absent in brain and lungs (Abe et al., 1996). CSE mRNA has been detected in the rat 
pulmonary artery, thoracic aorta, tail artery and mesenteric artery (ranked in order of 
expression levels of CSE mRNA) (Zhao et al., 2001a). CSE mRNA is found in vascular 
smooth muscle cells but not in the endothelium, unlike NO synthase which is found in 
both endothelial cells and smooth muscle cells (Zhao et al., 2001a). It has not been 
possible to correlate the mRNA levels for CSE to H2S levels in different vascular tissues 
because the protein expression of CSE has not been determined (Wang, 2003), 
although it has been shown that vascular tissues produce measurable amounts of H2S 
(Hosoki et al., 1997). CSE is also present in the heart.
MST receives relatively little coverage in the literature although its presence has been 
reported in the proximal tubular epithelium in the kidney, pericentral hepatocytes in 
the liver, cardiac tissue, and in the brain (Griffith, 1987). The MST pathway is reported 
to contribute to H2S production in the myocardium (Griffith, 1987; Swaroop et al., 
1992). In mitochondria, MST can produce H2S from 3-mercaptopyruvate or oxidise its 
sulphur to sulphite and thiosulphate. In the cytosol, thiocysteine formed by CSE can 
act as an acceptor of the sulphur transferred from 3-mercaptopyruvate by MST (Tang 
et al., 2006a).
37
Chapter 1 General Introduction
1.9.3 Physiological concentrations and metabolism of HzS
H2S is detectable within blood and many tissues (see Figure 1.6). In some reports, 
concentrations of up to 160 pM in brain and 100 pM in blood are quoted. Although 
the liver has a high H2S-generating capacity and may be responsible for maintaining 
the concentration of H2S in the blood, 100 pM H2S would be readily detectable by the 
human nose while, clearly, blood does not normally smell of free H2S. There is some 
uncertainty about the reliability of H2S assay methods and the fact that total sulphate 
and sulphite has been measured in some studies, rather than free H2S, may account 
for this apparent anomaly. However, concentrations of unoxidised H2S are detectable 
although likely to be far lower than initially estimated.
Organ/location Species H2S conc. (pM) Reference
Rat 1 0 (Mason et al., 1978)
Blood
Human 1 0 - 1 0 0 (Richardson et al., 2000)
Rat 46 (Mason et al., 1978)
Plasma
Human 160 (Abe et al., 1996)
Brain
Rat
Human >- 50 -16 0
(Goodwin et al., 1989)
Bovine
(Warenycia et al., 1989)
Figure 1.6 Summary o f the endogenous tissue concentrations o f H2S in rat, bovine; 
and human. Note that all the concentrations are in the micro-molar range, which 
would be readily detectable by the human nose, but despite this human blood does not 
normally smell o f free H2S.
Intracellular and tissue concentrations of H2S appear to be regulated by a number of 
metabolic pathways. Metabolism is principally via oxidation in mitochondria, or by 
cytosolic methylation. H2S can also be scavenged by methaemoglobin, metallo- or 
disulphide-containing molecules such as oxidised glutathione (Beauchamp et al.,
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1984). H2S is excreted mainly by the kidney as free or conjugated sulphate 
(Beauchamp etal., 1984).
In LPS induced endotoxic shock in the rat, inhibition of H2S synthesis lowers ALT levels, 
which is a specific marker for hepatic parenchymal injury in the liver (Collin et al.f
2005). This was implied by Zhao et ol. (2003a), who also showed that the production 
of H2S in the rat liver was greater than in the vascular tissue, suggesting that the liver 
may be responsible for maintaining the concentration of H2S in circulation.
1.9.4 Toxicity o f H g :
The threshold of detection of H2S by the human nose is between 0.02 and 0.13 ppm 
(Costigan, 2003). 50% of the human population are able to detect 0.005 ppm. At 
concentrations greater than 100 ppm olfactory fatigue can occur, suggesting that 
odour perception is unreliable as a warning of high exposure to H2S (Costigan, 2003). 
In humans a single short term exposure to H2S greater than 500 ppm can be fatal 
(Costigan, 2003). Exposure for a few minutes to concentrations of 1000 ppm and 
above are likely to cause rapid unconsciousness and death (Costigan, 2003). At high 
concentrations of H2S, death is caused by depression of the respiratory centres, whilst 
at lower concentrations, death is due to pulmonary oedema and congestion (Costigan, 
2003). It is estimated that H2S poisoning accounts for 30 deaths per year.
The reported toxic level of H2S is less than two fold greater than the endogenous 
levels reported in rat brains (Warenycia et al., 1989). This suggests that there must be 
a steep dose-response relationship of H2S in the physiological concentration range 
before it becomes toxic (Zhao et al., 2001a). Therefore there must be a fine 
homeostatic control mechanism to regulate H2S levels at a physiological level (Wang
2003). The LD50 for H2S in the rat has been reported as 15mg/kg (192 pmol/kg) 
(Warenycia et al., 1989).
Acute intoxication of H2S results in a loss of central respiratory drive (Costigan, 2003). 
H2S acts by complexing with the Fe3+ of mitochondrial cytochrome oxidase resulting in
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the blockade of oxidative metabolism. It may also target carbonic anhydrase 
(Mangani etal., 1992) and monamine oxidase (Warenycia etal., 1989).
1.10 H2S interaction with NO
A specific sulphide receptor has not been identified, but H2S is known to interact with 
other biological mediators and signal transduction components to produce its effects 
in the cardiovascular system. It has been reported that there is an interaction 
between NO and H2S, since the production of both gases can be increased by pro- 
inflammatory mediators in haemorrhagic shock (Mok et al., 2004) and bacterial 
lipopolysaccharide (Li et al., 2005). However, the precise relationships between H2S 
and NO and the physiological significance of their interactions are far from clear. H2S 
has been shown to both enhance (Zhao et al., 2002) and attenuate (Hosoki et al.,
1997) the relaxant effect of NO in the rat aorta, whilst NO has been shown to enhance 
the release of H2S in rat vascular tissues and increase the expression of CSE in cultured 
vascular smooth muscle cells (Zhao et al., 2001a). There is evidence that NO and 
peroxynitrite react with H2S to form a novel nitrosothiol, which has been proposed to 
regulate the physiological effects of NO and H2S (Whiteman et al., 2006).
In homogenates of rat aorta, NO donors increased CSE-dependent H2S generation in a 
cGMP-dependent manner (Zhao et al., 2003a). Prolonged incubation of cultured 
vascular smooth muscle cells with NO donors produced an increase in CSE mRNA and 
protein levels (Zhao et al., 2001a). Conversely, circulating H2S levels, CSE gene 
expression and enzymatic activity in the cardiovascular system were reduced in rats 
chronically treated with an NO synthase inhibitor, highlighting the physiological 
significance of NO in the regulation of H2S production in the cardiovascular system 
(Lowicka et al., 2007). Interestingly H2S (50-200 pM) has been shown to inhibit NO 
production and down regulate inducible NO synthase expression in 
lipopolysaccharide-stimulated macrophages via a mechanism that involves heme 
oxygenase expression and CO production (Oh et al., 2006). The H2S donor compound 
NaHS has also been shown to inhibit the activity of eNOS in a concentration 
dependent manner, in a biochemical assay using recombinant bovine eNOS (Kubo et 
al., 2007).
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As well as NO regulating H2S generation, endogenous H2S has been proposed to have 
a role in the regulation of vascular NO production (AN et al., 2006). Combining NaHS 
with NO donor compounds inhibited the vasorelaxant effect of acetylcholine and 
histamine, in rat aortic rings. Intravenous infusion of NaHS in anaesthetised rats 
caused a significant increase in mean arterial blood flow, which was reduced in the 
presence of the NO synthase inhibitor L-NAME. These findings suggest that H2S and 
NO react together under physiological conditions to form a product that has little or 
no vascular activity in vitro or in vivo. This molecule may be a nitrothiol as previously 
proposed by Whiteman et ol. (2006). Therefore, it is conceivable that a major 
physiological role of H2S in the vasculature may not be to act as a vasodilator, but 
rather to regulate local concentrations and activity of NO. Furthermore, the 
observation that concentrations of H2S (200 pM) greater than those found 
physiologically (50-160 pM) are needed to produce a vasodilator response (AN et al.,
2006), supports a regulatory role of native H2S in the vasculature, as opposed to a 
direct vasodilator effect.
1.11 General physiology of H2S in cardiovascular tissues
1.11.1 Regulation of vascular tone
Hosoki et al. (1997) showed that exogenous H2S produced concentration-dependent 
relaxations of rat thoracic aorta and portal vein and guinea pig ileum. Zhao et al. 
(2001a) subsequently reported that intravenous bolus injections of H2S caused a 
transient decrease in the blood pressure of rats. This hypotensive effect was 
mimicked by the K At p  channel opener pinacidil and blocked by glibenclamide, a K ATp 
channel blocker. Since heart rate was not significantly affected, the in vivo action of 
H2S was believed to be specific to vascular smooth muscle. Exogenous H2S caused 
relaxation of precontracted rat isolated aortic rings. These effects were again blocked 
by glibenclamide and mimicked by pinacidil confirming the involvement of K At p  
channel opening as a key mechanism of the vasorelaxant effect (Zhao et al., 2001a). 
However, a recent study investigating the effect of H2S in aortic rings has questioned 
the role of K ATp channels (Kubo et al., 2007) since glibenclamide did not inhibit the 
actions of H2S in mouse aortic rings. It is also uncertain whether endogenous H2S is a
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vasorelaxant under normal physiological conditions, since the vascular effect of H2S is 
dependent on tissue concentration. There is also evidence that H2S promotes rapid 
vasoconstriction in well-oxygenated isolated vessel models (Koenitzer etal., 2007). Ali 
et al. (2006) have also shown that concentrations of NaHS (10-100 pM) that cause 
constriction of aortic rings are attenuated after removal of endothelial cells, 
suggesting an indirect effect of H2S on vascular smooth muscle cells. Concentrations 
of NaHS greater than 100 pM resulted in aortic relaxation. This dual vasodilator and 
vasoconstrictor effect of H2S has also been observed in human intestinal mammary 
artery. These apparently contradictory findings are consistent with the notion that 
there may be a role of H2S to quench NO when applied at low concentrations, 
resulting in constriction. There also appears to be a time dependent effect of NaHS 
administration which determines its effective concentration.
H2S donors in animals produce a transient hypotensive effect, whilst pharmacological 
inhibitors of enzymatic H2S production have no haemodynamic effect (Zhao et al., 
2001a). This is in distinction to NO synthesis inhibitors which cause a significant 
vasoconstrictor effect in normal animals and increase peripheral vascular resistance 
(Koenitzer et al., 2007). These findings suggest that under normal physiological 
conditions H2S may not be directly responsible for regulating blood pressure but does 
so via its interaction with the NO pathway (Ali et al., 2006). However, Yang et al. 
(2008) recently showed that CSE knock-out mice exhibited pronounced hypertension 
and diminished endothelium dependent vasorelaxation, suggesting that H2S may in 
fact be a physiological vasodilator and regulator of vascular blood pressure.
In disease states, it is possible that alterations of H2S generation play a more direct 
role in influencing vascular tone. In lung tissue from rats with experimentally induced 
hypoxic pulmonary hypertension and in in vivo hypertensive rats, a reduction in CSE 
expression and activity was seen (Chunyu et al., 2003; Zhong et al., 2003). Parenteral 
administration of H2S opposed a rise in pulmonary arterial pressure and in part 
prevented pulmonary vascular remodelling, identified by the thickness of the vascular 
wall in isolated rat lung (Chunyu et al., 2003). This implies that H2S deficiency might 
be related to pulmonary vasoconstriction and intimal thickening which are
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pathological factors associated with pulmonary hypertension (Moore et al., 2003). In 
rats, the NO synthase inhibitor L-NAME produced a time dependent elevation in 
systolic blood pressure associated with inhibition of CSE gene expression and H2S 
production. Exogenous H2S prevented the development of hypertension induced by L- 
NAME (Zhong et al., 2003).
There is also the possibility that excessive levels of H2S could contribute to 
hypotension associated with either sepsis or endotoxaemia. In endotoxin-treated rat 
arteries there was significant elevation of H2S production (Hui et al., 2003). 
Endogenous H2S has been shown to play a role in haemorrhagic shock in the rat (Mok 
et al., 2004). In rats, withdrawal of blood induced haemorrhagic shock with profound 
lowering of arterial blood pressure, associated with a transient increase in plasma H2S 
levels beyond 60 minutes. Inhibitors of CSE produced a partial restoration of the 
lowered arterial blood pressure in a time-dependent manner. Pre-treatment with a 
CSE inhibitor increased the arterial pressure after 60 minutes, suggesting that H2S 
does not have a role in the immediate response to haemorrhagic shock, but is 
involved in the later stages (Mok et al., 2004). Liver CSE mRNA was also significantly 
increased after 60 minutes (Mok et al., 2004). However, the cells/tissues responsible 
for increased synthesis of H2S after blood withdrawal are unknown. Therefore further 
studies are required to identify the cell types involved in H2S synthesis following 
haemorrhagic shock.
1.11.2 Effects on angiogenesis
Cai et al. (2007) reported a pro-angiogenic role of H2S and a potential for the 
involvement of the prosurvival PI3K/Akt signalling pathway. The pro-angiogenic effect 
of H2S (10-20 pM) was observed in an in vitro endothelial cell culture assay. The 
ability of H2S to promote proliferation, adhesion, migration, and tube-like structure 
formation in endothelial cultures was observed. The PI3K inhibitor LY294002, 
inhibited the pro-angiogenic effects of H2S in endothelial cells. Interestingly, NaHS 
was also shown to increase Akt phosphorylation, which was inhibited in the presence 
of the PI3K inhibitors LY294002 and wortmanin. These observations suggest that H2S 
may illicit its pro-angiogenic effect via PI3K/Akt signalling. A pro-angiogenic role of
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H2S, at physiologically relevant concentrations (10-50 pmol/kg/day), was also 
demonstrated in an in vivo mouse matrigel plug assay (Cai et al.f 2007). There appears 
to be no other published work to date on this potentially novel therapeutic approach.
1.11.3 Vascular smooth muscle cell proliferation
S-diclofenac, a novel H2S releasing derivative of a non-steroidal anti-inflammatory 
drug (NSAID), has been shown to inhibit aortic smooth muscle cell proliferation 
(Baskar et al., 2008). The anti-apoptotic effect of H2S in smooth muscle cells has also 
been demonstrated using NaHS (Sivarajah et al., 2008). A mechanism of action 
involving opening of K At p  channels has been proposed (Sivarajah et al., 2008). The 
anti-apoptotic effect of H2S may be of importance for the prevention of cell 
proliferation in vascular occlusive disorders and prevent atherosclerosis, vascular graft 
occlusion and restenosis after angioplasty (Sivarajah et al., 2008). Interestingly, 
endogenously produced H2S has also been shown to have pro-apoptotic effects in 
human aortic smooth muscle cells over-expressing the H2S synthesising enzyme CSE 
(Yang et al., 2005a). The difference in findings between these studies may be as a 
result of differences in experimental protocols, or most likely the concentration of 
H2S. H2S has also been shown to concentration dependently suppress the 
proliferation of smooth muscle cells through the mitogen activated protein kinase 
(ERK1/2) pathway (Du et al., 2002).
1.11.4 Inotropic and chronotropic effects
In the heart, NaHS had a concentration-dependent negative inotropic effect in both 
isolated perfused rate hearts and in vivo rat models (Geng etal., 2004c). These effects 
were partially blocked in the presence of glibenclamide, suggesting a role of KAtp  
channel opening in mediating the inotropic effect of H2S. This is consistent with the 
negative inotropic effects of other K ATp channel activators which induce cell 
membrane hyperpolarisation. K ATp activation can also result in blockade of L-type 
calcium channels, resulting in reduced calcium entry and myocardial contractility (Cole 
et al., 1991). The effect on H2S on isolated cardiac myocyte contractility and 
electrically-induced Ca2+ transients were investigated during p-adrenergic stimulation.
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NaHS significantly attenuated the effects of isoproterenol and forskolin. NaHS also 
reversed isoproterenol-induced cAMP elevation and forskolin-stimulated adenylyl 
cyclase activity. These findings suggest that H2S may antagonise negative 
consequences of sympathetic over activation by generating negative feedback to 
cAMP production (Yong etal., 2008b).
NaHS has been shown to exert a concentration-dependent negative chronotropic 
effect in rat isolated hearts (Ji et al., 2008). This action has also been observed in mice 
receiving 1 mg/kg NaHS at reperfusion in an in vivo model (Elrod et al., 2007). NaHS 
also caused a concentration-dependent reduction in the firing rat of rabbit pacemaker 
cells in sinoatrial nodes. This negative chronotropic effect was blocked in the 
presence of glibenclamide, again implicating an increase in potassium efflux through 
the K At p  channels to mediate the effect in pacemaker cells (Xu et al., 2008).
Two emerging areas of H2S biology that may have particular pathophysiological and 
therapeutic applications will now be discussed.
1.12 Cytoprotective actions of H2S in myocardial ischaemia/reperfusion injury
During the last 20 years, a number of endogenous mediators have been observed to 
play key roles in determining the cellular responses to ischaemia/reperfusion, 
attenuating the processes of irreversible injury that result in cell death, as described in 
Part I. A number of these mediators, or chemical derivatives of them participated in 
IPC and/or IPOST (Ferdinandy et al., 2007). Recent evidence suggests that H2S may 
exert preconditioning and postconditioning cytoprotective actions. Geng et al. (2004a) 
showed that H2S could be endogenously generated in the heart as a physiological 
cardiac regulator protecting cardiac function. In rat hearts subjected to isoprenaline- 
induced necrosis, exogenous H2S caused a reduction in mortality and improved 
cardiac function (Geng et al., 2004a). Johansen et al. (2006) provided the first 
evidence that exogenous H2S can limit infarct size induced by ischaemia/reperfusion in 
the rat heart in a concentration-dependent manner. It was shown that the K At p  
channel blockers glibenclamide or sodium 5-hydroxydecanoate (mitochondrial K At p  
channel selective blocker) attenuated the protective effect of NaHS, supporting the
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involvement of K At p  channel opening in the protective mechanism of action. Bian et 
al. (2006) further reported that exogenous H2S (33 jxM) reduced the incidence and 
severity of ischaemia/reperfusion arrhythmias in the isolated rat heart.
The evidence summarised above suggests that exogenously administered H2S is 
protective. There is however a discordance in the literature regarding the role of H2S 
in ischaemic preconditioning. Bian et al. (2006), Pan et al. (2006), and Hu et al. (2008) 
showed endogenous H2S to play a protective role, whilst Siverajah et al. (2006) 
showed no involvement of endogenous H2S. Whether endogenously-generated H2S 
plays a role in the natural phenomenon of ischaemic preconditioning is an unresolved 
issue.
1.13 Pro- and anti-inflammatory actions of H2S
There is currently considerable interest in the roles of H2S as a mediator in 
inflammation. The majority of in vivo models imply that H2S is a pro-inflammatory 
mediator (Lowicka et al., 2007). For example it has been reported that the plasma H2S 
concentration, and CSE expression and activity are increased in lipopolysaccharide- 
treated mice (Li et al., 2005) and in a caecal ligation and puncture model of sepsis in 
the mouse (Zhang et al., 2006). The findings of the latter study imply that H2S 
enhances the inflammatory response and end organ damage associated with sepsis. 
For example, in a mouse lung and liver model of sepsis, the CSE inhibitor compound 
PAG was shown to attenuate the inflammatory response, indicated by a reduction in 
myeloperoxidase activity, a marker of neutrophil infiltration. PAG was also shown to 
reduce mortality after caecal ligation and puncture (Zhang et al., 2006). The 
mechanism through which H2S exerts these pro-inflammatory actions in vivo is 
unclear.
Data from in vitro models are more ambiguous and support anti-inflammatory actions 
of H2S. H2S donors have been shown to inhibit aspirin-induced leucocyte adhesion to 
the endothelium of rat mesenteric venules, whilst inhibitors of H2S synthesis caused 
an increased adhesion of leucocytes (Zanardo et al., 2006). CSE expression has also 
been shown to be up-regulated by LPS and pro-inflammatory cytokines (Nagai et al.,
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2004), which could account for the increased H2S production during inflammation. 
Overproduction of H2S during inflammation may be detrimental by enhancing the 
inflammatory response and associated tissue damage. For example fMLP-activated 
neutrophils are able to non-enzymatically covert H2S to sulphite in an NADPH and ROS 
dependent manner (Mariggio et a!., 1997). An increased concentration of serum 
sulphite was observed in LPS-treated rats (Mitsuhashi et al., 1998) and in patients with 
pneumonia (Mitsuhashi et al., 2004). Sulphite is highly toxic, despite low levels having 
an important bactericidal action. Sulphite stimulates the production and release of 
ROS from neutrophils (Labbe et al., 1998) and the adhesion of neutrophils to the 
endothelium (Shigehara et al., 2002). It can also react with peroxynitrite to form toxic 
sulphur radicals (Reist et al., 1998). Therefore there appears to be a paradoxical role 
of H2S in inflammation, because whilst a small increase in H2S production enhances 
non-specific host defence, an excessive concentration may result in inflammation and 
tissue damage. This may explain the differences in role of H2S in inflammation 
observed between models. It is also important to note that increased H2S 
concentrations in a given disease state may not be deleterious. It is still unclear if it is 
the increased H2S that is responsible for the pathogenesis of disease or if H2S is 
elevated in an attempt to counteract the pathogenic agent.
H2S has been shown to up-regulate anti-inflammatory and cytoprotective genes 
including heme-oxygenase in pulmonary smooth muscle cells In vivo (Oh et al., 2006), 
and macrophages in vitro (Qingyou et al., 2004). The up-regulation of heme- 
oxygenase is thought to occur downstream of ERK activation and results in the 
production of CO, a well characterised cytoprotectant and anti-inflammatory gas 
(Ryter et al., 2006).
In the past decade, interest in H2S as an endogenously-produced biological mediator 
has broadened research in this field considerably beyond its toxicology, resulting in an 
exponential increase in the annual number of published reports since 1995. The range 
of body systems and cell types extends beyond cardiovascular effects of H2S and it 
seems likely that this field of investigation is set to expand. There are still a number 
of unanswered questions surrounding its physiological and pathophysiological
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relevance and roles, notably relating to specific molecular targets of H2S and 
mechanisms of action. Indeed it is feasible that as a highly reactive thiol, native or 
unconjugated H2S reacts with numerous biological targets and elicits actions through 
multiple non-specific mechanisms.
1.14 Overview and scope of the work presented in this thesis:
Current findings from World Heath Organisation predict that as far as 2030, 
cardiovascular disease will remain the leading cause of mortality in the world 
(Mathers et al., 2006), there is a need for more effective solutions to protect patients 
suffering from acute myocardial infarction. Due to the unpredictable nature of the 
onset of acute myocardial infarction, clinical therapies should ideally be aimed at the 
time of reperfusion when flow is restored to the heart and minimise reperfusion 
injury. The recent discovery of the RISK pathway, and its expanding components and 
activators, provides the basis for a greater understanding of the cardioprotective 
mechanisms that occur at reperfusion and various algorithms that can be used to 
prime this pathway, therefore suggesting a novel target for cardioprotection. The 
increased interest in H2S over the past decade has led to its discovery in the 
myocardium and also revealed the potential cardioprotective effect of exogenous H2S, 
suggesting a potential endogenous mediator of cardioprotection. However, there is 
only a weak characterisation of the enzymes that synthesise H2S in the myocardium 
and the effect of ischaemia-reperfusion on their ability to function. As yet a 
pharmacological target for H2S has not been identified or a specific mechanism of 
action determined.
Major points of focus:
The aim of the studies described in this thesis was to characterise H2S synthesis in the 
myocardium and elucidate potential cardioprotective roles of H2S during ischaemia- 
reperfusion.
The general hypothesis underpinning this work was that H2S synthesising enzymes 
exist in the myocardium and the resulting H2S provides cardioprotection against 
ischaemia-reperfusion.
48
Chapter 1 General Introduction
The specific questions addressed are:
1. Does the rat myocardium contain H2S synthesising enzymes and is there a 
predominant isoform?
2. What effect does ischaemia-reperfusion have on the ability of the rat 
myocardium to synthesise H2S?
3. Does exogenous or endogenously stimulated H2S protect the rat myocardium 
against regional ischaemia-repefusion injury?
4. Does H2S activate the RISK pathway to induce cardioprotection in the rat 
myocardium?
The approach to these scientific questions involved using a variety of experimental 
techniques and rat myocardium. The techniques undertaken included PCR and 
Western blotting to identify the presence of the mRNA and protein for the H2S 
synthesising enzymes in rat myocardium (Chapter 3). Cloning of the H2S synthesising 
enzymes and transfection into cell lines, to validate the specificity of a custom 
synthesised antibody to CSE used for Western blotting studies. Isolated perfused rat 
hearts were used to investigate the effect of regional ischaemia-reperfusion and 
observe the effects of exogenous and endogenously stimulated H2S on infarct size 
limitation (Chapter 4). The isolated perfused hearts were also used to decipher the 
mechanism of cardioprotection elicited by H2S by use of pharmacological tools to 
inhibit components of the RISK pathway (Chapter 6). Biochemical assays were also 
performed to measure the tissue concentration of H2S and also determine the 
maximal H2S synthesising capacity of exogenously stimulated enzymes and observe 
the effect of ischaemia and reperfusion (Chapter 5).
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Chapter 2: General methods
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2.1 Langendorff perfused isolated rat hearts
2.1.1 Isolated perfused rat hearts according to Oscar Langendorff
In 1897 Oscar Langendorff developed his isolated perfused mammalian heart 
preparation (Skrzypiec-Spring et al., 2007). Prior to his discovery, the idea of perfusing 
mammalian hearts had been briefly investigated by Carl Ludwig (Zimmer, 1998). 
However their model was of limited success because the hearts being perfused were 
empty, beating, non-ejecting hearts and were of limited physiological value. Isolated 
frog hearts had also been perfused, a technique discovered by Elias Cyon in 1866 
(Zimmer, 1998), but these hearts lacked coronary arteries and again this model was of 
limited physiological value. Langendorffs technique was unique because he was able 
to maintain perfusion of hearts for several hours in a model that mimicked the 
physiological flow of blood through the heart (Zimmer, 1998). Langendorff was the 
first to demonstrate that the coronary arteries are responsible for the delivery of 
oxygen and nutrients to the heart and the cardiac mechanical function is reflected by 
changes in coronary circulation (Taegtmeyer, 1995). He was also able to confirm 
previous findings relating to the negative chronotropic effect of both vagal nerve 
stimulation and administration of muscarinic agonists, demonstrated the positive 
chronotropic effect of atropine, and also discovered that postassium chloride arrests 
the heart (Taegtmeyer, 1995).
Despite many modifications over the years, the principles of Langendorffs isolated 
perfused hearts remains the same (Sutherland et al., 2000). Essentially, hearts are 
cannulated via the ascending aorta and perfused with either blood or a crystalloid 
buffer. The force of the perfusate forces the aortic value shut, resulting in retrograde 
flow of the perfusate through the coronary arteries via the ostia at the aortic root. 
The perfusate then drains into the right atrium and exits the heart via the coronary 
sinus (Sutherland et al., 2000).
The Langendorff isolated perfused heart model has been used widely in cardiovascular 
research over the past century due to its ability to produce highly reproducible data, 
relative low cost, and the ability to measure a wide range of experimental parameters.
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2.1.2 Animal species for use in Langendorff isolated heart perfusion
The Langendorff technique is suitable for any mammalian heart, although Langendorff 
himself originally used cat hearts as well as hearts obtained from dogs and rabbits 
(Zimmer, 1998). The rat is now the most commonly used heart donor animal and is 
the most characterised (Sutherland et al., 2000). More recently, with the emergence 
of knock-out mice the mouse heart has started to receive increased interest 
(Sutherland et al., 2000). The only limitation with the rat heart is its short action 
potential (Hearse et al., 2000). Guinea pig hearts can also be perfused, but cannot be 
used for experiments investigating regional ischaemia. This is owing to their extensive 
collateral vessels (Sutherland et al., 2000), which make the task of inducing regional 
ischaemia, via reversibly tying the left main descending coronary artery, impossible. 
Guinea pigs do however have a role in global ischaemic experiments where all the 
flow to the heart can be stopped.
2.1.3 Application of the Langendorff isolated perfused heart preparation
The Langendorff isolated perfused heart preparation can be used for a variety of 
cardiovascular studies with various parameters measured. A common application of 
this model is to measure infarct sizes in hearts subjected to ischaemia-reperfusion and 
assess the infarct limitations of potential cardioprotective or cardiotoxic drugs. 
Ischaemia can either be induced regionally by occluding flow through the left anterior 
descending coronary artery, or regional ischaemia or low flow ischaemia can be 
induced by either stopping or reducing flow respectively (Sutherland et al., 2000). 
Ischaemia can also be induced to pre- or post-condition the heart and the protective 
effect observed. Other studies include accessing arrhythmia scores as an indication of 
cardioprotection, as well as accessing the underlying cause of arrhythmias (Skrzypiec- 
Spring et al., 2007). The effects of Hypoxia and anoxia can be investigated by altering 
the oxygen content of the perfusate, which in an in vivo model may compromise the 
survival of the animal (Skrzypiec-Spring et al., 2007). The model can also be used to 
prepare heart samples for protein analysis using Western blotting and quantifying 
proteins of interest after various treatment protocols.
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2.1.4 Perfusion algorithms
There are two algorithms for perfusing isolated hearts, depending on the 
experimental parameters to be measured. A fixed pressure system is achieved by 
using a constant hydrostatic pressure of the perfusate. This is achieved by maintaining 
the volume of perfusate at a fixed height to generate the desired pressure. The 
advantage of this setup is that is more physiologically relevant since in vivo the mean 
perfusion pressure is maintained in the intact coronary circulation (Skrzypiec-Spring et 
al., 2007). A constant flow system can also be used which utilises a mechanical pump 
to deliver the perfusate the heart. This ensures that a constant amount of perfusate is 
delivered to the heart irrespective of the physiological functioning of the heart. This 
enables coronary perfusion pressure changes to be monitored and used as an index of 
the coronary vascular resistance. The main disadvantage of this system being the 
autoregulatory mechanisms of coronary arteries being overridden and the absence of 
shear mediated endothelium-derived relaxing factor production (Sutherland et al., 
2000). However, its advantages include: the increased ability to measure coronary 
perfusion pressure with a pressure transducer than monitor coronary flow, the 
vasoactive properties of drugs can be easily observed, and the constant flow ensures 
that the concentration of drug that reaches the heart is constant even if vasoactive 
drugs are used (Skrzypiec-Spring et al., 2007). Since the studies conducted in this 
thesis are concerned with the infarct size limitation during ischaemia-reperfusion a 
constant pressure system was used, since it is thought to be the most physiologically 
relevant in relation to ischaemia (Doring, 1990). The constant flow system overrides 
the autoregulatory mechanisms, resulting in the amount of perfusate delivered to the 
heart not being physiologically altered in response to changes in heart rate or 
contraction during ischaemia (Skrzypiec-Spring etal., 2007).
2.1.5 Limitations of the model
As with any animal model used to mimic human physiology there are limitations and 
the Langendorff isolated heart perfusion is without exception. The main disadvantage 
owing to the fact the heart is in isolation and therefore receives no neuronal input 
from the autonomic and central nervous systems, as well as no influence from other
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organs (Skrzypiec-Spring et al., 2007). This however, may be classed as an advantage 
since it allows direct actions of drugs to be observed on the heart in the absence of 
peripheral influences. As with any experimental model, the isolated heart is also a 
constantly deteriorating preparation, with an observable run-down in function over 
the course of the experiment. However, hearts maintain sufficient function for 
experiments of three hours or longer to be conducted. The robustness and 
reproducibility of the data obtained by the Langendorff isolated perfused heart 
preparation far outweigh the disadvantages and make for a very reliable model for 
investigating a variety of cardiovascular studies.
2.2 Setup of Langendorff isolated perfused hearts
2.2.1 Excision of rat heart
Male Sprague Dawley rats (270-350) were terminally anaesthetized with a mixture of 
sodium pentobarbitone (60 mg/kg) and heparin (100 units) i.p. Barbiturates are the 
anaesthesia of choice because they can be easily administered and have minimal 
depressive action on the functioning of the heart. Once the animal was under a 
suitable level of anaesthesia, as determined by lack of a pedal withdrawal reflex, a 
transabdominal incision was made to expose the xiphoid process and the diaphragm. 
A bilateral incision along the rib cage opened the thorax. The heart was exposed by 
moving the thoracic cage upwards. Once the heart was exposed it was gently cradled 
in the hand and excised to ensure a good length of aorta was obtained. The excised 
heart was then immediately arrested in ice cold modified Krebs-Henseleit buffer.
2.2.2 Cannuiation and perfusion of the isoiated rat heart
The excised cold arrested heart was carefully removed from the Krebs buffer using 
forceps and the aortic root gently opened and inserted over a plastic cannula. The 
aorta was tied to the cannula using three 3-0 silk ties, and retrogradly perfused with 
modified Krebs-Henseleit buffer (NaCI 118.5 mM, NaC0 3  24.8 mM, d-Glucose 11 mM, 
KCI 4.7 mM, MgS04.7H20  1.2 mM, KH2P04 1.2 mM, CaCI2.2H20 2.25 mM) at a constant 
perfusion pressure of 74 mmHg produced at 100 cm of water. Initially, whilst 
cannulating the aorta, the flow was reduced to aid the process, before being returned
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to full flow once the heart was in situ. Care was taken to ensure that the heart was 
orientated so that the ostium of the left anterior descending coronary artery was 
facing forward, enabling a 3-0 silk suture (Ethicon, UK) was passed around the left 
anterior descending coronary artery close to its origin near the left atrial appendage. 
A snare was formed by passing the ends of the suture through a small plastic tube. 
The snare was left un-tightened until regional ischaemia was induced at the 
appropriate time in the experiment. The left atria was cut away to reveal the entrance 
to the left ventricle. A fluid filled latex balloon was inserted into the left ventricle and 
left ventricular end-diastolic pressure set between 5 and 10 mmHg. The left 
ventricular diastolic and systolic pressures were measured at timed intervals 
throughout the experiment, by use of a pressure transducer connected to a PowerLab 
running Chart (Version 4.0). From these parameters the developed pressure in the 
heart could be calculated. The heart rate was calculated by the PowerLab data 
acquisition system by counting the number of left ventricular peaks per second which 
is then transposed into beats per minute (bpm). Coronary flow rate was measured by 
timed collection of the coronary effluent over a 30 second period and expressed as 
flow rate in mis per minute. Throughout the experiment the Krebs buffer was 
maintained at a constant 37 °C to ensure that the heart was kept normothermic. This 
was achieved by a thermostatically controlled water circulator continually pumping 
water, containing 0.5% copper sulphate to kill bacteria, through a jacketed pre­
warmer column and a Baker coil. This ensured that as the Krebs buffer flowed from 
the reservoir, passed through the pre-warmer jacket, and Baker coil before entering 
the cannula and subsequently the heart, it was maintained at 37 °C. The heart was 
also immersed in a heart jacket also connected to the circulator that ensured it 
remained normothermic especially during regional ischaemia when flow was reduced. 
The reservoirs containing the Krebs buffer were also continually bubbled with 
carbogen (95% 0 2 and 5% C02), to ensure that the pH of the Krebs buffer remained at
7.4 and to oxygenate the myocardial tissue. A K-type temperature probe, connected 
to a digital thermometer, was inserted into the pulmonary sinus to enable the internal 
temperature of the heart to be monitored during the experiment. A diagram of the 
setup is shown in figure 2.1 and heart canulation shown in detail in figure 2.2.
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Figure 2.1 Summary diagram of the Langendorff constant pressure perfused isolated rat heart. Hearts were randomised between left and right rigs to 
ensure no bias was placed on the preparations. Note that although not shown in the diagram, the pre-warmer columns, Baker coils, and heart jackets are 
connected in parallel to ensure even distribution o f pre-warmed water and constant temperature of Krebs perfusate.
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2.2.3 Treatment groups
Hearts were randomised to treatment groups to ensure no bias was placed on the 
study. The specific treatment protocols for each series of experiments are outlined in 
the subsequent experimental chapters. In all studies where infarct limitation was the 
end point of the study, the hearts received a stabilisation period ranging from 20-30 
minutes, followed by 35 minutes of regional ischaemia, and 120 minutes of 
reperfusion. 35 minutes of regional ischaemia was induced by tightening the snare 
that was placed over the suture that surrounded the left anterior descending coronary 
artery. After 35 minutes the snare was released and reperfusion commenced. This 
was characterised by an increase in coronary flow and often accompanied by 
ventricular fibrillation in the heart. 120 minutes of reperfusion was necessary for 
infarct size study experiments because it ensured that sufficient wash-out of enzymes 
and co-factors from irreversibly damaged cells, which would otherwise interfere with 
the Tetrazolium staining process.
2.2.4 Sources of rats used for isolated rat heart studies
During the course of my PhD. the source of rats obtained for the studies varied 
depending on the institution at which I studied and also the availability of rats within a 
specific weight range. However, as far as possible within each study group the source 
of animals remained constant and frequent randomisation to control showed no 
difference between sources. From the period of October 2006 to April 2007, whilst 
studying at the Royal Veterinary College London, male Sprague Dawley rats (270-350 
g) were predominantly obtained from Harlan UK Ltd. (Oxon, UK). In the instance that 
rats could not be obtained in this weight range, rats were obtained from Charles River 
Laboratories Inc. (Maidenhead, UK). Since moving to Cardiff University in April 2007, 
male Sprague Dawley rats (270-350 g) were obtained solely from B & K Universal Ltd. 
(Bristol, UK). At no point were data from control or treatment groups pooled between 
institutions. The handling, care, and experimental use of animals was conducted in 
accordance with the UK Home Office guidelines on the Animals Scientific Procedures 
Act 1986 (The Stationary Office, London, UK). Prior to use, animals were acclimatised 
in the institution animal house for 7 days. Prior to experimental usage the animals
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were subjected to 12 hour light-dark cycles and received chow, containing 4% fat and 
18% protein, and water ad lib. On the day of experimentation rats were housed in 
transportation boxes for minimal time periods before being sacrificed.
Plastic cannula o f balloon 
connected to pressure 
transducer (not shown)
Temperature probe inserted 
into pulmonary conus
Top of balloon inserted 
into left ventricle
Untied ends of silk suture 
surrounding left main 
coronary artery
Krebs perfusate 
exiting heart
Heart chamber with 
CUSO4 circulating 
at 37°C
Figure 2.2 Close-up image o f the cannulated heart. After removal o f the left atria a 
latex balloon is inserted into the left ventricle. The balloon allows a basal diastolic 
pressure to be set and allows developed pressure within the ventricle to be measured 
as well as the heart rate calculated. The Krebs perfusate, seen exiting the heart, is 
measured by timed collection to determine the flow  rate. The silk suture passed 
around the left main coronary artery can be tightened with snare to induce regional 
ischaemia. Release o f the snare allows reperfusion to occur.
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2.2.5 Exclusion criteria
To ensure that data was as reproducible within treatment groups and not biased 
between groups, strict exclusion criteria were used. Hearts were excluded from the 
study if they failed to obtain a developed pressure less than 50 mmHg during the 
stabilisation period, had a heart rate less than 200 bpm, and failed to have a flow rate 
of between 10 and 15 ml/min. Hearts were also excluded on technical grounds during 
experiments such as pulling the suture out during ischaemia, failing to reduce 
coronary flow by at least a third during the first 5 minutes of ischaemia, or failing to 
restore coronary flow at reperfusion.
2.2.6 Determination of infarct size
After 120 minutes of reperfusion, the suture around the left main coronary artery was 
tied off using a surgeons knot and the heart was perfused with 1ml Evan's blue (0.5%) 
to stain the non-ischaemic tissue (as shown in figure 2.3). The heart was then frozen 
for 24 hours at -20 °C and then cut into 5, 2 mm transverse sections using a scalpel. 
The sections were incubated in a 1% triphenyltetrazolium chloride solution (Sigma- 
Aldrich, UK) at 37°C for 20 minutes with frequent agitation. The triphenyltetrazolium 
chloride solution reacts with dehydrogenase enzymes and co-factors in the viable 
tissue to form formazin pigments which are shown as a red stain. Necrotic tissues lack 
these enzymes and therefore remain unstained and appear white. The sections were 
then fixed in formalin (3.7%) for at least 12 hours.
After fixation, the heart sections were scanned, being held in place with a transparent 
ruler which allowed calibration of the image analysis software. The use of the image 
analysis software ImageJ 1.38x (National Institute of Health, USA) enabled the three 
regions in each heart section to be digitally analysed using planimetry. During infarct 
analysis the blue region represented the normally perfused tissue, the red 
represented the risk zone, and the white unstained tissue represented the infarcted 
tissue (as shown in figure 2.3). The volumes of the regions were calculated by 
multiplying the areas by 0.2 cm (the thickness of the tissue sections). The infarct size 
was expressed as a percentage of the risk zone. The larger the infarct size the more
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severe the irreversible damage to the myocardium. Infarct sizes in hearts were 
measured blind, to ensure that no bias was placed on specific treatment groups.
Suture tied off using 
surgeons knot
Heart before occluding 
the coronary artery 
with the suture
Position of Left 
main coronary 
artery
Surgeons
knot
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perfused
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Area at risk
/  j
Infusion of Evans blue dye stains 
the normally perfused tissue. 
Heart then frozen at -20°C.
Transverse heart sections incubated 
in triphenyltetrazolium chloride at 
37°C
InfarctedNormalor ally I f r t  tissue
perfused tissue
Figure 2.3 Preparation o f Evans blue and triphenyltetrazolium chloride double stained 
transverse heart sections. The blue region represents the normally perfused tissue„  
the red represents the area at risk, and the white unstained tissue represents the 
infarcted necrotic tissue. The regions would be traced round and measured using 
planimetry software ImageJ. Volumes o f the zones are calculated by multiplying the 
areas by the thickness of the sections (0.2 cm and average between the 5 sections. A 
ruler is also scanned with the sections to calibrate the ImageJ software.
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2.3 Protein determination of tissue samples
The BCA (bicinchoninic acid) protein assay was performed to enable the colorimetric 
detection and quantification of total protein to be determined in the tissue samples. 
Protein concentrations in the tissue samples were determined with reference to 
bovine albumin serum (BSA) standards prepared at known concentrations (0-10 
mg/ml) and assayed alongside the tissue samples. The assay was performed in a 96 
well flat bottom plate. 10 pi of each sample was transferred into a 96 well flat bottom 
plate in duplicate. 200 pi of "working reagent", supplied in the Pierce BCA™ Protein 
assay kit, was added to each well and the plate placed on a shaker for 30 seconds. The 
working reagent consisted of a 50:1 mixture of solution A and B. The plate was 
covered in foil and incubated at 37 °C for 30 minutes. The plate was cooled to room 
temperature and then read on a plate reader at 562 nm. A standard curve to BSA was 
plotted in Excel and the concentrations of the protein samples determined using the 
equation for the straight line.
2.4 Statistical analysis
All numerical data are presented as arithmetic mean values ±  the standard error of 
the mean (SEM). Data analysis was performed using GraphPad Prism (Version 4.00) 
Analysis of variance (ANOVA) was used to compare the mean values of different 
groups. A test for normality for each data set was performed using the Kolmogorov- 
Smirnov test prior to ANOVA calculations. Normal distribution was observed in all 
data sets. One-way ANOVA was used to compare differences in infarct sizes and H2S 
production rates between groups. Repeated measures ANOVA was used when 
comparisons were made between the haemodynamic parameters measured in the 
Langendorff model. In all cases post hoc analysis was performed using a Newman- 
Keuls test. The probability (p) level of 5% (p<0.05) was defined as the level at which 
data was said to be significantly different and was indicated on graphs by the use of 
the standard star notation system (*). P values obtained from the statistical tests that 
was <0.01 were said to be highly significant and shown on graphs by the use of the 
standard star notation system (**).
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Chapter 3 Characterisation of the H2S synthesising enzymes cystathionine-y-lyase 
(CSE) and cystathionine-p-synthase (CBS) within the rat heart
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3.1 Introduction
It was reported in Chapter 1, that CSE was the predominant H2S synthesising enzyme 
in the myocardium (Abe et al., 1996; Geng et al., 2004c). This statement has been 
supported by numerous published studies reporting the detection of CSE mRNA 
using PCR (Abe et al., 1996; Geng et al., 2004c; Wu et al., 2006; Yang et al., 2006; 
Zhao et al., 2001a; Zhong et al., 2009; Zhong et al., 2003; Zhu et al., 2007). Whilst 
the detection of mRNA does suggest the potential for a tissue to express CSE protein, 
it does not necessarily mean that the tissue will. At the time of performing the 
Western blotting studies, there were no published studies of CSE protein expression 
in the myocardium. This is surprising given the extensive claims in the literature that 
the CSE protein predominates in the myocardium. The lack of a commercially 
available antibody probably accounts for this and also raises questionability into the 
accuracy of the published studies. It therefore appears that there is lack of in depth 
characterisation of the mRNA and protein expression of CSE in the myocardium, and 
in particular in different regions of the heart. The experiments performed in this 
chapter were an attempt to provide robust evidence for whether CSE is the 
predominant H2S synthesising enzyme in the myocardium through the use of both 
PCR to detect mRNA, and a custom synthesised antibody to CSE to detect protein. In 
addition CBS mRNA and protein expression was also explored in the myocardium to 
complete the characterisation.
3.1.1 Polymerase chain reaction (PCR)
PCR is a commonly used technique for the detection of DNA for a specific gene of 
interest, which was first introduced by Mullis in 1983 (1992). The technique relies on 
the use of specific primers, which are short sequences of around 20 bases that are 
complimentary to a sequence of DNA on the gene of interest. Both forward (3'-5') 
and reverse (5'-3') primers are used which enables a specific DNA sequence, usually 
up to lOkb, of interest to be amplified. The PCR reaction involves using a 
thermocycler to repeatedly heat and cool the PCR reaction mix, enabling 
denaturation of the DNA strands, annealing of the primers and extension of the 
sequence to occur, each time this sequence of events occurs it is called a cycle.
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Typically between 20 and 40 cycles are performed in a PCR reaction. The PCR 
reaction mix consists of a DNA template that contains the sequence of interest. 
Typically this can be produced from tissue by the extraction of mRNA and then 
converting it to cDNA in a reaction. The reaction mix also contains the forward and 
reverse primers that are complimentary to the DNA sequence of interest, Taq 
polymerase, Deoxyribonucleotide triphosphates (dNTPs) which are the bases from 
which the Taq polymerases synthesises a new DNA strand, and a buffer solution that 
contains magnesium ions. The PCR products can be separated by gel elecrophoresis 
on an agarose gel and the use of DNA ladders enables the produce size to be 
determined (Bartlett etal., 2003).
3.1.2 Western blotting
Western blotting is a technique used for the detection of a specific protein in a cell 
lystate by use of the knowledge that a specific antibody will bind to a specific 
antigen. An antibody is a protein with a unique structure that enables it to bind 
specifically to a particular substance known as its antigen. This enables a protein of 
interest to be detected amongst a group of proteins. The term Western Blot was 
originally coined by Burnette (1981) which was a play on the "Southern Blot" 
technique name, a DNA detection technique developed by Edwin Southern (1992). 
Initially proteins are separated by size using SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE), with the lightest proteins travelling the furthest down the gel. The size 
separated cells are then transferred from the gel to a nitrocellulose membrane 
(Towbin et al., 1979), which provides a stable support for the remainder of the 
technique. The protein of interest can then be detected by incubating the 
membrane with a specific antibody that can react with the SDS-solubilised protein. 
The bound antibodies are then revealed using a secondary anti-immunoglobulin 
antibody bound to a luminescent label. This binds to the primary antibody and the 
resulting luminescence can be detected on photographic film. Colourimetric, 
fluorescent, and radioactive techniques can also be employed. The greater amount 
of protein, the greater the binding of antibody, and the greater the density of the 
band of light detected. Densitometry can be used to measure the intensity of the
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resulting bands and these can be compared between samples in semi-quantitative 
manner. The use of a ladder marker enables the size of the protein detected to be 
compared to the expected size so confirm its presence (Blancher et al., 2001).
3.2 Aim
The aim of the studies conducted in this chapter was to characterise the expression 
of the H2S synthesising enzymes CSE and CBS within the rat myocardium at both the 
mRNA and protein level.
3.3 Hypothesis
1. CSE mRNA will be predominantly expressed over CBS in the left and right 
ventricles of rat myocardium
2. CSE protein will be predominantly expressed over CBS in the left and right 
ventricles of rat myocardium
3.4 Objectives
The validity of these hypotheses was tested as follows:
1. To determine the mRNA expression levels of CSE and CBS in the rat 
myocardium using PCR and specific primers
2. To use selective CSE and CBS antibodies and perform Western blotting to 
determine the relative protein expression levels of the two synthesising 
enzymes in the rat myocardium
3. To confirm the selectivity of the CSE antibody using cloning and over­
expression of the CSE protein in a GH3 cell line
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3.5 Methods
3.5.1 PCR
3.5.1.1 Detection o f tissue CSE and CBS mRNA using PCR
PCR was performed in tissue left ventricle (LV), right ventricle (RV), atria (A), liver (Li) 
and cerebellum region of the brain (B) from rats to determine if there was mRNA 
expression of the CSE and CBS enzymes in the rat heart.
3.5.1.2 Source o f primers used
The CSE and CBS primers were designed from gene sequences and purchased from 
Sigma-Aldrich, UK with a forward and reverse sequence selected for each gene of 
interest. A BLAST search was performed to check that the primers were intro 
spanning to ensure that they were specific to the mRNA of interest. The primers 
were prepared in dH20 to produce 100 pM stocks and then were diluted a further 
1:10 in dH20 prior to use (10 pM).
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1 CCGTCCC AG CATG CAG AAG G ACG CCTCCTCCAGCGG CTTCCTGCCCAG CTTCCAG CACTT 
61 TGCCACTCAGGCCATCCACGTGGGACCAGAGCCGGAGCAATGGAGTTCGCGTGCTGTGGT 
121 GCTGCCCATTTCGCTGGCCACCACGTTCAAACAGGACTCTCCAGGCCAGTCCTCGGGTTT 
181 TGTATACAGCCGCTCTGGAAATCCGACGAGGAATTGCTTGGAAAAAGCAGTGGCTGCACT 
241 GGATGGGGCAAAGCACTGTTTGACCTTCGCTCGGGGCCTTGCCGCCACCACAACGATTAC 
301 CCATCTTTTAAAAGCAGGAGATGAAGTCATTTGCATGGATGAAGTGTATGGAGGCACCAA 
361 CAGGTACTTCAGGAGGGTGGCATCCGAGTTTGGACTGAAGATTTCTTTTGTGGATTGTTC 
421 CAAAACCAAATTGCTGGAGGCAGCGATCACACCACAGACCAAGCTTGTTTGGATTGAAAC 
481 ACCCACAAACCCAACCTTG AAGTT GGCCGACAT CAAAGCCTGCGCACAAATTGT CCACAA 
541 ACACAAAGACATCATTCTGGTTGTAGATAACACTTTCATGTCTGCATATTTCCAGAGACC 
601 TTTGGCTCTGGGTGCTGATATTTGTATGTGTTCTGCCACAAAATACATGAACGGCCACAG 
661 TGATGTTGTCATGGGCTTAGTGTCTGTTACTTCCGATGACCTCAACGAACGGCTTCGTTT 
721 CCTGCAGAATTCTCTCGGGGCAGTTCCTTCTCCTTTCGATTGTTACCTCTGCTGCCGAGG 
781 CCTGAAGACACTGCAGATCCGGATGGAGAAACACTTCAGGAATGGGATGGCAGTGGCCCG 
841 TTTCCTGGAGTCTAATCCCCGGGTAGAAAAGGTTATTTATCCTGGGCTACCGTCTCACCC 
901 TCAGCATGAGCTCGCCAAACGTCAGTGCACGGGCTGCCCCGGGATGGTCAGTTTCTATAT 
961 CAAGGGTACTCTGCAGCATGCTCAGGTCTTCCTCAAAAATATAAAGCTGTTTGCTCTGGC 
1021 TGAGAGCCTGGGAGGATATGAGAGTCTGGCTGAGCTTCCAGCAATCATGACCCATGCCTC 
1081 CGTGCCT G AG AAGG ACAG AG CT ACCCT CGG G AT CAGT G ACACACT GAT CCG ACTTT CT GT 
1141 GGGCCTAGAGGATGAAAAGGACCTTCTCGAAGACCTGGGTCAAGCTTTAAAGGCAGCGCA 
1201 CCCTTAAAGTTCG AGTCAAAGCCG G C ATTCCAGTGCTG CCATCAG CAG CAG CAG CCAAG G 
1261 GGCCAGACCTTCTGAATAACTGGACAGACCATTAAGGAGCATCTGCAGAACTTCGCAGTG 
1321 AACATTTTAAG ACCCTAGTG ATTTTACAG CTGTAACCTTACAG GG ATCTTCCCTTAAG G A 
1381 CTGTCTTCTGCTAACAGGTTGTTCTGTTAGTATCATTCTGATAGTTTTGCTGTATTTGTG 
1441 TTCAAGGAAGAGAGTTGTATTATTTTGGGGATCATGTTGCTTCI I I I I ICCTTTTTCTTT 
1501 CTT CG GTAG CCTAAG AT AT GTTTTAAT CAT GTTT ACAAAATTTAGT ATT GAT GTTTT AT G 
1561 AAGTTAAATTATTCAATGAACGGTCTTAAATCAACTGTAGGGGTTn I I I I I IGAAAAAT 
1621 TATTGAAAGTGGGGGGTCTTTATTTAATTACCATAAGCCAAAAAAATCAAATATTTGGAA 
1681 TATCTACTGTGAAATTCTAGTGATTAAAGGTTGTACTTGATACTTGTTGTTTTTCTTAAA 
1741 TGG
Figure 3.1 CSE primer design showing the region o f amplification fo r forward and 
reverse primers respectively. Forward primer starts at base 225 and spans 18 bases 
AAGCAGTG6CTGCACTGG. Reverse primer starts at base 458 and spans 18 bases 
TCTGTGGTGTGA TCGCTG.
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1 TTTCCC6CGTCTG AGTCTAG CTG CACCCTG CTCCTTGTCTCCCATCCTTG CAA AG CTTGT 
61 CTGAGTGGAGCCAACACGCCCAGAGGGGGACAGGAGAGTCAACTACTAAACCAACAGGTT 
121 TCT GCG ACCT CAG CAAAT CCCAGCAT G CCTT CAG G G ACAT CCCAGT GTG AAG ATG GCTCT 
181 GCAGGGTGCCCCCAGGACTTGGAGGTACAGCCAGAAAAAGGGCAACTGGAGAAGGGAGCC 
241 TCAGGGGACAAGGAAAGAGTCTGGATCTCGCCTGATACCCCAAGCAGATGTACTTGGCAG 
301 CTGGGCAGGCCCATGGCGGATTCCCCACATTACCACACAGTGCCGACAAAATCCCCGAAA 
361 ATTTT G CCAG AT ATT CT G AG G AAAATT GG CAACACCCCT ATG GT CAG AAT CAACAG G AT C 
421 TCCAAGAATGCAGGACTCAAGTGCGAGCTGTTGGCCAAGTGTGAGTTCTTCAACGCCGGT 
481 GGGAGTGTGAAGGACCGCATCAGCCTCCGGATGATTGAAGACGCTGAGCGAGCCGGAACC 
541 TTGAAGCCCGGAGACACGATCATTGAGCCAACTTCTGGCAACACAGGGATCGGGCTGGCT 
601 CTGGCAGCTGCTGTGAAGGGCTATCGCTGCATTATCGTGATGCCTGAGAAGATGAGTATG 
661 GAGAAGGTGGATGTGCTGCGAGCTCTGGGAGCTGAGATTGTGAGGACGCCCACCAACGCC 
721 AGATTCGATTCCCCCGAGTCCCACGTAGGAGTGGCATGGCGACTGAAGAACGAAATCCCC 
781 AATT CT CAC ATT CT G G ACCAGT ACCG CAAT G CCAG CAACCCCTT GG CG CACT ACG AT G AC 
841 ACCGCAGAGGAGATCCTGCAGCAGTGCGACGGGAAGGTGGACATGCTGGTGGCTTCAGCA 
901 GGCACGGGTGGCACCATCACGGGTATCGCGAGGAAGCTGAAGGAGAAGTGCCCAGGTTGT 
961 AAAATCATCGGTGTAGATCCCGAGGGGTCCATCCTCGCGGAGCCCGAGGAGCTGAACCAG 
1021 ACGGAGCAAACAGCCTATGAGGTGGAAGGGATCGGCTACGACTTCATCCCCACCGTCCTG 
1081 GACAGGGCGGTGGTGGATAGGTGGTTCAAGAGCAATGATGACGATTCCTTCGCCTTCGCC 
1141 CGCATGCTCATCTCCCAGGAGGGACTGCTGTGCGGTGGGAGTTCAGGCAGCGCTATGGCC 
1201 GTGGCTGTGAAGGCTGCCCAGGAGCTAAAGGAAGGACAGCGCTGTGTGGTCATCCTGCCC 
1261 GACTCTGTGCGCAACTACATGTCCAAGTTCTTGAGTGACAAATGGATGCTGCAGAAAGGC 
1321 TTCATGAAGGAGGAGCTCTCCGTGAAGAGACCCTGGTGGTGGCATCTGCGTGTCCAAGAG 
1381 CTGAGCCTATCAGCACCGCTGACCGTGTTGCCCACTGTCACCTGTGAGCACACCATCGCC 
1441 ATCCTCCGGGAGAAGGGTTTTGACCAGGCACCTGTGGTCAACGAGTCTGGGGCCATCCTA 
1501 GGGATGGTGACTCTCGGGAACATGTTGTCCTCCCTGCTTGCTGGGAAGGTGCGGCCATCA 
1561 GACGAAGTCTGCAAAGTCCTCTACAAGCAGTTCAAGCCGATCCACCTGACCGACACACTG 
1621 GGCATGCTCTCCCACATCCTGGAGATGGACCACTTCGCCCTGGTGGTCCATGAGCAGATC 
1681 CAATACCGCAACAATGGCGTGTCCAGCAAGCAGCTGATGGTGTTTGGTGTTGTCACCGCC 
1741 ATTGACCTGCTAAACTTCGTGGCAGCCCGTGAGCAGACCCGGAAATAGAGTTCAGAAGTC 
1801 AGGACTGGCTTCCATCCTCCCTGCTGGGACTTCTTGGCTTTCAGAGACACCGACTGGTTT 
1861 CCAC ACCCAAGT CCAG CAGGTGGCTGCTGAGG CCAG CACCCT CCCCT CCT AACG CT CAG C 
1921 TCCCTATAGGAATCCTCTATGTCCGAGTAGCTTACGTGGGCTTTCCTCTGGTGTCCCAGA 
1981 ACCAAGGAATGGCAGCCAGGAAAGATAGGCACAGACTACACTCGCCACAAGACTCAGGGT 
2041 GCCTAGGAAAGTGTCCTCTCCAGAGAGGGCTCCAGCCTGAGAAAGGGCAAACCCTGGACT 
2101 GACTGTGCTCATCCTCAGGGGGCAGTGCTGGCCCCAGCAAGGGAGCATGTGGGTTTTAAA 
2161 TGAAGGTGCGTTCCAGTGACCTGAGACCCACAGCTGTGAAGTAAACGTCGTGCCTGTACG 
2221 GAGTGTCACCACCTGGGTCATGACCCTGCTTAGCAGTTCCTCCTCACATCTCCCTCCTTT 
2281 CCCG ACAAG CACCTACTTT CTGTCT CAACT CTT CCTATAAAT G AAT CACATACCTGTGGT 
2341 CATGTCTACCTAATTTTCCTGGAATGAGTGCCTTGTGTTTTCCTGTTATGGCCTGTGTCA 
2401 GAGTTTCGTTCCTTTCCATGGCTGAGGGAGCCCATTGTGTGGATGGGTGGTTCTTATTTT 
2461 CTGGGCATCGGTATGCTTGAATACATTTCCCCGCTGGGGTGTAGCCCGGTTGGGCTCACT 
2521 G C AAA AAAA AAAA A AAA A A
Figure 3.2 CBS primer design showing the region of amplification fo r forward and 
reverse primers respectively. Forward primer starts base 567 and spans 18 bases 
GCCAACTTCTGGCAACAC. Reverse primer starts at base 891 and spans 19 bases 
CACCAGCATGTCCA CCTTC.
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Primers for the two house-keeping genes GAPDH and L19 were also used. GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase), codes for an enzyme that is vital to 
the glycolytic pathway. These genes are known to be constitutively expressed in all 
cell types. Since housekeeping genes are constitutively active, they produce a 
constant level of mRNA. They are therefore often used as a loading control to verify 
that identical amounts of sample were added. Since equal volumes of cDNA as 
opposed to equal concentrations were loaded, the housekeeping genes can be used 
to test the integrity of the cDNA. They also enabled a comparison of the expression 
to be made across different tissues, although the type of PCR conducted was not 
quantitative. However, the expression level of house-keeping genes may vary 
among tissues or cells and may change under certain circumstances. Therefore, by 
selecting two house-keeping genes there is a reduced probability of both varying and 
proving a more accurate quality control.
3.5.1.3 Sample preparation
Tissue samples from 6 male Sprague Dawley rats (270-350 g) were taken after 
terminal anesthesia with an i.p. injection of a mixture of sodium pentobarbitone (65 
mg/kg) and heparin (100 units). The heart was excised and dissected, separating the 
left and right ventricles, and the left and right atria. 6 samples were taken from the 
left ventricle, 4 samples from the right ventricle and the pooled left and right atria 
formed a single sample. The central lobe of the liver was removed and divided into 6 
samples. The head of the rat was removed and the brain carefully dissected. The 
cerebellum was identified and divided into 3 samples. The remainder of the brain 
was divided into 3 sections. The samples were washed in sterile filtered PBS and blot 
dried on tissue. The samples were placed in individual 0.5 ml sterile Eppendorf tubes 
and immediately snap frozen in liquid nitrogen. The samples were stored at -80°C 
until required for experimentation.
3.5.1.4 Extraction o f RNA
30 mg of left ventricle, right ventricle, liver and brain (cerebellum), previously snap 
frozen in liquid nitrogen, were crushed using a dry ice cooled mortar and pestle. The
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resulting powder was transferred into 2 ml Eppendorf tubes. RNA was extracted 
from the tissue samples using a Qiagen Rneasy Mini kit. An optional on-column 
DNase digestion with an RNase-free DNase kit was performed during the RNA 
extraction. Cardiac tissue is far more fibrous than the liver and brain, therefore a 
proteinase K digest stage was required at the start of the RNA extraction protocol to 
remove these proteins. After this stage the protocol for RNA extraction was the 
same at that used for the liver and brain tissue. A total of 50 pi of RNA solution was 
eluted for each tissue sample. A lOpI aliquot was taken and frozen at -20 °C, so that 
it could be run on a gel to check for the presence of RNA. 5 pi of loading dye was 
added to each of the lOpI samples so that it could be run on a 1.6% agarose gel using 
electrophoreses and the presence of mRNA bands at 18s and 28s detected. The 
remainder of the RNA sample was frozen at -80°C.
3.5.1.5 Synthesis o f cDNA
An Amersham Biosciences first-strand cDNA synthesis kit was used for the 
generation of full-length cDNA from the RNA templates prepared from the tissue 
samples. Due to the expense of the kit and large number of samples to process, the 
volumes of components in the first-strand reaction mix were slightly altered from 
those suggested by the manufacturer. 7 pi of Bulk first-strand reaction mix was 
added, along with lp l of the first strand primer Not l-d(T)is, lp l DTT solution, 12 pi 
RNA and 21 pi First volume first-strand reaction. The Not l-d(T)i8 primer initially 
received a 1:25 dilution in dF^O prior to the addition to a first strand reaction 
mixture. The results however, remained unaffected.
3.5.1.6 PCR reaction
PCR was performed using the cDNA synthesised from the rat tissue samples. Primers 
for the CSE and CBS enzymes were selected from those previously published in the 
literature (Zhao et al., 2001a). For detection of CSE mRNA the forward sequence 
used was 5'-AAGCAGTGGCTGCACTGG-3', and the reverse primer sequence used was 
5'-TCTGTGGTGTGATCGCTG-3'. The PCR reaction consisted of 35 cycles of 95 °C for 
30 seconds to denature, 51 °C for 30 seconds for annealing and 72 °C for 1 minute
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for extension. A final extension period of 72 °C for 10 minute was added at the end 
of the 35 cycles (PCR conditions summarised in figure 3.3). The PCR product size was 
234 bp. For detection of CBS mRNA the forward sequence used was 5'- 
GCCAACTTCTGGCAACAC -3', and the reverse primer sequence used was 5'- 
CACCAGCATGTCCACCTTC -3". The PCR reaction consisted of 35 cycles of 95 °C for 30 
seconds to denature, 55.4 °C for 30 seconds for annealing and 72 °C for 1 minute for 
extension. A final extension period of 72 °C for 10 minute was added at the end of 
the 35 cycles (PCR conditions summarised in figure 3.3). The PCR product size was 
325 bp. The PCR conditions were determined by entering the primer sequences and 
product sizes into the PCR thermal cycler (G-storm). Each sample contained 15 pi of 
the master mix (see Appendix 3 for composition) plus 5pl of respective cDNA in an 
autoclaved sterile 200 pi PCR tube. House keeping genes, GAPDH and L19, were 
tested alongside the tissue sample to ensure the reactions were successful. At the 
end of the PCR reaction cycles, the products were removed and 5pl of loading dye 
was added to each of the samples (see Appendix 3 for composition).
Primer Melting Annealing Extension Final extension
CSE 30" @ 95°C 30" @ 51°C V  @ 72°C 10’ @ 72°C
CBS 30" @ 95°C 30" @ 55.4°C V @ 72°C 10’ @ 72°C
Figure 3.3 Summary o f the PCR conditions fo r the CSE and CBS primers. Each sample 
underwent 37 cycles o f melting, annealing and extension, before a fina l 10 minute 
extension step.
10 pi of each of the samples were run on a 1.6% agarose gel (see Appendix 3 for 
composition), with the addition of a 1 kb and 2-log marker, to ensure that the 
products were in the correct position. The remainder of the sample was stored at - 
20 °C.
3.5.1.7 Negative controls
Negative control samples were prepared from the tissue samples of one of the rats 
used in this study. In the PCR reaction mix a DEPEC water was used in the place of
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cDNA, to ensure that the water used to prepare and dilute the constituents of the 
PCR reaction mix was not contaminated. Also in the PCR reaction mix, cDNA was 
substituted with RNA for each of the tissue samples to confirm the absence of 
genomic DNA. These samples underwent the PCR reaction alongside experimental 
samples. At the end of the PCR reaction cycles, the products were removed and 5pl 
of loading dye was added to each of the samples. 10 pi of each of the samples were 
run on a 1.6% agarose gel, with the addition of a 2-log marker. The remainder of the 
sample was stored at -20°C. The absence of contamination of the DEPEC water and 
RNA with genomic DNA was confirmed by the lack of bands in these sample lanes (as 
shown in figure 3.4).
Atria - Atria+ LV- LV+ RV- RV+ Liver- Liver+ Brain- Brain+ dH-O
Figure 3.4 Negative controls fo r PCR. RNA (-) and DEPEC H20 (dH20) were used in 
the place o f cDNA in the PCR reaction mix, to ensure that the water and RNA used 
wasn't contaminated with genomic DNA which could falsify the results.
3.5.1.8 Sequencing o f products
The products from the PCR reactions were sequenced in order to confirm that they 
were the CSE and CBS enzymes that were being detected. Initially the PCR products 
were run on a new agarose gel (1.6%), but with a blank lane in between each 
sample. The chosen DNA band was excised with a scalpel under ultraviolet light. 
DNA extraction was achieved using a QIAquick Gel extraction kit. The sample was 
frozen at -20 °C prior to being sequenced by Kathy Dominy (RVC, London).
The samples were sequenced using an ABI 3100 Genetic Analyzer and a BigDye® 
Terminator v3.1 Cycle Sequencing Kit. A BLAST search was performed to confirm the 
presence of the CSE and CBS DNA in the gel extracted PCR samples.
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3.6 Western Blotting
3.6.1 Detection of CSE and CBS protein expression using Western biotting
Western blotting was used to determine if there was protein expression of the 
enzymes CSE and CBS enzymes in the rat heart. This is because the PCR alone only 
gave an indication of the presence of the mRNA and not whether they were 
translated to protein.
3.6.1.1 Source o f antibodies used
Due to the lack of commercially available CSE antibodies, Sigma-Genosys custom 
designed and synthesised an antibody to the CSE enzyme. Using the rat CSE peptide 
sequence, an antigenic peptide was designed and the sequence chosen was KLH- 
[CJHASVPEKDRATL. The reason for choosing this sequence is that this peptide 
sequence is very hydrophilic and located towards the C-terminus of the rat CSE 
peptide sequence. This will facilitate the binding of the resulting antibody to the CSE 
protein in the tissue samples tested. The antibodies were raised in two New Zealand 
White rabbits, using the antibody production schedule outlined below in figure 3.5.
Day Date_________ Action
0 12/06/06 Pre-immune serum collection 5 ml
0 12/06/06 Immunise 200 i^g CFA
14 26/06/06 Immunise 100 fig IFA
28 10/07/06 Immunise 100 jig IFA
42 24/07/-6 Immunise 100 jig IFA
49 31/07/06 Bleed Test bleed #1 ELISA (5 ml)
56 07/08/06 Immunise 100 i^g IFA
63 14/08/06 Bleed Test bleed # 2 (5 ml)
70 21/08/06 Immunise 100 jig IFA
77 28/08/06 Bleed Test bleed #3
Figure 3.5 CSE antibody production schedule performed over a 77 day incubation 
period. Test bleed samples 1 and 2 were used fo r Western blotting against rat 
ventricle, atria, liver and cerebellum samples to test fo r specificity. A t the end o f the 
77 day incubation period, the rabbits were scarified and a fina l bleed (test bleed 3) 
was performed. The antibody was supplied in rabbit serum and was the most specific 
o f the samples obtained. CFA = Complete Freund's adjuvant, IFA = Incomplete 
Freund's adjuvant.
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During the 77 day incubation program two test bleeds were taken at day 49 and day 
63 so that the antibody could be tested for its specificity to detect the CSE protein. 
ELISA was also performed by Sigma-Genosys to measure the quantity of peptide- 
specific antibody present in the serum sample from test bleed 1. The final test-bleed 
was believed to be the most specific antibody to CSE due to the increased incubation 
period in the rabbit.
In addition to the synthesised CSE antibody, anti-probasin antibodies were also used 
for the detected of CSE protein. These were a kind gift from Dr Nishi (Department of 
Endocrinology, Kagawa Medical School, Japan) (Nishi et al., 1992; Nishi et al., 1994). 
The anti-probasin antibodies had previously detected an unknown 40 kDa protein in 
rat liver and kidney urinary tubules (Nishi et al., 1992). Investigation of its amino 
acid sequence (Nishi et al., 1994) revealed it to be almost completely identical with 
the rat cystathionase reported by Erickson (1990). Probasin and CSE are not 
homologous, except for the area in which the probasin antibody detected against. 
Previously these antibodies have successfully been used by Cheng et al. (2004) to 
investigate CSE protein expression in rat mesenteric arteries. Antibodies to the CBS 
protein were commercially available and a CBS antibody previously tested in rat 
tissue was purchased from Santa Cruz, USA. Complementary secondary antibodies 
were purchased from Upstate Cell Signalling Solutions, UK. With the exception of 
the CSE antibody which was prepared in rabbit serum, the antibodies were prepared 
in dh^O.
3.6.1.2 Sample preparation
Initially protein extracts were prepared by homogenising small quantities (5x5 mm) 
of snap frozen tissue samples in liquid nitrogen and suspending them in 210 pi of 
lysis buffer containing a protease inhibitor cocktail (Sigma-Aldrich, UK) (see Appendix 
3 for composition). Tissue sample from rat left ventricle, right ventricle, liver and 
brain (cerebellum) were used. The resuspended samples were sonicated for 5 
seconds and spun at 13k rpm for 15 minutes. The supernatant was collected and 
aliquoted. An equal volume of Laemmli sample buffer (see Appendix 3 for
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composition) (4% sodium dodecyl sulphate (SDS), 20% glycerol, 10% 2- 
mercaptoethanol, 0.0004% bromophenol blue, 0.125 M Tris HCI), was added prior to 
storage at -80°C. A 20 pi aliquot of protein sample prior to the addition of loading 
dye was kept lo  be used in the bicinchoninic acid (BCA) protein assay to determine 
the protein concentrations in the tissue samples (see Chapter 2, section 2.3).
3.6.1.3 Separation o f proteins
The protein samples were heated to 95 °C for 5 minutes. Equal protein 
concentrations were loaded onto a 4% stacking gel (see Appendix 3 for composition), 
with a maximum volume of 20 pi being loaded to achieve the desired concentration. 
The specific protein concentrations loaded for each antibody are shown in figure 3.6. 
5 pi of Bio-Rad precision plus protein standard (Bio-Rad Laboratories Inc., UK) was 
also loaded. The proteins were separated on a 10 % resolving gel (see Appendix 3 
for composition) for 1 hour at 150 V using a mini-PROTEAN 3® cell and tank system 
(Bio-Rad Laboratories Inc., UK).
3.6.1.4 Preparation o f PVDF membrane and probing fo r CSE protein 
Electrophoretic transfer was used to transfer the separated proteins to a 
polyvinylidene difluoride (PVDF) membrane (Hybond P, Amersham Biosciences Ltd., 
UK). The PVDF membrane was initially activated by soaking in methanol for 1 
minute and then washing in dH20. The protein transfer took 1 hour and was 
performed using the mini Trans-Blot module® (Bio-Rad Laboratories Inc., UK) with 
the power pack set to 100 V and 400 mA. After the protein transfer was complete 
the membrane was with blocked in a 5% (w/v) milk solution (5 ml), made up in Tris- 
buffered saline TBST (see Appendix 3 for composition), with constant agitation on a 
roller shaker for 60 minutes. The membrane was then placed in a 5% (w/v) milk 
solution containing a 1:1000 dilution of primary antibody.
The generalised probing method is as follows. The specific antibody concentrations 
and blocking conditions for each protein of interest are summarised in figure 3.6. 
The blots were incubated with the primary antibody at 4 °C overnight on a roller
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shaker. The following morning 3, 5 minute washes of the membrane were 
performed in 10 ml of TBST buffer solution. The membrane was then incubated in a 
5% (w/v) milk solution containing secondary antibody for 90 minutes. The secondary 
antibodies were raised in a different species to the primary antibody, and cross 
reacted. The membrane received a further 3, 5 minute washes in TBST. The bound 
antibodies were detected by the secondary antibody conjugated to horseradish 
peroxidase and visualised by chemiluminescence (ECL plus™ Western Blotting 
Detection Reagents, Amersham Biosciences Ltd., UK). The bands were captured on 
photographic film (Hyperfilm™ ECL, Amersham Biosciences Ltd., UK). After 
development and fixation on the films, they were scanned on an EPSON perfection 
2480 photoscanner (EPSON Ltd., UK).
Antibody [optimum protein] 
(ng/ni)
o nJ o Blockingagent
CSE 100 1:500 1:20k 5% milk
CBS 100 1:500 1:20k 5% milk
Probasin-
monoclonal 37 1:1000 1:10k 5% milk
Probasin-
polyclonal 37 1:1000 1:10k 5% milk
Figure 3.6 Summary o f the optimum Western blotting conditions fo r each o f the 
antibodies used to characterise CSE and CBS enzyme expression in the rat 
myocardium, liver and cerebellum.
After developing and scanning the blots, they were stripped of the primary and 
secondary antibodies by washing in 5 ml stripping buffer (Restore™, Pierce, UK) for 
30 minutes on a roller shaker. The blots were washed briefly in 10 ml TBST and then 
received 2,10 minute washes in 20 ml TBST. The blots were then re-probed with an 
antibody to beta actin (1:5000) in 5% (w/v) milk overnight. The blots received 3, 5 
minute washes in TBST and were then incubated with secondary antibody (1:5000) 
in 5% milk for 90 minutes. The bound antibodies were detected by the secondary 
antibody conjugated to horseradish peroxidase and visualised by chemiluminescence 
as described previously. This method was also used for the stripping and re-probing
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the CSE and CBS antibody probed blots, except that they were re-probed with either 
the CSE or CBS antibody in an attempt to reduce to reduce the excess protein that 
results in non-specific binding reducing the clarity of the bands of interest.
The effect of blocking the membranes in 5% BSA was also investigated to see if it was 
more effective than milk. However, the resulting blots had far more non-specific 
binding and so 5% (w/v) milk was used as a blocking agent in all subsequent 
experiments.
3.7 Use of a HiTrap™ protein G HP purification column for purification of CSE 
antibody
A 1ml HiTrap™ protein G HP purification column (GE Healthcare LTD, UK) was 
washed with 15 volumes of binding buffer (15ml total) (see Appendix 3 for 
composition) at a rate of 1 ml/min. 1ml of rabbit final bleed was applied to the 
column. The column was left plugged at room temperature for 1 hour. The column 
was washed with 15 volumes of binding buffer (15ml total) before the antibody was 
eluted with 8 column washes of elution buffer (8ml total) (see Appendix 3 for 
composition). Each of the 1 ml eluted fractions was collected into an eppendorf 
tube containing 50pl Tris-HCI (1 M, pH 9.0). The protein concentrations of the eluted 
fractions were measured on a Labtech ND 1000 spectrophotometer (Fisher Thermo 
Scientific, UK) connected to a computer running analysis software version 3.2.1. The 
second fraction was found to contain the greatest amount of protein and was used 
as the primary antibody sample for all subsequent CSE western blotting, at a dilution 
of 1:500.
3.8 Cloning ond over-expression of the CSE enzyme
Cloning and over-expression of the CSE enzyme in a GH3 cell line was performed by 
Dr. Rob Fowkes and Dr.Steve Allen (RVC, London), as outlined in Appendix 1. Whilst I 
did not perform the experimental work myself I was involved in the planning and
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concepts behind the studies. I did however peform the Western blot analysis of the 
transfected cell line over-expressing the CSE enzyme.
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3.9 Results
3.9.1 PCR studies fo r CSE and CBS mRNA expression
3.9.1.1 CSE mRNA expression in rot tissue samples:
The CSE mRNA expression levels were investigated in rat tissue samples using PCR. 
The aorta, left ventricle and right ventricle tissue homogenates from rats all showed 
weak expression of CSE mRNA. Liver and brain homogenates contained stronger 
expression levels (as shown in figure 3.7). It is not possible to quantify the 
expression levels because unequal amounts of cDNA were used in each sample.
^ 0 .5 K b
Rat 1 — °-3Kb
■~-~~-0.2Kb
Rat 2
Rat 3 
Rat 4
Rat 5
Figure 3.7 CSE mRNA expression in aorta, left ventricle, right ventricle, live r, and 
brain (cerebellum) from 5 different rats was detected by PCR (234 b.p., 35 cycles). 
Bands appear in all tissue samples confirming the expression o f CSE mRNA.
3.9.1.2 CBS mRNA expression in rat tissue samples
The CBS mRNA expression levels were investigated in rat tissue samples using PCR. 
The aorta, left ventricle, right ventricle, liver, and cerebellum tissue homogenates
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from rats all contained detectable mRNA for CBS. The liver and cerebellum appeared 
to contain stronger expression levels (as shown in figure 3.8).
CD
Rat 1
Rat 2 
Rat 3
Rat 4 
Rat 5
Figure 3.8 CBS mRNA expression in aorta, left ventricle, right ventricle, live r, and 
brain (cerebellum) from 5 different rats detected by PCR (325 b.p., 35 cycles). Bands 
appear in all tissue samples confirming the expression o f CBS mRNA.
3.9.1.3 GAPDH and L19 house keeping gene mRNA expression is rat tissue samples 
The expression levels of the house keeping genes GAPDH and L19 were investigated 
in rat tissue samples using PCR. All of the samples contained strong expression levels 
of mRNA for the house keeping genes GAPDH (as shown in figure 3.9) and L19 (as 
shown in figure 3.10), except in the cerebellum sample from rat 5 where surprisingly 
no GAPDH expression was detected.
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Figure 3.9 GAPDH mRNA expression in aorta, left ventricle, right ventricle, liver, and 
brain (cerebellum) from 5 different rats detected by PCR (294 b.p., 35 cycles). Bands 
appear in all tissue samples confirming the expression o f GAPDH mRNA.
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0.5Kb
0.3Kb
0.2Kb
Rat 2 
Rat 3
Figure 3.10 L19 mRNA expression in aorta, left ventricle, right ventricle, live r, and 
brain (cerebellum) from 3 different rats detected by PCR (194 b.p., 35 cycles). Bands 
appear in all tissue samples confirming the expression of L19 mRNA.
3.9.2 Western blotting for CSE protein expression
3.9.2.1 Western blotting using the CSE antibody from test bleed 1
Western blotting was used to characterise the expression of the CSE enzyme in the 
rat myocardium, cerebellum and liver. The initial Western blotting was performed 
with the test bleed 1 serum, containing the CSE antibody, and showed bands present 
around the position of 40 kDa which is the weight of the CSE protein (data not 
shown). The bands were most prevalent in liver and cerebellum samples. The left 
and right ventricles contained fainter bands. The blots also showed a large amount 
of non-specific binding and refinements were made to the Western blotting to 
improve the quality of the blots (as outlined in the methods section).
3.9.2.2 Western blotting using the housekeeping protein beta actin
Antibodies against the house keeping protein beta actin were used to reprobe the 
initial blots after they had been stripped of the CSE antibodies. The blots showed
<D
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very strong bands in the liver and cerebellum between the 37 and 50 kD markers, 
but were fainter in the heart samples (as shown in figure 3.11).
50 kDa
37 kDa Beta actin
Figure 3.11 Western blot using a beta actin antibody that detects the protein at 40 
kD. Protein samples were obtained from rat left ventricle (LV), right ventricle (RV), 
brain (cerebellum) (B), and liver (Li).
3.9.2.3 Western blotting using the CSE antibody from test bleed 3 
After refinement of the Western blotting technique, the study was repeated using 
the CSE antibody from the final test bleed (bleed 3) to test for the expression of the 
CSE enzyme protein. The blot shows two sets of bands appearing in all of the protein 
samples between the 35 and 50 kD markers suggesting CSE protein may be present 
in the left ventricle, right ventricle, cerebellum and liver tissue samples from the rat 
(as shown in figure 3.12). However, due to multiple bands appearing within close 
proximity of each it is difficult to distinguish which band is at the correct molecular 
weight, 40 kDa, for CSE. The blots also appear to still contain a large amount of non­
specific binding and noise, but are a vast improvement on the initial blots obtained 
with test bleed 1 and 2. Stripping and re-probing with the same primary antibody 
also produced a marked improvement in clarity of the bands if interest, compared 
with un-stripped blots.
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LV RV Li B
35 kDa
50 kDa CSE
Figure 3.12 Western blot using a custom CSE antibody, raised in the rabbit by Sigma 
Genosys, that detects the CSE enzyme at 40 kD. Protein samples were obtained from  
rat left ventricle (LV), right ventricle (RV), and liver (Li), and brain (cerebellum) (B).
3.9.2.4 Western blotting using a polyclonal probasin antibody 
The results from Western blotting performed using a polyclonal probasin antibody 
(IgG fraction) from Dr Nishi showed bands appearing in right ventricle, cerebellum 
and liver protein samples between the 37 and 50 kD markers suggesting the CSE 
enzyme protein is present (as shown in figure 3.13).
Figure 3.13 Western blot using a polyclonal probasin antibody that detects the CSE 
enzyme at 40 kD. Protein samples were obtained from rat left ventricle (LV), right 
ventricle (RV), brain (cerebellum) (B), and liver (Li). 30pg o f protein was loaded in 
each lane.
LV RV B Li
CSE >•
37kD
50kD
84
Chapter 3 Expression of CSE and CBS in Myocardium
3.9.2.5 Western blotting using a monoclonal probasin antibody 
A monoclonal form of the probasin antibody was also tested in the rat protein 
samples, with bands appearing only in right ventricle protein sample. These were 
further towards the top of the blot, suggesting a different larger product detected 
than CSE (43 kD). A band was also detected in the cerebellum sample lane, but this 
was beyond the 37 kD marker and was therefore not a protein of interest (as shown 
in figure 3.14).
LV RV B Li
50kD
37kD
Figure 3.14 A Western blot using a monoclonal probasin antibody, that can detect 
the CSE enzyme at 40 kD. Protein samples were obtained from rat left ventricle (LV), 
right ventricle (RV), brain (cerebellum) (B), and liver (Li). 30 pg of protein was loaded 
in each lane.
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3.9.2.6 Western blotting using the CBS antibody
When probing with the CBS antibody only a band was detected in the liver sample, 
but this was not at the expected size of 63 kDa and appears to be closer to 40 kDa 
(as shown in figure 3.15). There appears to be no CBS protein in the myocardium 
and cerebellum samples. Stripping and re-probing the blots with the CBS antibody 
showed a marked improvement in clarity of the bands if interest, compared with un­
stripped blots but still did not produce bands in the other sample lanes.
LV RV Li B
70 kDa
50 kDa
35 kDa
CBS
Figure 3.15 Western blot using an CBS antibody to detect the CBS enzyme at 63 kD. 
Protein samples were obtained from rat left ventricle (LV), right ventricle (RV), liver 
(Li), and brain (cerebellum) (B).
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3.9.2.7 Western blotting using the CSE over-expressing GH3 cells and CSE antibody 
There is a band that appears at approximately 40 kDa across all the GH3 cells over­
expressing CSE protein which appeared to increase in expression coincident with an 
increase in the amount of CSE expression vector transfected (as shown in figure 
3.16). Bands also appeared at the same position in the heart and liver samples 
which acted as positive controls.
1 2 3 4 5 6 7 8 9  10
Figure 3.16 A Western blot probed using the CSE antibody to detect increasing 
concentrations o f CSE protein in over-expressing GH3 cells (lanes 2-7, 0-1750pg), rat 
heart (lane 8, 50 pg, lane 9, 70 pg) and liver samples (lane 10, 50 pg) acting as 
positive controls. 1:2501°, 10 sec exposure time.
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3.10 Discussion
The findings of this study can be summarised briefly as follows:
1. PCR has shown that mRNA for both the CSE and CBS enzymes is present in 
the aorta, left ventricle, right ventricle, liver and cerebellum samples from 
rat. Relativeiy stronger CSE mRNA expression was observed in the liver, 
whilst the cerebellum and liver showed stronger bands for CBS mRNA.
2. The use of Western blotting to confirm the presence of CSE and CBS protein 
expression was of limited success. The presence of multiple bands around 40 
kDa made it difficult to determine which band represents CSE, resulting in 
ambiguity when interpreting which tissues express CSE protein. The liver is 
the only sample to show a band on the CBS biot but at a lower molecular 
weight than expected. The myocardium and cerebellum samples show no 
bands with the CBS antibody.
3. Cloning, transfection, and subsequent over-expression of the CSE protein in a 
GH3 cell line was an attempt to decipher which of the bands observed with 
the CSE antibody was the correct molecular weight for CSE. However, this 
work was inconclusive, providing further evidence that the CSE antibody 
exhibited strong non-specific binding.
3.10.1 PCR
3.10.1.1 CSE mRNA is present in all tissue samples
The PCR results using the CSE primers suggest that CSE mRNA expression exists in rat 
aorta, left ventricle and right ventricle. There appears to be stronger CSE mRNA 
expression in the rat liver, although this was not a quantitative technique. The liver 
acted as a positive control for the expression of CSE mRNA. It has been previously 
reported in that CSE mRNA is predominantly expressed in myocardial tissues (Abe et 
al., 1996). However, there appears not to have been any previous studies that have 
divided the heart into specific regions, as in this series of experiments. Also the 
definition of myocardial tissue appears vague and may in fact refer to the aorta and
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other regions of the cardiovasculature rather than specific major components of the 
heart such as the atria and ventricles. This makes a comparison of results with the 
literature difficult. CSE mRNA expression was also reported to be undetectable in 
the brain (Abe et al., 1996), but results from this study suggest that weak expression 
levels of CBS mRNA expression were present.
3.10.1.2 CBS mRNA is also present in all tissue samples
The results from the PCR using the CBS primers, suggest that the CBS mRNA is 
expressed in all of the rat tissue samples tested. There appears to be stronger 
expression in the liver and the cerebellum, although again this was not a quantitative 
technique. This supports previous findings that the liver and cerebellum strongly 
express the CBS enzyme (Abe et al., 1996; Hosoki et al., 1997). The expression of 
CBS protein in the rat myocardium requires confirmation using Western blotting. 
Previously, no expression of CBS protein in human atrium and ventricle tissues has 
been shown (Chen et al., 1999). It would be interesting to see if there is a species 
difference in the CBS protein expression between human and rats.
It is not surprising that the liver contained strong expression of CSE and CBS mRNA, 
since it has been reported that the liver strongly expresses these enzymes (Hosoki et 
al., 1997); (Wang, 2002). Another explanation for the strong expression of CSE and 
CBS mRNA in the liver is that a better preparation of mRNA may have been obtained, 
since it is does not contain as much collagen and therefore it may be easier to 
extract the RNA than the myocardial tissues. As a result this may have improved the 
cDNA synthesis and PCR reactions, producing brighter bands on the gel. The mRNA 
expression of the house keeping genes GAPDH and L19 are positive in all but one 
tissue sample (rat 5 cerebellum sample used to detect GAPDH), suggesting that the 
integrity of the cDNA was sufficient for the PCR reactions to be successful. It also 
appears that there is expression is consistent both within and between tissue types.
It has been proposed in the literature that there may be an age dependent 
expression of CSE in cardiovascular tissue (Levonen et al., 2000). This idea was
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proposed based on the observation that in fetal, premature, and full term neonatal 
liver tissue there is an absence of CSE activity, compared with the adult liver 
(Levonen et al., 2000). This suggests that there is an age dependent 
posttranscriptional regulation of the CSE enzyme. After 5 weeks the activity of the 
CSE enzyme has reached levels comparable to adults (Kuo et al., 1983). Since the 
liver tissue samples from all of the rats, showed strong CSE mRNA expression, it 
suggests that if CSE activity was age related and that the rats used in this study (7-8 
weeks old) were mature enough to express the CSE enzyme. Therefore the weak 
expression in the myocardium was not as a result of their young age. The age 
dependent expression of CSE present in cardiovascular tissues has not previously 
been studied (Wang, 2003).
3.10.1.3 Limitations associated with PCR
The main limitations associated with the PCR technique used to obtain the data 
presented in this chapter are: poor precision, low sensitivity, short dynamic range, 
low resolution, and the data obtained are not quantitative. It is also a relatively 
labour intensive technique due to being non-automated and requires post PCR 
processing of the products. Perhaps the major limiting factor though is that data is 
obtained from a single point at the end of the amplification process. This means that 
is if all the samples have replicated from differing amounts of DNA, but have all 
reached the plateau phase by the end of the series of cycles, then the measurement 
taken at the plateau phase is not representative of the initial amounts of starting 
material. It would be far more accurate to take measurements during the 
exponential phase when the samples are amplifying exponentially.
3.10.1.4 Quantitative PCR techniques
Real time PCR (RT-PCR) enables quantitative determination of total RNA expression. 
RT-PCR collects data in the exponential growth phase of the experiment and 
measures the amount of total RNA at time points throughout the duration of the 
experiment. This technique relies on a reporter fluorescent signal that increases 
proportionally to the number of amplicons generated. It is a more accurate
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technique for DNA and RNA quantification and doesn't require laborious post PCR 
processing.
3.10.2 Western blotting
3.10.2.1 Initial blots with the CSE antibody suggests impurities in the serum 
Preliminary results from Western blotting using the CSE antibodies suggest that the 
rabbit serum containing the CSE antibody was not that pure and there may be other 
factors present resulting in non-specific binding of the antibody. Attempts were 
made to improve the clarity of the blots by reducing the primary antibody 
concentration, increasing the concentration and duration of milk blocking, reducing 
the amount of protein loaded, and stripping and re-probing the blots to reduce non­
specific binding. These measures appear to have significantly improved the clarity of 
the blots, but they are still far from ideal. Purification of the antibody by running the 
sample through an IgG column was also performed in an attempt to reduce the 
possibility of non-specific binding from other serum factors. However, despite these 
refinements to the Western blotting techniques, there still appears to be too much 
non-specific binding which creates ambiguity as to which bands represent CSE.
The blot in figure 3.12 shows two series of bands between the 35 and 50 kDa 
marker. The series of bands that appear at 45 kDa in all of the tissue samples 
suggest the presence of CSE protein. There is also an additional band in the liver 
sample lane at a slightly higher molecular weight with a greater band intensity. This 
implies that the liver could be expressing a splice variant with a heavier molecular 
weight. It is possible that the CSE protein in the liver sample is more abundantly 
expressed due to being more active. As a result increased activation may result in 
increased phosphorylation and an increase in molecular weight. Running a BLAST 
search with the peptide sequence for CSE, revealed that there are two possible 
phosphorylation sites, as well as two PKC-target sites. These may account for a slight 
change in molecular weight of the CSE protein. However, CSE is unlikely to be 
heavily phosphorylated due to the reducing conditions used for the protein 
separation. The series of bands that occur just above the 35 kDa marker are less
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likely to be CSE because the liver band is very weak, which seems uncharacteristic of 
its strong mRNA expression.
The CSE protein expression in the rat myocardium was unconfirmed using Western 
blotting due to the lack of specificity of the antibody. An attempt to over-come the 
poor specificity of antibody was performed by preparing transcripts containing 
increasing amounts of a CSE expression vector that were inserted into the GH3 cell 
line, to create cells with corresponding increases in CSE protein expression. When 
these cells were lysed and Western blotting was performed with the CSE antibody, 
there was an expected increase in the band density across the blot as the amount of 
CSE expression vector and subsequent CSE protein increased. The idea behind this 
method was that the position of the bands of increasing density represented the CSE 
protein, allowing it to be distinguished from the multiple series of bands appearing 
on the blots. Nevertheless, due to the considerable extent of the non-specific 
binding observed in the transfected GH3 extracts, it is difficult to determine whether 
the band at 40 kDa truly represented the immunoreactive CSE protein. What these 
findings do confirm is that the antibody to CSE was highly unspecific, making the 
antibody of limited use for protein determination using Western blotting.
3.10.2.2 Lack of experimental evidence fo r CSE expression in the myocardium 
It has been reported that the expression of CSE in the myocardium is unknown (Geng 
et al., 2004c), and the lack of a commercially available CSE antibody (Zhao et al., 
2001a) has prevented the robust detection of the CSE protein. Studies conducted by 
Ishii et al. (2004) who produced their own CSE antibody, gave equivocal evidence of 
CSE protein expression in the myocardium. A recent study by Chuah et al (2007) has 
confirmed the presence of CSE protein in the left ventricle from rats, although no 
details of the source of antibodies is given. Therefore the evidence supporting 
statements in the literature by authors such as Fiorucci et al. (2005) and Geng et al. 
(2004c) that CSE is the predominant enzyme in the myocardium appears somewhat 
unfounded. Clearly there is a great need for a commercially available CSE antibody to
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improve the quality of Western blots and enable confident characterisation the CSE 
protein expression.
3.10.2.3 Polyclonal anti-probasin antibody detects CSE in right ventricle and liver 
The anti-probasin mono and polyclonal antibodies were a generous gift from Dr. 
Nishi in Japan (Nishi et al., 1992). The blots presented in this chapter using the 
polyclonal antibodies suggest expression of the CSE protein in the right ventricle, 
cerebellum and liver. Surprisingly there appears to be an absence of a band in the 
left ventricle lane, suggesting the absence of the CSE enzyme. There appears to be 
no reason as to why the right ventricle would express the protein and the left would 
not. Previously reported data from Dr. Nishi's laboratory using the polyclonal 
antibody show has shown bands at 43 kDa in aorta, mesenteric artery, tail artery 
smooth muscle, and pulmonary artery from rat tissue samples (Cheng et al., 2004). 
The results using the monoclonal form of the antibody were less encouraging with 
no bands of the correct size in any of the tissue samples tested. There were only 
bands observed in right ventricle and cerebellum column much further up the blot 
suggesting the presence of heavier proteins. It was surprising that even the liver 
sample didn't show a band since it appears to be a robust tissue sample that has 
consistently shown expression with the other antibodies tested. These findings 
suggest that either the antibody was either not that specific to the CSE protein 
making it unable to detect it, or it had become denatured making it ineffective at 
detecting the CSE protein.
3.10.2.4 CBS antibody has poorselectivity fo r CBS
The liver was the only tissue sample to show a band when using the CBS antibody. 
The position of the band was also at approximately 45 kDa as opposed to the 
expected molecular weight of 63 kDa. However, it is known that a dimer of CBS 
exists with a molecular weight of 48 kDa (Skovby et al., 1984). It this thought that 
CBS is originally formed into a tetrameter structure of 63 kDa and that the dimer 
form occurs as a result of a specific protease activity. The 48 kDa dimer form is 
thought to be the catalytically active form of the 64 kDa tetrameter. In fact previous
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attempts to purify CBS protein from mammalian livers have yielded enzyme 
containing subunits with a molecular weight lower than 63 kDa (Borcsok et al., 1982; 
Kraus et al., 1978). However, the existence of a dimer form of CBS is unlikely to be 
detected using the Western blotting techniques outlined in this chapter, due to the 
reducing conditions when separating the proteins. Only if the reducing conditions 
were not entirely efficient, would enable protein-protein interactions remain.
There appears to be no CBS protein in the myocardium and cerebellum samples. 
Whilst it has been previously reported that CBS expression is weak/absence in the 
myocardium (Zhao et al., 2002), the lack of a band in the cerebellum sample which is 
thought to predominantly express the CBS express was an unexpected finding. 
These findings suggest that the Santa Cruz antibody used to detect CBS perhaps had 
poor selectivity for CBS. Ideally a CBS antibody from a different company should 
have been tested and the results compared. However, at the time of 
experimentation Santa Cruz were the only suppliers of a CBS antibody that had been 
tested in rat and was therefore the primary choice.
Another possible explanation for the lack of bands in the cerebellum and 
myocardium lanes is that the liver contained such a high abundance of CBS that it 
masked the weaker expression in the other tissues in the short exposure times of the 
blots to the photographic film. This could have been investigated by exposing the 
blots to the photographic film for longer to see if any bands appeared in the lanes of 
the cerebellum and myocardium samples. However, previous experience of over­
exposed films usually resulted in increased background noise making it very difficult 
to determine the position of the bands on interest.
3.10.2.5 Further uses fo r antibodies
The antibodies used in the Western blotting could also be used for 
immunohistochemistry to enable localisation of the H2S producing enzymes in the 
myocardium. Sections from different regions of the heart could be prepared and the 
presence of the enzymes investigated to see if there is regional variation in
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distribution. Some preliminary work has been conducted using transverse sections 
of heart tissue. Unfortunately, the unspecific nature of the CSE antibody resulted in 
a large amount of background noise appearing on the slides, making it difficult to 
conclude with confidence the areas that were actually staining positive for CSE. 
Immunohistochemistry with the CBS antibody showed no staining in any of the 
regions of rat myocardial tissue samples. Taken in isolation there results suggest 
that the rat myocardium lacks the CBS enzyme. However, taking these findings in 
the context of the Western blotting studies showing a lack bands in the positive 
control cerebellum sample, suggest that these findings are of limited value and can't 
be confidently accepted. Had time permitted it would have been interesting to 
repeat these studies and also use slices of cerebellum and liver tissue to act as 
positive controls to give greater confidence in the observed results.
3.11 Conclusion
The poor performance of the antibodies, in particular CSE, used in the Western 
blotting studies makes it difficult to draw a definitive conclusion about the 
expression of the H2S synthesising enzymes in the myocardium from the studies in 
this chapter. This issue of poor selectivity was addressed during the course of the 
studies and a conscious effort was made to try and characterise the CSE antibody 
further through the use of an expression vector for CSE in a GH3 cell line. However, 
this too was of limited success, but did act to further highlight the issue surrounding 
the poor selectivity of the CSE antibody, as opposed to the Western blotting 
technique. Therefore it can be concluded that the CSE antibody appears highly 
unspecific to the CSE protein and also contains contaminants in the serum which 
effect the quality of the blots. However, the PCR data suggests that the rat 
myocardium, liver and cerebellum all contain CSE and CBS mRNA expression, which 
suggests these tissue have the potential to express CSE and CBS protein enabling H2S 
production. Further evidence to support the existence of H2S synthesising enzymes 
is provided in studies investigating the production of H2S gas after endogenous 
stimulation with substrate and co-factor, which are presented in chapter 4 and 5.
Chapter 4 Exogenous stimulation of H2S production
Chapter 4 Exogenous stimulation of H2S production using L- 
cysteine to limit infarct size during ischaemia-reperfusion
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4.1 Introduction:
An extensive overview of the H2S synthesis pathway has been reviewed in Chapter 1. 
Studies performed in the previous chapter (chapter 3) attempted to explore the 
expression of the H2S synthesising enzymes (CSE and CBS) in the rat myocardium at 
both the mRNA and expressed protein level. Whilst the results from the PCR studies 
confirm the potential for protein expression from positive mRNA findings, there was 
no definitive proof from Western blotting studies of protein expression. The studies in 
this chapter aimed to build on these previous findings and further characterise the 
existence of the CSE/CBS enzymes in the rat myocardium, by exogenously stimulating 
H2S production and observing the effect on infarct size limitation. As mentioned 
previously in Chapter 1, endogenous H2S synthesis predominantly occurs via the CSE 
and CBS enzymes that use L-cysteine as substrate (Szabo, 2007) and pyridoxal-5'- 
phosphate (P-5'-P) as co-factor (Stipanuk et al., 1982). Therefore in the studies 
conducted in this chapter and in Chapter 5, endogenous H2S synthesising conditions 
were mimicked. A specific pharmacological inhibitor to CSE, DL-propagylglycine (PAG), 
was also used to confirm the involvement of the CSE enzyme, since this is thought to 
be the key enzyme responsible for H2S production in the myocardium (Abe et al., 
1996; Geng et al., 2004b).
The table in figure 4.1 summarises a number of published PCR studies characterising 
the H2S synthesising enzymes in various tissue samples including the myocardium, 
providing further evidence to support the potential to exogenously stimulate H2S in 
the myocardium.
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Species___________________Tissue______________________Reference
Rat Heart, brain, thoracic aorta (Geng et al., 2004c)
Rat Thoracic aorta (Zhong et al., 2003)
Rat Left ventricle, right ventricle
(Zhu et al., 2007)
Rat
Aortic vascular smooth muscle cells 
from (Zhong et al., 2009)
Rat Aorta (Wu et al., 2006)
Endothelium-free pulmonary artery,
Rat mesenteric artery, tail artery, aorta, (Zhao et al., 2001a)
liver
Human Aortic smooth muscle cells (Yang et al., 2006)
Figure 4.1 Summary o f published PCR studies characterising the CSE enzymes in 
various tissues including the myocardium.
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4.2 Aim
The aim of this series of experiments was to investigate if exogenous stimulation of 
the H2S synthesising enzyme CSE, with its substrate L-cysteine and co-factor P-5'-P, 
limits infarct size in Langendorff perfused rat hearts subjected to regional ischaemia- 
reperfusion.
4.3 Hypotheses
1. Stimulated H2S production using L-cysteine, will limit infarct size in rat hearts 
subjected to regional ischaemia-reperfusion
2. Addition of the CSE co-factor P-5'-P will enhance H2S production and further 
limit infarct size in rat hearts subjected to regional ischaemia-reperfusion
4.4 Objectives
The validity of these hypotheses was tested as follows:
1. To determine of the optimum concentration of L-cysteine to induce 
cardioprotection
2. To determine if cardioprotection is induced by L-cysteine stimulated H2S 
production using the CSE specific inhibitor PAG
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4.5 Methods
4.5.1 Source of compounds
The CSE substrate L-cysteine, the CSE inhibitor DL-propagylglycine (PAG) and the CSE 
co-factor P-5'-P (P-5'-P) were purchased from Sigma-Aldrich, UK. All compounds were 
dissolved in Krebs Buffer and therefore required no vehicle controls.
4.5.2 Preparation of Langendorff perfused isolated rat hearts
4.5.2.1 Setup o f isolated heart perfusion
Heart samples used for the maximal H2S synthesising capacity assay and endogenous 
H2S tissue concentration experiments, were prepared from rat isolated perfused 
hearts.
Isolated rat hearts were Langendorff perfused using the methods described in Chapter 
2, section 2.2. All hearts received an initial 10 minute stabilisation period after initially 
being cannulated to enable a regular sinus rhythm to be obtained. The hearts were 
then randomly assigned to one of the groups within each study described below. 
Throughout the experiments the cardiodynamic parameters were measured (heart 
rate, developed pressure, and coronary flow rate) to ensure that the hearts were 
maintaining function and to observe any drug induced effects on the normal 
functioning of the hearts.
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4.5.2.2 Treatment protocols
Study 1: Optimum L-cysteine concentration for infarct size limitation
Group 1 - Control: After 20 minutes of stabilisation, hearts were subjected to 35 
minutes regional ischaemia, and a 120 minute reperfusion period. For the duration of 
the experiment hearts were perfused with Krebs buffer.
Group 2 - L-cysteine 0.1 mM: After 10 minutes of stabilisation, hearts were perfused 
with Krebs containing L-cysteine 0.1 mM for the remaining 10 minutes of stabilisation 
until the first 10 minutes of reperfusion.
Group 3 - L-cysteine 1 mM: As per group 2 except hearts were perfused with L- 
cysteine 1 mM.
Group 4 - L-cysteine 10 mM: As per group 2 except hearts were perfused with L- 
cysteine 10 mM.
The greatest reduction in infarct size was seen with L-cysteine 1 mM, so this 
concentration was used for the subsequent studies.
- 20’ - 10’ 35’ 45’
Group 1 -  Control
Group 2 -  L-cysteine (0.1 mM) perfusion 
Group 3 -  L-cysteine (1.0 mM) perfusion
Group 4 -  L-cysteine (10 mM) perfusion |
20’ stabilisation 35 regional ischaemia 120’ reperfusion
155’
Figure 4.2 Summary o f the perfusion protocol fo r study Study 1: Optimum L-cysteine 
concentration fo r infarct size limitation. In all treatment groups, 35 minutes o f 
regional ischaemia was induced, after a 20 minute stabilisation period, by tightening 
the snare on the suture passed around the left main coronary artery. Each heart 
received 120 min reperfusion following ischaemia. After 10 minutes of reperfusion, the 
treatment hearts were perfused with Krebs fo r the duration o f the perfusion period.
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Study 2: Effect of L-cysteine and P-5'-P on infarct size
Group 1 - Control: After 20 minutes of stabilisation, hearts were subjected to 35 
minutes regional ischaemia, and a 120 minute reperfusion period. For the duration of 
the experiment hearts were perfused with Krebs buffer.
Group 2 - L-cysteine 1 mM: After 10 minutes of stabilisation, hearts were perfused 
with Krebs containing L-cysteine 1 mM for the remaining 10 minutes of stabilisation 
until the first 10 minutes of reperfusion.
Group 3 -  P-5'-P 50 pM: As per group 2 except hearts were perfused with P-5'-P 50 
|iM.
Group 4 -  L-cysteine 1 mM and P-5'-P: As per group 2 except hearts were perfused 
with L-cysteine 1 mM and P-5'-P 50 pM.
- 20’
Group 1 -  Control 
Group 2 -  L-cysteine (1 mM) perfusion t
Group 3 -  L-cysteine + P-5-P perfusion i
Group 4 -  P-5-P (50 pM) perfusion
- 10’ 0’ 35’ 45’i i i i
155’
1
20’ stabilisation 1 J 1 1120’ reperfusion
i i i  i i  i
Figure 4.3 Summary o f the perfusion protocol fo r study 2: Effect o f L-cysteine and P-5'- 
P on infarct size. In all treatment groups, 35 minutes o f regional ischaemia was 
induced, after a 20 minute stabilisation period, by tightening the snare on the suture 
passed around the left main coronary artery. Each heart received 120 min reperfusion 
following ischaemia. After 10 minutes o f reperfusion, the treatment hearts were 
perfused with Krebs fo r the duration o f the perfusion period.
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Study 3: Effect of PAG on infarct size limitation by L-cysteine
Group 1 -  Control: After 20 minutes of stabilisation, hearts were subjected to 35 
minutes regional ischaemia, and a 120 minute reperfusion period. For the duration of 
the experiment hearts were perfused with Krebs buffer.
Group 2 - L-cysteine 1 mM: After 10 minutes of stabilisation, hearts were perfused 
with Krebs containing L-cysteine 1 mM for the remaining 10 minutes of stabilisation 
until the first 10 minutes of reperfusion.
Group 3 -  PAG ImM: After 5 minutes of stabilisation, hearts were perfused with 
Krebs containing PAG ImM until the first 10 minutes of reperfusion.
Group 4 -  L-cysteine Im M  + PAG 1 mM: After 5 minutes of stabilisation, hearts were 
perfused with Krebs containing PAG ImM, then after an additional 5 minutes hearts 
were perfused with Krebs containing PAG Im M  and L-cysteine 1 mM for the 
remaining 10 minutes of stabilisation until the first 10 minutes of reperfusion.
- 20 ’ - 10’ 0’ 35’ 45’ 155’i i i ij  i
20’ stabilisation 35’ regional ischaemia 120’ reperfusion
Group 1 -  Control 
Group 2 -  L-cysteine (1 mM) perfusion r
Group 3 -  L-cysteine + PAG perfusion t
Group 4 -  PAG (1 mM) perfusion
Figure 4.4 Summary o f the perfusion protocol fo r study 3: Effect o f PAG on infarct size 
limitation by L-cysteine. In all treatment groups, 35 minutes o f regional ischaemia was 
induced, after a 20 minute stabilisation period, by tightening the snare on the suture 
passed around the left main coronary artery. Each heart received 120 min reperfusion 
following ischaemia. After 10 minutes o f reperfusion, the treatment hearts were 
perfused with Krebs fo r the duration o f the perfusion period.
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4.6 Results
4.6.1 Exclusion criteria
To ensure that data was as reproducible within treatment groups and not biased 
between groups, strict exclusion criteria were used. Hearts were excluded from the 
study if they failed to obtain a developed pressure less than 50 mmHg during the 
stabilisation period, had a heart rate less than 200 bpm, and failed to have a flow rate 
of between 10 and 15 ml/min. Hearts were also excluded on technical grounds during 
experiments such as pulling the suture out during ischaemia, failing to reduce 
coronary flow by at least a third during the first 5 minutes of ischaemia, or failing to 
restore coronary flow at reperfusion.
In total 63 rat hearts were used for the experiments performed in these studies. Of 
these 63 hearts, 8 were excluded on technical grounds, resulting data from 55 rat 
hearts being presented in this chapter.
4.6.2 Study 1: Optimum L-cysteine concentration for infarct size limitation
In the Langendorff isolated perfused rat heart model L-cysteine limited infarct size in a 
concentration-dependent manner, with Im M  being the most protective concentration 
and produced a significant reduction compared to control (24.3 ± 3.4% vs. 36.4 ± 2.4%, 
p<0.05). L-cysteine concentrations of 0.1 and 10 mM produced slight reductions in 
infarct size compare to control, but these were not significant (31.8 ± 2.2% and 29.3 ± 
3.5% vs. 36.4 ± 2.4% for 0.1, 10 mM l-cysteine and control respectively) (data 
summarised in figure 4.5).
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*
Figure 4.5 Summary o f infarct to risk ratios (%) fo r L-cysteine concentration ranging 
studies. L-cysteine 1 mM was the most effective at infarct size limitation and was used 
fo r subsequent studies. *p<0.05, one-way ANOVA + Newman Keuls post-hoc test.
4.6.3 Study 2: Effect of L-cysteine and P-5'-P on infarct size:
Co-perfusion of L-cysteine 1 mM and P-5'-P 50 |iM, produced no additional protective 
effect at infarct size limitation compared to L-cysteine alone (24.3 ± 3.4% vs. 25.2 ± 
5.1% for L-cysteine alone and L-cysteine + P-5'-P respectively) (data summarised in 
figure 4.6).
*
Figure 4.6 Summary o f infarct to risk ratios (%) fo r L-cysteine and P-5'-P perfused 
hearts. Co-perfusion of L-cysteine and P-5'-P produced no additional cardioprotection 
over L-cysteine alone. *p<0.05, one-way ANOVA + Newman Keuls post-hoc test.
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4.6.4 Study 3: Effect of PAG on infarct size limitation by L-cysteine
Pre-treatment with the CSE inhibitor, PAG 1 mM, partially attenuated the protective 
effect of L-cysteine 1 mM (30.4 ± 5.9 vs. 24.3 ± 3.4 % )  (data summarised in figure 4.6). 
PAG alone had no significant effect on the size of the infarct compared to control (31.0 
± 5.6 vs. 36.4 ± 2.4) (data summarised in figure 4.7).
*
Figure 4.7 Summary o f infarct to risk ratios (%) fo r  L-cysteine and PAG perfused 
hearts. PAG partially attenuated the cardioprotective effects o f L-cysteine. *p<0.05, 
one-way ANOVA + Newman Keuls post-hoc test.
4.6.5 Coronary flow  and contractility data
Baseline cardiodynamic data (heart rate, coronary flow rate, developed pressure and 
rate pressure product for the hearts in each of the three study groups is shown in 
figure 4.8. The rate pressure product and coronary flow rate of the hearts throughout 
the experiments is presented in figure 4.8. There were no significant effects of any of 
the compounds tested on the measured parameters. Regional ischaemia caused a 
reduction in rate pressure product and coronary flow rate in all treatment groups as 
expected (as shown in figure 4.9A). Run-down of the hearts is demonstrated by a 
reduction in rate pressure product in all treatment groups as expected (as shown in 
figure 4.9B).
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Treatment group n CFRml/min
HR
BPM
LVDP
mmHg
RPP 
mmHg/min x103
RV and LV vol. 
cm3
Risk zone vol. 
cm3
Control 12 16.4 ±1.4 288 ±8 78.2 ± 5.4 22.5 ±1.7 0.70 ± 0.03 0.35 ± 0.03
L-cysteine 0.1 mM 4 17.6 ±1.3 265 ± 22 65.9 ± 5.9 17.6 ±2.6 0.63 ± 0.07 0.31 ± 0.05
L-cysteine 1 mM 10 17.2 ±1.1 290 ±14 79.0 + 5.6 22.7 ±1.6 0.78 ± 0.03 0.38 ± 0.04
L-cysteine 10 mM 6 16.3 ±1.3 251 ±15 63.8 ±4.1 15.9 ±1.2 0.87 ± 0.03 0.49 ± 0.05
PAG 1 mM 6 1J.7 ±1.1 249 ±8 71.9 ±5.7 17.7 ±0.9 0.77 ±  0.04 0.43 ± 0.05
L-cysteine + PAG 6 19.7 ±0.9 279 ± 24 73.9 ± 3.9 20.6 ± 2.1 0.56 ± 0.03 0.36 ± 0.03
P-5’-P 50 pM 6 14.8 ±0.7 288 ±15 55.3 ± 3.0 16.0 ±0.9 0.76 ± 0.03 0.48 ± 0.03
L-cysteine + P-5-P 5 15.1 ±1.4 258 ± 26 83.3 ± 9.0 21.3 ±2.0 0.77 ±0.02 0.38 ± 0.04
Figure 4.8 Baseline cardiodynamic data fo r hearts used in the three studies investigating the role o f exogenously stimulated H2S synthesis on 
cardioprotection. Abbreviations: LV = left ventricle, RV = right ventricle, CFR = coronary flow  rat, HR = heart rate, LVDP = left ventricular 
pressure, RPP = rate pressure product (HR x LVDP).
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Figure 4.9 Rote pressure product (RPP) (A) and coronary flow  rate (CFR) (B) in each o f 
the treatment groups taken throughout the duration o f the experiments. 
Stab.=stabilisation period (20 mins), lsch.=Regional ischaemia (35 mins), Re perfusion 
(120 mins). Each value shown is the mean from 4-12 individual rats. SEM error bars 
have been removed fo r clarity.
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4 .7  Discussion
The findings of this study can be summarised briefly as follows:
1. It was possible to limit infarct size during ischaemia-reperfusion in isolated rat 
hearts perfused with L-cysteine for the 35 minute duration of regional 
ischaemia and initial 15 minutes of reperfusion.
2. The infarct limiting effect of L-cysteine was partially attenuated in the 
presence of the selective CSE inhibitor PAG, suggesting a role of CSE in H2S 
production.
3. The addition of the CSE co-factor P-5'-P caused no additional infarct limitation.
4.7.1 Study 1 - Investigation of the cardioprotective effects of L-cysteine
4.7.1.1 L-cysteine perfusion reduced infarct size in a concentration dependent manner 
The effect of exogenous L-cysteine at reducing infarct size in the Langendorff perfused 
isolated rat heart, suggest that exogenous L-cysteine protects against irreversible 
ischaemia-reperfusion injury in the myocardium in a concentration dependent 
manner, with 1 mM eliciting the greatest cardioprotection by increased stimulation of 
the CSE enzyme to produce H2S. The observation that 10 mM L-cysteine was less 
protective than 1 mM L-cysteine, but caused a greater protective effect than 0.1 mM, 
suggests that higher concentrations of substrate may saturate the enzyme and limit 
the H2S production or H2S is produced at levels that are cytotoxic rather than 
protective. The cytoxicity of NaHS at higher concentrations has been implicated by 
Johansen et al. (2006), in which it was reported that exogenously supplied NaHS 
caused a biphasic concentration dependent reduction in infarct size in the Langendorff 
perfused rat hearts (0.1-10 pM). At 10 pM, the protective effect was diminished and 
10 pM NaHS was associated with cytotoxic, metabolic or other non-specific effects of 
either the H2S or its metabolites HS' or S2', or another unknown impurity, that 
overwhelm the protective action seen at a lower concentration.
109
Chapter 4 Exogenous stimulation of H2S production
4.7.12 L-cysteine may have acted as a free radical savenger to induce 
cardioprotection
An alternative mechanism to explain the cardioprotective effect observed with L- 
cysteine was that it was acting as a free radical scavenger. It is has been reported in 
the literature that cysteine containing moieties are effective free radical scavengers 
(Shackebaei et al., 2005). A study by Saez et al. (1982) showed that when working 
with concentrations of L-cysteine 4 mM and above, it was prone to autoxidation with 
the formation of thiyl and hydroxyl radicals, resulting in membrane damage and 
depletion of ATP and glutathione. This may explain why L-cysteine 10 mM was 
produced less cardioprotection than 1 mM. Concentrations of L-cysteine greater than 
1 mM have also been shown to cause a decrease in the left ventricular developed 
pressure under normal conditions (Tani, 1990), which is interesting since there was a 
tendency, although not significant, for a reduction in the rate pressure product in the 
L-cysteine 10 mM group during reperfusion.
L-cysteine 0.5 mM has been shown to be cardioprotection in rat hearts subjected to 
45 minutes global ischaemia using the same L-cysteine perfusion algorithm as used for 
the studies presented in this chapter (Shackebaei et al., 2005). Whilst infarct size was 
not the measured endpoint, a significant increase in functional recovery and 
preservation of ATP and glutathione levels were reported compared to control. 
Proposed mechanisms of action include direct scavenging of free radicals or improved 
antioxidant capacity through the preservation of glutathione levels.
4.7.1.3 L-cysteine may interact with NO to form S-nitrothiols
L-cysteine, at concentrations in the milimolar range, has also been shown to interact 
with nitric oxide to form S-nitrothiols (Stamler, 1994). The formation of these S- 
nitrothiol complexes act as nitric oxide carriers and stabilise the activity of nitric oxide 
free radicals. Therefore an additional mechanism by which L-cysteine may have 
induced cardioprotection in these experiments was by the formation of S-nitrothiols 
stabilising the large amount of free nitric oxide free radicals which would be formed at 
reperfusion. It could also be speculated that L-cysteine may also interact with other 
free radicals formed at reperfusion such as the superoxide anion ( 02) and the hydroxyl
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radical ( OH), formed from the reintroduction of oxygen, acting to stabilise them and 
resulting in cardioprotection.
However, a recent study by Khanna et al. (2008) showed that preconditioning with N- 
acetyl cysteine, an analogue of L-cysteine, 1 mM attenuated physiological and 
pharmacological preconditioning in isolated rat hearts, and also inhibited remote 
preconditioning in an in vivo rat model. Interestingly, a cysteine containing nitric 
oxide donor, SP/W-518, has been shown to attenuate post-ischaemia myocardial 
injury in isolated perfused rabbit hearts (Liu et al., 1998). However, an analogue 
compound of SP/W-518, SPW/-6373, lacking the nitric oxide moiety, induced no 
cardioprotection. These findings suggest that cysteine may not have a 
cardioprotective action as many have proposed, and can in fact be inhibitory to the 
cardioprotective actions of other stimuli. However, the findings from the study 
presented in this chapter oppose these findings, but differences in experimental 
protocols and the fact that N-acetylcysteine as opposed to L-cysteine was used may 
also explain these contradictory findings.
4.7.2 Study 2 - Effect of the addition of P-5'-P to the cardioprotective effect of L- 
cysteine
4.7.2.1 Perfusion with P-5'-P produced no additional cardioprotection 
The addition of pyridoxal 5'phosphate, the cofactor of the CSE enzyme, produced no 
additional reduction in infarct size when used in combination with L-cysteine, 
compared to L-cysteine ImM alone. In fact it slightly increased the infarct size and as 
a result there was not a significant cardioprotective effect observed. This suggests 
that sufficient cofactor was already present in the myocardium to enable maximal 
production of H2S. Alternatively this finding suggests that not a high enough 
concentration of P-5'-P was tested, resulting in limited H2S production. The latter 
explanation seems unlikely though since the concentration tested was based on an 
estimate of physiological levels. Perhaps a better explanation is that the P-5'-P was 
unable to cross internal membranes and reach the site of the H2S synthesising 
enzymes and therefore unable to further increase H2S production. This may have 
been due to the size or the charge on the compound impeding its access.
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Some interesting clinical studies have been conducted with pyidoxal-5'-phosphate to 
investigate its cardioprotective actions. In a phase II pilot study it has been shown 
that patients pre-treated with P-5'-P monohydrate (MC-1) prior to percutaneous 
coronary intervention, had a significant reduction in myocardial ischaemic injury, 
determined by measurement of the area under the curve of creatine kinase, 
compared to placebo control (Kandzari et al., 2003). These findings suggest that P-5'- 
P induces cardioprotecitve and may therefore be a useful therapeutic intervention 
prior to percutaneous coronary intervention. Further trials in patients at risk from 
developing myocardial ischaemia, infarction or reperfusion injury are required to 
further explore this potential therapeutic intervention.
P-5'-P levels measured in French-Canadian patients suffering from coronary artery 
disease, have been shown to be significantly reduced compared to healthy subjects 
(Dalery et al., 1995). It has been suggested that reduced P-5'-P levels may be a 
contributing factor to elevated homocysteine levels observed in patients with 
coronary artery disease. Homocysteine levels have been identified as a risk factor for 
atherosclerotic disease although the link is poorly understood (Verhoef et al., 1997). 
A proposed atherogenic mechanism involves the inhibition of growth of endothelial 
cells and stimulation of smooth cell proliferation by homocysteine, resulting is 
thickening of aterial walls. Therefore patients suffering from coronary artery disease 
could potentially be treated with P-5'-P supplements, to lower homocysteine levels 
and reduce atheroma formation.
In view of these findings, it suggests that P-5'-P alone has the ability to produce 
cardioprotection. However, in the studies presented in this chapter it showed no 
cardioprotective effect when tested alone or in combination with L-cysteine. A 
possible explanation for the lack of cardioprotection on its own is that whilst it may 
have the potential to play an important role in cardioprotection, it may have more of 
an involvement in preventing the progression of atherosclerosis and reducing 
associated damage to the heart in a more indirect manner. Therefore in a model of 
acute myocardial infarction direct cardioprotection is unlikely to occur.
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4.7.3 Study 3 - Effect of cardioprotective effect of L-cysteine in the presence of PAG
4.7.3.1 PAG attenuated the cardioprotective effect o f L-cysteine 
The finding that the protective effect of L-cysteine was partially attenuated in the 
presence of PAG suggests that the cardioprotective effect of L-cysteine may at least be 
partially mediated through the activation of the enzyme CSE, resulting in H2S 
generation and subsequent cardioprotection. The other small amount of remaining 
cardioprotection observed with L-cysteine in the presence of PAG may be due to L- 
cysteine's ability to act as a free radical scavenger or the generation of H2S from 
another source.
The use of a CSE inhibitor with a different mechanism of action would help to confirm 
this, since it may be more potent and therefore able to totally abolish the 
cardioprotection. The use of a specific CBS enzyme inhibitor, such as aminooxyacetic 
acid, would also be interesting, since it has been reported that in the myocardium CSE 
is the main enzyme responsible for H2S production (Tang et al., 2006a) and this could 
be used to confirm these findings. This does not rule out a contribution of H2S from 
the CBS enzyme, although findings by Chen at al. (1999) reported that there was no 
activity or expression of CBS in human atrium and ventricles. This suggests that MST, 
the third H2S producing enzyme, may be responsible for the small protective effect 
observed during ischaemia when the CSE enzyme would be expected to be inhibited 
by PAG. The use of a selective CBS inhibitor (e.g. aminooxyacetic acid) in combination 
with a selective CSE inhibitor (PAG) would enable the potential contribution of the 
MST enzyme to H2S production to be determined. This may provide evidence as to 
whether MST is another H2S synthesising enzyme that could be targeted for 
protection against ischaemia- reperfusion injury.
113
Chapter 4 Exogenous stimulation of H2S production
4.7.4 Further studies
The Langendorff isolated perfused rat heart model could be developed further by 
using a constant flow system to investigate the effect of L-cysteine perfusion and 
whether it effects coronary tone. A reduction in coronary tone, may indicate the 
generation of H2S, providing a greater insight into the cardioprotective mechanism of 
action of L-cysteine perfusion. From the studies conducted with L-cysteine it was not 
possible to determine when L-cysteine was inducing its cardioprotective since hearts 
were perfused over ischaemia and early reperfusion. Perfusing hearts with L-cysteine 
at different time points and observing when it produces its greatest cardioprotection, 
would determine if it has an optimum time point of action. Experiments performed in 
Chapter 5 investigated the effect of perfusing the heart with an H2S donor compound 
and observing the effect on infarct size, as well as measuring the H2S tissue 
concentration in rat hearts stimulated with L-cysteine, and the effect of ischaemia- 
reperfusion on the maximal H2S synthesising capacity of the myocardium.
4.8 Conclusion
Taken together, the findings of these three studies show that exogenous L-cysteine 
exhibited a concentration dependent reduction in infarct size, with a concentration of 
1 mM eliciting the greatest protection. This cardioprotective effect of L-cysteine was 
not enhanced in the presence of CSE's co-factor pyridoxal-5-phosphate. The 
protective effect of L-cysteine was attenuated in the presence of the selective CSE 
enzyme inhibitor PAG, suggesting that exogenous L-cysteine may have stimulated 
increased H2S production via the CSE enzyme. To determine if increased H2S 
production did occur after stimulation with L-cysteine, a concentration determining 
assay could be performed. This would assist in deciphering the mechanism of 
cardioprotection induced by L-cysteine, as currently there remains a level of 
uncertainty as to whether L-cysteine was acting as a free radical scavenger to induce 
cardioprotection or whether its cardioprotective action was through the generation of 
H2S gas, and if it was through the generation of H2S, which enzyme(s) was responsible.
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Chapter 5: Measurement of the maximal H2S synthesising 
capacity and tissue concentrations of H2S, in hearts subjected 
to ischaemia-reperfusion or L-cysteine perfusion
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5.1 Introduction
As described in detail in the Chapter 1 the myocardium predominantly expresses the 
H2S synthesising enzyme CSE. This was investigated further in Chapter 3 by 
characterising the mRNA and protein expression, and also in Chapter 4 where 
stimulated H2S production caused infarct size limitation. Measurement of the 
stimulated activity of this enzyme can be determined experimentally, as well as 
endogenous tissue concentrations of H2S and would provide a greater understanding 
of the role of H2S and the effect of ischaemia-reperfusion its production. Stipanuk and 
Beck (1982) outline a method for the measurement of exogenously stimulated 
enzymatic production of H2S gas from homogenised tissue samples which has been 
widely adopted. The technique relies on using the substrate L-cysteine and co-factor, 
P-5'-P, to stimulate the H2S generating enzymes to produce H2S gas. The resulting gas 
is then trapped on zinc acetate soaked filter paper. The trapped gas then causes a 
colorimetric change in a ferric chloride solution as the iron is oxidised. The resulting 
solution is measured spectrophotometrically and the use of H2S standards prepared 
from the donor NaHS enables a standard curve and the concentration of the sample to 
be determined. Examples of the broad spectrum of tissues used to investigate 
stimulated enzymatic production of H2S are shown in figure 5.1. This also highlights 
the diversity of the units of expression for the maximal enzyme synthesising capacity, 
and also the limited number of studies investigating the myocardium.
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Species Tissue Conditions H2S production Reference
Liver 280 mM L-cys, 3 mM P-5'-P 0.403pmol/min/g wet tissue (Stipanuk et al., 1982)
Kidney 0.192|imol/min/g wet tissue
Liver 160 mM L-cys, 2 mM P-5'-P, 3 mM 2-oxo, 3 mM dithio 2.31pmol/min/g wet tissue
Rat Kidney 1.96pmol/min/g wet tissue -
Liver
Kidney
2 mM L-cys, 0.05 mM P-5'-P 0.017pmol/min/g wet tissue 
0.013pmol/min/g wet tissue
Liver 2 mM L-cys, 0.05 mM P-5'-P, 0.5 mM 2-oxo, 0.05 mM dithio 0.019|imol/min/g wet tissue
Kidney 0.018|imol/min/g wet tissue
Rat Myocardium 10 mM L-cys, 2 mM P-5'-P 18.64nmol/min/g protein (Geng et al., 2004c)
Rat" Liver 10 mM L-cys,ImM P-5'-P 40 nmol/mg protein (Mok et al., 2004)
Kidney 17 nmol/mg protein
Thoracic aorta 10 mM L-cys, 2 mM P-5'-P 4 pmol/min/mg wet tissue (Hui et al., 2003)
Rat Pulmonary artery 5 pmol/min/mg wet tissue
Mesenteric artery 
Tail artery
6 pmol/min/mg wet tissue 
8 pmol/min/mg wet tissue
Mouse Liver
Kidney
10 mM L-cys, 2 mM P-5'-P 0.59 nmol/mg protein 
0.127 nmol/mg protein
(Li etai., 2005)
Rat Mesenteric artery bed 1 mM L-cys 22.5 nM/min/g wet tissue (Cheng et al., 2004)
Ileum 10 mM L-cys, 2 mM P-5'-P 20.3 nMol/min/g protein (Hosoki et al., 1997)
Rat Portal vein 
Thoracic aorta
19.6 nMol/min/g protein
33.7 nMol/min/g protein
Marine invertebrate 
Tissue (clam and 
lugworm)
Gill 
Foot 
Mantle 
Body wall
10 mM L-cysteine, 2 mM P-5'-P 0.25 nmol/g/min 
0.045 nmol/g/min 
0.047 nmol/g/min 
0.37 nmol/g/min
(Julian eta i, 2002)
Figure 5.1 Examples o f the broad spectrum o f tissues used to investigate stimulated enzymatic production o f H2S. Note the diversity o f the 
units of expression fo r the maximal enzyme synthesising capacity; and also the limited number of studies investigating the myocardium.
117
I Chapter 5 Investigating CSE enzyme activity
Stipanuk and Beck's method has subsequently been adapted by Mok et al. (2004) to 
enable the amount of H2S contained within a tissue sample to be measured. It relies 
on the same principle of trapping the gas and the H2S undergoing a colour change to 
determine the concentration. Whilst relativity simple in principle, these assays are 
labour intensive having multiple steps with opportunity for error to occur. However, 
despite this limitation they appear to be reproducible and have widespread use in the 
literature.
5.2 Aim
The aim of the studies conducted in this chapter was to investigate the endogenous 
H2S synthesising ability of the rat myocardium.
5.3 Hypotheses
The hypotheses tested in this series of experiments were as follows:
1. Exogenous stimulation of H2S synthesising enzymes within the heart will enable 
the maximal production rate of H2S to be measured
2. The maximal activity of H2S synthesising enzymes will be altered in hearts 
subjected to ischaemia and reperfusion
3. The H2S concentration will be altered in left ventricle samples from hearts 
subjected to ischaemia and reperfusion
5.4 Objectives
The validity of these hypotheses was tested through the following specific objectives:
1. To develop and apply an assay to enable the maximal H2S synthesising ability 
of the heart tissue to be measured, after exogenous stimulation.
2. To develop and apply an assay to enable the H2S concentration in the 
myocardial tissue to be released and measured.
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5.5 Methods
Two series o f experiments were undertaken (as summarised in figure 5.2). In the  firs t 
the effects o f ischaemia-reperfusion were investigated in Langendorff perfused rat 
hearts. In the second the effects o f L-cysteine stim ulated H2S production were 
investigated. Samples obtained were then used in assays to  measure maximal H2S 
enzyme synthesising capacity or to  determ ine the H2S concentration in the myocardial 
tissue.
Series 2:Series 1:
Tissue H2S 
conc. measured
Langendorff perfused 
rat hearts
Underwent
Ischaemia-reperfusion
Underwent
Ischaemia-reperfusion
Perfused with 
Krebs-Henseleit buffer only
Maximal H2S enzyme 
synthesising capacity 
measured
Tissue H2S 
conc. measured
Perfused with L-cysteine 
and PAG
Stimulated H2S productionEffects of 
Ischaemia-reperfusion
Figure 5.2 Flow diogrom to show the two series o f experiments that were performed 
to prepare Langendorff perfused hearts samples to investigate either the specific 
effects o f ischaemia-reperfusion (Series 1) or the effect o f exogenously stimulated H2S 
production (Series 2). Samples from Series 1 were used to measure the H2S 
concentration or the maximal H2S synthesising capacity in the myocardial tissue. 
Samples from Series 2 were used only to measure the H2S concentration in the 
myocardial tissue.
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5.5.1 Source o f compounds
The H2S donor NaHS was purchased from Acros Organics, UK. The CSE substrate L- 
cysteine and the CSE inhibitor DL-propargylglycine (PAG) were purchased from Sigma- 
Aldrich, UK. All compounds were dissolved in Krebs-Henseleit buffer and therefore 
required no vehicle controls.
5.5.2 Preparation o f Langendorff perfused ra t heart
5.5.2.1 Setup of isolated heart perfusion:
Heart samples used for the maximal H2S enzyme synthesising capacity assay and to 
measure the tissue concentration of H2S, were prepared from rat isolated perfused 
hearts, using the methods described in Chapter 2, section 2.2. The hearts were 
subjected to the treatment protocols outlined below. The Langendorff perfused rat 
hearts were subjected to two different treatment protocols: Series 1: The effects of 
ischaemia-reperfusion, and Series 2: The effects of L-cysteine stimulated H2S 
production. Both protocols involved the induction of ischaemia and reperfusion, and 
only differed in respect to the perfusate used, with the introduction of drugs into the 
Series 2 Krebs-Henseleit buffer perfusion buffer.
Series 1 -  Effects o f ischaemia-reperfusion
These experiments were performed to determine the effects of ischaemia-reperfusion 
of Langendorff perfused rat hearts. The samples obtained were used to determine 
the maximal H2S synthesising enzyme capacity and also for the measurement of the 
basal concentration of H2S in the myocardial tissue.
Treatment protocols for this study are illustrated in Figure 5.3.
Group 1 -  Baseline control: Hearts were perfused with Krebs-Henseleit buffer for the 
duaration of the 20 minute stabilisation period.
Group 2 -  Regional ischaemia: As per group 1, except that at the end of the 
stabilisation period hearts were subjected to 35 minutes regional ischaemia.
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Group 3 - Regional ischaemia and reperfusion: As per group 2 w ith  the addition o f 15 
minutes reperfusion fo llow ing 35 m inutes regional ischaemia.
At the end o f the perfusion experiments, hearts from  all experimental groups were 
briefly washed in PBS, b lo t dried, the le ft and right ventricles separated and snap 
frozen in liquid nitrogen. The samples were stored at -80 °C prior to  measurement o f 
the H2S concentration or maximal H2S synthesising enzyme capacity in the 
myocardium.
- 20 ’
G ro u p  1 -  ba se lin e  controls  
G ro u p  2  -  2 0 ’ s tab . +  3 5 ’ I
G ro u p  3  -  2 0 ’ s tab . +  3 5 ’ I +  1 5 ’ R
15’ reperfusion20’ stabilisation 35’ regional ischaemia
Hearts
harvested
Figure 5.3 Summary o f the Series 1: Krebs-Henseleit buffer perfused hearts protocols. 
Stabilisation period consisted of 20 minutes o f perfusion with Krebs-Henseleit buffer. 
Hearts were then either harvested (groupl), went on to receive 35 minutes regional 
ischaemia (group 2), or received 35 minutes ischaemia followed by 15 minutes 
reperfusion before harvested, (group 3). At time o f harvesting, hearts were removed 
from the cannula and dissected into left and right ventricle. The sections were then 
washed briefly in PBS, blot dried and snap frozen in liquid nitrogen, before storage at 
-80°C. Samples from this protocol were used fo r the determination o f the maximal H2S 
synthesising enzyme capacity and also fo r the measurement o f the basal H2S 
concentration in the myocardial tissue.
Series 2 -  L-cysteine perfused hearts
A second series o f experiments were perform ed to  determ ine the effect o f L-cysteine 
stimulated H2S production on the concentration o f H2S in the myocardial tissue.
Treatm ent protocols fo r this study are illustrated in Figure 5.4.
Group 1 -  Baseline control: Hearts were perfused w ith  Krebs-Henseleit buffe r fo r the 
20 m inute stabilisation period.
121
Chapter 5 Investigating CSE enzyme activity
Group 2 -  L-cysteine 1 mM: As per group 1, except that for the final 10 minutes of 
stabilisation hearts were perfused with Krebs-Henseleit buffer containing L-cysteine 
ImM.
Group 3 - PAG 1 mM: As per group 2, except that hearts were perfused with Krebs- 
Henseleit buffer containing PAG 1 mM for the final 10 minutes of stabilisation.
Group 4 - L-cysteine 1 mM and PAG 1 mM: After 5 minutes of stabilisation hearts were 
perfused with Krebs-Henseleit buffer containing PAG 1 mM after a further 5 minutes, 
hearts were perfused with a combination of PAG ImM  and L-cysteine 1 mM for the 
remaining 10 minutes of stabilisation.
Group 5 -  Ischaemia-reperfusion time matched control: After a 20 minute stabilisation 
period, hearts were subjected to 35 minutes regional ishaemia followed by 15 minutes 
reperfusion. For the duration of the experiment hearts were perfused with Krebs- 
Henseleit buffer.
Group 6 - L-cysteine 1 mM: As per group 1, except that after 10 minutes of 
stabilisation and until 10 minutes reperfusion hearts were perfused with Krebs- 
Henseleit buffer containing L-cysteine 1 mM.
Group 7 - PAG 1 mM: As per group 6, except hearts were perfused with PAG 1 mM.
Group 8 - L-cysteine 1 mM and PAG 1 mM: After 5 minutes of stabilisation hearts 
were perfused with PAG 1 mM, after a further 5 minutes hearts were perfused with L- 
cysteine and PAG 1 mM until 10 minutes reperfusion.
At the end of the perfusion experiments, hearts from all experimental groups were 
briefly washed in PBS, blot dried, the left and right ventricles separated and snap 
frozen in liquid nitrogen. The samples were stored at -80 °C prior to measurement of 
the concentration of H2S.
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Figure 5.4 Summary o f the Series 2 - Drug perfused hearts protocols. Once 
cannulated, hearts were left to stabilise fo r at least 10 minutes until a steady sinus 
rhythm was obtained. The experimental stabilisation period lasted 20 minutes during 
which time all hearts were perfused with Krebs-Henseleit buffer fo r the firs t 10 
minutes. For the remaining 10 minutes o f stabilisation, hearts were perfused with L- 
cysteine, PAG or a combination o f drugs. Time-matched control hearts were perfused 
with Krebs fo r the remainder o f the experiment. Hearts were then either harvested 
(groups 1-4) or went on to receive ischaemia and reperfusion (groups 5-8). When 
combinations of L-cysteine and PAG were used, the PAG was perfused after 5 minutes 
of the stabilisation period to give it a chance to act. Regional ischaemia was induced 
fo r 35 minutes and followed by 15 minutes o f reperfusion. For the final 5 minutes o f 
reperfusion hearts were perfused with Krebs-Henseleit buffer alone. Hearts were then 
harvested at this point in the protocol (groups 5-8). At the end of perfusion the 
sections were washed briefly in PBS, blot dried and snap frozen in liquid nitrogen, 
before storage at -80°C. Samples from this protocol were used fo r the measurement 
of H2S concentrations in the myocardial tissue.
At the end of the perfusion experiments, hearts from all experimental groups were 
briefly washed in PBS, blot dried, the left and right ventricles separated and snap 
frozen in liquid nitrogen. The samples were stored at -80°C prior to the measurement 
of the H2S concentration in the tissue.
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5.5.3 Processing tissue samples fo r the measurement o f the maximal H25 enzyme 
synthesising capacity o f rat myocardium
5.5.3.1 Validation studies
The H2S production assay was adapted from methods previously published in the 
literature for liver and kidney tissue (Stipanuk et al., 1982). The assay therefore 
required initial refinement and validation to enable stimulated H2S production in rat 
myocardium to be measured. Preliminary data are shown in Appendix 2.
5.5.3.2 Sample preparation
Tissue samples were obtained by subjecting Langendorff perfused hearts to the Series 
1 -  Effects o f ischaemia-reperfusion experimental protocol as outlined in figure 5.1 of 
this chapter. 10% (w/v) of left ventricle and right ventricle homogenates were 
prepared by suspending crushed tissue samples, in ice cold sodium phosphate buffer 
(pH 7.4) (see Appendix 3 for composition). Liver samples obtained from rats were also 
tested as a positive control. The homogenates prepared were stored on ice until 
assayed.
5.5.3.3 Protein determination in tissue samples
The protein concentrations of the tissue samples were determined using the BCA 
assay as described in Chapter 2, section 2.3. Protein determination has enabled the 
production rates of H2S per g of protein to be calculated and allows a more accurate 
comparison of the maximal H2S synthesising capacity between tissues.
5.5.3.4 H2S production and collection
25 ml wide neck Erlenmeyer flasks were used to perform the H2S production assay and 
were set up such that a 2 ml Eppendorf tube was suspended in each flask using a 
thread. The thread was secured to the neck of the flaks using a thin strip of parafilm, 
enabling the Eppendorf tube to be securely suspended inside the flask. A 15:1 (v/v) 
mixture of 1 % (w/v) zinc acetate solution and 12 % (w/v) sodium hydroxide solution 
was added to the suspended Eppendorf tube. A piece of Whatman 0.34 mm 
chromatographic paper (2 x 2.5 cm), folded into a fan shape, was placed in the
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Eppendorf tube. The filter paper absorbed the zinc acetate and sodium hydroxide 
solution enabling the trapping of H2S gas. 500 pi of sodium phosphate buffer (pH 7.4), 
100 pi of a 12.1 mg/ml stock of L-cysteine, and 100 pi of a 5.3 mg/ml stock of pyridoxal 
5'phosphate was added to the 25 ml Erlenmeyer flask. The final assay concentrations 
of L-cysteine and pyridoxal 5'phosphate were 10 mM and 2 mM respectively. The 
flasks were then flushed with N2 for 20 seconds and 300 pi of tissue homogenate was 
added. In the case of control samples 300 pi of sodium phosphate buffer was added 
instead of tissue homogenate. The total volume of the reaction mixture in the assay 
was 1 ml. The flasks were double sealed with parafilm and incubated in a covered 
water bath at 37 °C with regular mixing of the contents. The reaction was stopped 
after 15 minutes by the injection of 0.5 ml of 50 % (w/v) trichloroacetic acid. The 
flasks were then sealed with another layer of parafilm, before being returned to the 
water bath for 60 minutes to allow complete trapping of the gas. During this period 
the content of the flasks were regularly mixed. The content of the Eppendorf tube 
was thoroughly washed into a test tube containing 3.5 ml of dH20. 400 pi of N,N- 
dimethyl-p-phenylenediamine sulphate (20 mM) in 7.2 M HCI was added. Then 400 pi 
of FeCb (30 mM) in 1.2 M HCI was added and the test tube gently shaken. After 10 
minutes a blue colour formed to indicate the presence of H2S gas. The absorbance of 
the solution was read on a spectrophotometer at 670 nM (Jenway Model 6305). The 
spectrophotometer was calibrated on the day of experiment to the 0 pM H2S sample 
(dH20).
5.53.5 Standard curve to NaHS
Standard curves to NaHS, an H2S donor, were produced to enable equivalent H2S 
concentrations to be determined by the tissue samples in the assay. By calibrating to 
the 0 pM H2S sample the standard curve for NaHS passed through the origin. The use 
of NaHS allowed the concentration of H2S to be determined more precisely than if H2S 
gas was simply bubbled through water. When NaHS dissociates in water it forms Na+ 
and HS\ The HS‘ then associates with H+ to form H2S. In solution at pH 7.4 and 37 °C, 
approximately one third of H2S exists in the undissociated form H2S and the remaining 
two thirds exists as HS‘ which is at equilibrium with H2S. Therefore when making a
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stock of H2S from a donor it is important to take into account that only one third of 
the H2S will be in the undissociated form (Cheng et al 2004). However, it was assumed 
that if this is how the H2S behaved when made from the donor, the H2S released from 
the tissue would behave in the same manner. Therefore the NaHS concentration was 
not adjusted to compensate for this. A 600 pM final assay concentration stock of 
NaHS was prepared fresh on the day of experimentation. This was necessary because 
it had been identified in preliminary studies that frozen aliquots of NaHS were not 
stable at -20 °C. The 600 pM final assay concentration (FAC) stock was then diluted to 
produce 400 pM, 100 and 0 pM FAC stocks. 300 pi samples of each of these 
concentrations were added in place of tissue homogenates. This meant that four 
reaction flasks containing the NaHS standards could be run alongside the sample 
flasks. A standard curve for NaHS in each experiment ensured an accurate estimation 
of H2S production and also acted as an internal control.
Standard curves to NaHS were plotted in Excel and the equation of the line used to 
predict the concentration of H2S produced in the tissue samples based on the 
absorbance values obtained.
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5.5.4 Measurement o f the H2S concentration in the left ventricle
The following method for the measurement of the H2S concentrations within 
myocardial tissue was adapted from Mok et al. (2004). Tissue samples were obtained 
by subjecting Langendorff perfused hearts to the Series 1 -  Effects of ischaemia- 
reperfusion and Series 2 -  L-cysteine perfused hearts experimental protocols as 
outlined in figures 5.2 and 5.2 in this chapter. 40% (w/v) tissue homogenates of left 
ventricle samples were prepared, by initially homogenising 40 mg snap frozen tissue 
samples with a mortar and pestle. The mortar was cooled on dry ice, and filled with 
liquid nitrogen to prevent degradation of the sample. 1 ml of phosphate buffer was 
added and the tissue samples further homogenised, with a mortar and pestle, until a 
smooth homogenate was obtained (approx. 5 minutes of grinding). The resulting 
homogenate was spun at 13000 rpm for 5 minutes and 500 pi removed and added to 
750 pi TCA (10% w/v). The resulting precipitate was spun at 13000 rpm for 5 minutes. 
500 pi of the supernatant was removed and placed in an Eppendorf tube. 150 pi of 
Zinc acetate (1% w/v), 100 pi N,N-dimethyl-p-phenylenediamine sulphate (20 mM) in
7.2 M HCI, and 133 pi FeCI3 (30 mM) in 1.2 M HCI was then added. After 10 minutes, a 
20 pi aliquot of each tissue sample was placed in duplicate in a 96 well plate. The 
absorbance was read at 620 nM. The absorbance values were then compared to an 
NaHS standard curve conducted in the same plate (for details of the NaHS standard 
curve see section 5.5.3.S). A BCA assay was also performed to enable the protein 
concentrations of the samples to be determined (see Chapter 2, section 2.3).
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5.6 Results
5.6.1 Exclusion criteria
In total 73 rat hearts were used for the experiments performed in these studies. Of 
these 73 hearts, 11 were excluded on technical grounds. Data from 62 rat hearts are 
presented in this chapter taking into account that some tissue samples were used for 
both series of experiments.
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5.6.2 Effects of ischaemia-reperfusion on the maximal H2S enzyme synthesising 
capacity
Exogenously stimulated H2S production rates were measured as an indication of the 
maximal H2S synthesising capacity of left and right ventricle samples from Langendorff 
perfused hearts. In baseline stabilised rat hearts (group 1) the maximal H2S 
synthesising capacity did not differ between the left and right ventricle (1.21 ± 0.14 vs.
0.866 ± 0.37 pmol/g/min). There was an increase, although not significant, in the H2S 
production in both the left and right ventricles above baseline during ischaemia (group 
2). The ischaemic left ventricle produced 1.70 ± 0.30 vs. 1.21 ± 0.14 pmol/g/min for 
control, whilst the right ventricle produced 1.83 ± 0.5 vs. 0.866 ± 0.37 pmol/g/min for 
control. However, in hearts subjected to ischaemia and reperfusion (group 3), the left 
ventricle showed a significant reduction (p<0.05) in the maximal H2S synthesising 
capacity, whilst the right ventricle remained unaffected (0.396 ± 0.066 vs. 1.40 ± 0.28 
pmol/g/min) (p<0.05) (data summarised in figure 5.5).
•k *
Figure 5.5 Maximal H2S synthesising capacity in left and right ventricle samples from  
rat isolated Langendorff perfused hearts. The hearts received either 20 minutes of 
perfusion, 20 minutes o f perfusion followed by 35 minutes ischaemia, or 20 minutes of 
perfusion followed by 35 minutes ischaemia and 15 minutes reperfusion. The maximal 
H2S synthesising ability o f the samples was measured in a biochemical assay by 
stimulating the H2S synthesising enzyme, in homogenates o f the tissue samples, with 
the substrate L-cysteine and the co-factor pyridoxal 5'phosphate. Each value shown is 
the mean ± SEMfrom 6 individual hearts. *p<0.05. (1-way ANOVA).
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5.6.3 Measurement o f the H^S concentration in le ft ventricle
Left ventricle tissue samples from Langendorff perfused rat hearts that underwent 
Series 1 and 2 perfusion protocols (outlined in figures 5.3 and 5.4), were assayed to 
determine the H2S concentration.
5.6.3.1 Series 1 -  Effects o f ischaemia-reperfusion 
Measurement o f the basal H2S concentration
There was a significant increase (p<0.05) in the basal H2S concentration in Krebs- 
Henseleit buffer perfused hearts that underwent 20 minutes of stabilisation followed 
by 35 minutes of regional ischaemia (group 2) compared to hearts that had only 
undergone 20 minutes of stabilisation (group 1) (0.653 ± 0.052 vs. 0.410 ± 0.12 pmol/g 
protein). There was a very significant (p<0.01) increase in the basal H2S concentration 
in hearts that underwent 20 minutes of stabilisation, 35 minutes of regional ischaemia 
and 15 minutes of reperfusion (group 3) compared to hearts subjected to 20 minutes 
stabilisation (group 1) (0.872 ±  0.037 vs. 0.410 ± 0.12pmol/g protein) (data 
summarised in figure 5.6).
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Figure 5.6 Comparison o f the bosal H2S concentration in left ventricle samples from rat 
isolated heart samples perfused with Krebs-Henseleit bu ffe r, either subjected to 20 
minutes of stabilisation, 20 minutes o f stabilisation plus 35 minutes o f regional 
ischaemia, or 20 minutes o f stabilisation, 35 minutes o f regional ischaemia and 15 
minutes o f reperfusion. These results acted as time matched controls fo r subsequent 
drug perfused heart experiments. The basal H2S concentrations of the samples were 
measured in a biochemical assay, involving release and trapping o f the gas. Each 
value shown is the mean ± SEM from 6 individual hearts. *p<0.05, **p<0. (1-way 
ANOVA).
5.6.3.2 Series 2 -  Effects o f L-cysteine perfused hearts 
Measurement o f the H2S concentration in L-cysteine perfused hearts
Rat hearts perfused with CSE/CBS substrate L-cysteine (1 mM) during the 20 minute 
stabilisation period, showed a highly significant (p<0.001) increase in the H2S 
concentration, compared with baseline control (2.01 ± 0.069 vs. 0.639 ± 0.16 pmol/g 
protein). Hearts perfused with L-cysteine (1 mM) during ischaemia and reperfusion, 
showed no significant change in the H2S concentration from time-matched control 
(0.759 ± 0.11 vs. 0.825 ± 0.043 pmol/g protein) (data summarised in figure 5.7).
131
Chapter 5 Investigating CSE enzyme activity
***
O  2.0 ■
Figure 5.7 Comparison o f the H2S concentration in left ventricle samples from rat 
isolated heart samples perfused with L-cysteine (1 mM) fo r  either the final 10 minutes 
of stabilisation, or the final 10 minutes o f the stabilisation periodand  35 minutes of 
regional ischaemia and 10 minutes reperfusion. The Baseline control and time 
matched control were perfused with Krebs-Henseleit buffer fo r the duration o f the 
experiment The H2S concentrations o f the samples were measured in a biochemical 
assay, involving release and trapping o f the gas. Each value shown is the mean ± SEM 
from 5-6 individual hearts. ***P<0.01. (1-way ANOVA).
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Measurement o f the H2S concentration in PAG perfused hearts
Perfusion with the CSE-selective inhibitor PAG (1 mM) during the 20 minute 
stabilisation period caused a very significant (p<0.01) increase in the H2S 
concentration compared with baseline control (1.32 ± 0.086 vs. 0.639 ± 0.16 |imol/g 
protein). Hearts perfused with PAG (1 mM) during ischaemia and reperfusion, showed 
no significant change in the H2S concentration above control (0.607 ± 0.11 vs. 0.825 ±
0.043 pmol/g protein) (data summarised in figure 5.8).
★★
Figure 5.8 Comparison o f the H2S concentration in left ventricle samples from rat 
isolated heart samples perfused with PAG (1 mM) fo r either the final 10 minutes of 
stabilisation, or the final 10 minutes o f the 20 minute stabilisation period, or the final 
10 minutes o f stabilisation plus 35 minutes of regional ischaemia and 10 minutes 
reperfusion. The time matched controls were perfused with Krebs-Henseleit buffer fo r  
the duration o f the experiment. The H2S concentrations o f the samples were measured 
in a biochemical assay, involving release and trapping o f the gas. Each value shown is 
the mean ± SEMfrom 5-6 individual hearts. **p<0.01. (1-way ANOVA).
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Measurement o f the H2S concentration in L-cysteine and PAG pefused hearts
Dual perfusion of L-cysteine (1 mM) and PAG (1 mM) caused a highly significant 
(p<0.001) attenuation of the increased H2S concentration in the left ventricle seen 
with L-cysteine alone (1.17 ± 0.15 vs. 2.01 ± 0.069 pmol/g protein), but not below the 
baseline observed in control (1.17 ± 0.15 vs. 0.639 ± 0.16 vs. pmol/g protein) (data 
summarised in figure 5.9)
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Figure 5.9 Comparison of the H2S concentration in left ventricle samples from rat 
isolated heart samples perfused with L-cysteine (1 mM), PAG (1 mM) or in combination 
fo r the final 10 minutes o f the 20 minute stabilisation period. The time matched 
controls were perfused with Krebs-Henseleit buffer fo r the duration o f the experiment. 
The H2S concentrations of the samples were measured in a biochemical assay, 
involving release and trapping o f the gas. Each value shown is the mean ± SEM from  
5-6 individual hearts. **P<0.01, ***p<0.001. (1-way AN OVA).
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Perfusion w ith a com bination o f L-cysteine and PAG during ischaemia and reperfusion 
did not cause any change in the H2S concentration compared w ith  baseline (1.10 ±
0.15 vs. 0.825 ±  0.043 pm ol/g  protein (data summarised in figure 5.10).
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Figure 5.10 Comparison o f the H2S concentration in left ventricle samples from rat 
isolated heart samples perfused with L-cysteine (1 mM), PAG (1 mM) or in combination 
fo r the final 10 minutes o f stabilisation plus 35 minutes o f regional ischaemia and 10 
minutes reperfusion. The time matched controls were perfused with Krebs-Henseleit 
buffer fo r the duration o f the experiment. The H2S concentrations o f the samples were 
measured in a biochemical assay, involving release and trapping o f the gas. Each 
value shown is the mean ± SEM from 5-6 individual hearts. (1-way ANOVA revealed no 
significant differences).
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Summary o f the H2S concentration measurement data
All of the data have been combined in figure 5.11 to enable the significant changes 
within and between treatment groups to be highlighted.
★★★
Figure 5.11 Summary o f all the H2S concentrations in left ventricle samples. 
Comparison o f the H2S concentrations in left ventricle samples from rat isolated Krebs- 
Henseleit buffer left ventricle samples, either subjected to 20 minutes o f stabilisation, 
or 20 minutes o f stabilisation plus 35 minutes o f regional ischaemia and 15 minutes 
reperfusion. The H2S concentrations o f the samples were measured in a biochemical 
assay, involving release and trapping o f the gas. Each value shown is the mean ± SEM 
from 5-6 individual hearts. **p<0.01, ***p<0.001. (1-way ANOVA).
Effects of compounds tested on measured haemodynamic parameters
There was no measurable change in the haemodynamic parameters of the hearts 
under any of the treatment groups when compared to the control hearts (data not 
shown).
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5.7 Discussion
The findings of the two related studies can be summarised as follows:
5.7.1 Measurement of the maximal H25 enzyme synthesising capacity of rat
myocardial samples
1. It was possible to exogenously stimulate the production of H2S and measure 
the maximal enzymatic production rate in myocardium tissue from rats. The 
results showed no significant difference in the ability of the left and right 
ventricle to produce H2S in baseline control perfused hearts.
2. Exogenously stimulated H2S production was not altered in either the left or 
right ventricle in isolated rat hearts subjected to 35 minutes regional 
ischaemia. However, in hearts that underwent 35 minutes regional ischaemia 
and 15 minutes of reperfusion, there was a significant reduction in the ability 
of the left ventricle to synthesise H2S, whilst the right ventricle remained 
unaffected.
5.7.2 Measurement of the H2S concentration in rat myocardial samples
1. Left ventricle samples from hearts perfused with Krebs-Henseleit buffer 
during ischaemia and during ischaemia-reperfusion, showed a significant 
increase in the basal H2S concentration compared to baseline control.
2. Left ventricle samples from hearts perfused with Krebs-Henseleit buffer 
containing L-cysteine for 10 minutes during the stabilisation period, showed a 
highly significant increase in the H2S concentration compared to control.
3. This increased H2S production was attenuated in the presence of the selective 
CSE inhibitor PAG, but a basal level of H2S still remained in the left ventricle 
samples, suggesting an alternative (non)enzymatic source of H2S.
4. Perfusion with PAG alone during the 20 minute stabilisation caused a 
significant increase in the H2S concentration in the left ventricle samples, 
implicating a compensatory increase in H2S by an alternative source.
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5. Hearts perfused with L-cysteine during ischaemia-reperfusion showed no 
increase in the H2S concentration above the time matched control, but both 
levels were greater than the stabilisation control.
6. Hearts perfused with PAG alone or co-perfusion with L-cysteine did not 
reduce H2S levels below time matched control.
A discussion of each series of experiments is given below:
5.7.3 Measurement of the maximal H2S enzyme synthesising capacity of rat 
myocardial samples
5.7.3.1 H2S synthesising ability does not differ in left and right ventricle samples from  
stabilised hearts and hearts subjected to regional ischaemia
The maximal H2S synthesising capacity of H2S in baseline stabilised rat hearts did not 
differ between the left and right ventricles. These results are not surprising, since 
there is no reason as to why there should be differences in the maximal H2S 
synthesising capacity of the left and right ventricles during normal perfusion. The 
ischaemic left ventricle's maximal production rate increased 40%, whilst the right 
ventricle increased 111% compared to control. Neither of these increases were shown 
to be significantly significant, possibly due to the relativity large error bars. The 
observation that regional ischaemia had no deleterious effect on the H2S synthesising 
ability in either the left or right ventricle, suggests that adequate flow was maintained 
during ischaemia to preserve the integrity of the enzymes. A possible explanation for 
the potential of the enzymes to synthesise increased levels of H2S gas, is that they may 
have been stimulated to synthesise of H2S during ischaemia which may have been in 
preparation for the oxidative stress that occurs at reperfusion.
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5.7.3.2 The left ventricle has attenuated H2S synthesising ability i f  subjected to 
ischaemia-reperfusion
However, in hearts subjected to ischaemia and reperfusion, the left ventricle shows a 
significant 3-fold reduction in H2S synthesising ability, whilst the right ventricle 
remains unaffected. Only the flow to the left ventricle would be reduced during 
regional ishcaemia, whilst the flow to the right ventricle would be expected to remain 
constant since it is not served by the left main anterior coronary artery. These 
findings suggest that reperfusion may be responsible for the reduced ability of the left 
ventricle samples to produce H2S. A possible explanation for this observation is that 
reperfusion caused an increase in free radicals at reperfusion that may have damaged 
the enzymes, preventing H2S production.
It has previously been shown that elevated H2S levels can exert a negative feedback on 
the CSE enzymes to reduce the H2S production rate (Kredich et ai., 1973). This implies 
that if there was a reduction in the left ventricle's ability to synthesise H2S, such as we 
observed during ischaemia and reperfusion, then an alternative source of CSE may be 
stimulated to produce more H2S in a compensatory fashion. Therefore the right 
ventricle may have been stimulated to produce more H2S in an attempt to protect the 
left ventricle during ischaemia and reperfusion.
5.7.3.3 Relation to previous findings
Only one previous study (Geng et a i, 2004c) has investigated the stimulated H2S 
production rate of the myocardium (18.64 pmol/g protein/min). However, these 
authors did not specify which region of the myocardium was investigated, but an 
assumption can be made that it was the left ventricle, since this is the region of 
interest in regional ischaemia. Since they only investigated the myocardium and no 
other tissue types, it is difficult to put these rates into context with the H2S production 
rates for the myocardium obtained in the present study.
5.7.3.4 Efficiency of the H2S production assay may be a limiting factor
It is important to note that the efficiency of the H2S production assay may be limited. 
Julian et ai. (2002) implied that the assay may only be about 33% efficient, due to
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attempting to detect low concentrations of H2S and the possibility of the conversion of 
some H2S to volatile thiols, despite the anaerobic conditions of the assay. However, in 
the present investigation it is the relative changes between groups that are important 
rather than the absolute measurements. This assay has been successfully established 
after initial preliminary studies and has subsequently been used to obtain reliable and 
reproducible data.
5.7.3.5 Further studies
Further studies could be conducted, with confidence, to investigate the effects of 
inhibiting other H2S synthesising enzymes. Experiments using the CBS inhibitor 
aminooxyacetic acid and the MST inhibitor 3-mercaptopropionic acid could be used to 
establish if another enzymatic source of H2S is responsible for the basal level observed 
in the myocardium. Also, it would be very interesting to investigate whether there 
was a restoration of the H2S synthesising ability in the left ventricle if the period of 
reperfusion was increased or whether its functionality was permanently impeded.
5.7.4 Measurement o f the H25 concentration in ra t myocardial samples
5.7.4.1 Hearts subjected to ischaemia-reperfusion showed increased basal H2S levels: 
The basal concentrations of H2S were significantly increased (p<0.05) in left ventricle 
samples from hearts that underwent 20 minutes of stabilisation followed by 35 
minutes of regional ischaemia. There was a very significant (p<0.01) increase in the 
basal tissue concentrations of H2S in hearts that underwent 20 minutes of 
stabilisation, 35 minutes of regional ischaemia and 15 minutes of reperfusion. These 
findings suggest that the endogenous synthesis of H2S is elevated during ischaemia, 
and further more during ischaemia-reperfusion perhaps as a protective mechanism by 
the heart to limit irreversible cell injury. These findings will be discussed later in 
relation to the L-cysteine perfused hearts.
5.7.4.2 Perfusion with L-cysteine during stabilisation caused increased H2S synthesis 
The H2S concentration in the left ventricles of hearts perfused with L-cysteine (1 mM) 
during the 20 minute stabilisation period, or during ischaemia and reperfusion were 
measured and compared to time matched controls. There was a highly significant
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(p<0.001) 3-fold increase in the H2S concentrations in the left ventricle during the 20 
minute stabilisation period compared with control. These findings suggest that during 
the stabilisation period the H2S synthesising enzymes were viable and capable of 
exogenous stimulation to produce H2S. The increased H2S production was attenuated 
in the presence of PAG, but not below the basal level of the control group protein. 
This suggests that an alternative source of H2S, either enzymatic or non-enzymatic, 
may be responsible for a basal level of H2S in the left ventricle in the myocardium. 
Indeed it is known that there are two other H2S synthesising enzymes that may 
potentially exist in the myocardium, CBS and MST (Stipanuk et ai., 1982). Although 
CSE has been reported as the only H2S synthesising enzyme detected in the 
myocardium (Ishii et a i, 2004), these other enzymes may be weakly expressed and 
responsible for production of H2S when CSE is impaired or perhaps responsible for a 
continuous basal production of H2S. Further investigation using specific CBS and MST 
enzyme inhibitors could be used to investigate these enzymes contributions to H2S 
production.
5.7.4.3 Perfusion with PAG alone during stabilisation caused an elevation in H2S 
concentrations
Interestingly, perfusion with PAG (ImM) during the 20 minute stabilisation period, 
caused a very significant 2-fold increase in the basal H2S concentration compared to 
baseline control, but not as much as L-cysteine (3-fold). A possible explanation for this 
observation is that due to inhibition of the CSE enzyme with PAG, a compensatory 
increase in H2S may be produced by an alternative enzymatic source of H2S such as 
CBS or MST, or even a non-enzymatic source which may be responsible for 
maintaining the basal level in.the myocardium.
5.7.4.4 Perfusion with L-cysteine during ischaemia-reperfusion did not increase H2S 
synthesis above baseline
L-cysteine is the major sulphur-containing amino acid substrate for CSE and CBS. 
Perfusion with L-cytsteine (1 mM) under aerobic conditions produced a 3-fold increase 
in H2S tissue concentration. Perfusion with L-cysteine during ischaemia and 
reperfusion did not produce a further increase in H2S levels, compared with its time
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matched control or the initial baseline level in the myocardium. This observation may 
be due to inhibition of the H2S producing enzymes due to ischaemia and/or 
reperfusion, preventing a further increase in H2S production or a lack of ATP to drive 
active synthesis. This supports the data reported earlier in this study showing a 
significant impairment in the maximal H2S synthesising capacity of CSE in left ventricle 
tissue samples from hearts that underwent ischaemia-reperfusion. It was therefore 
not a surprising that co-perfusion of the hearts with L-cysteine and PAG during 
ischaemia and reperfusion caused no significant change in the measured H2S 
concentrations compared to time matched controls.
Interestingly it has been shown in chapter 4 that perfusion with L-cysteine during 
ischaemia and early reperfusion, produced a concentration dependent infarct size 
limitation, which 1 mM being the most cardioprotective. This reduction in infarct size 
was attributed to the production of H2S, which acted as a cardioprotective agent. 
However, the findings from the studies presented in this chapter suggest that H2S 
production may be impaired during ischaemia-reperfusion. This raises the question 
that perhaps it is not the H2S gas derived from the donor NaHS, but it is the reactive 
thiol group, -SH, that acts as a free radical scavenger to induce cardioprotective if the 
H2S synthesising enzymes are impaired during ischaemia-reperfusion. Furthermore, 
the results in this chapter show that perfusion with L-cysteine during baseline 
stabilisation produced a highly significant increase in the endogenous tissue 
concentration of H2S. This supports the idea that L-cysteine can stimulate H2S 
production but only under aerobic conditions and therefore during ischaemia- 
reperfusion L-cysteine may be acting as a free radical scavenger. In addition these 
findings provide further evidence of the existence of H2S synthesising enzymes in the 
rat myocardium, despite the limited data generated from the Western blotting studies 
in chapter 3.
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5.7.4.5 CSE enzyme in the right ventricle as a potential source o f H2S fo r left ventricle 
The right ventricle is a potential alternative source of H2S for the left ventricle since it 
is unlikely to have been effected by regional ischaemia as adequate flow was 
maintained thus preserving the CSE enzymes. However, since it was not possible to 
measure the tissue concentrations of H2S from right ventricle samples in this study, it 
is difficult to prove its involvement. If indeed the right ventricle was supplying the left 
with H2S during ischaemia-reperfusion, then the levels of H2S observed in the left 
ventricle would be expected to be elevated above the time matched control. This is 
because stimulated H2S synthesis would be expected to occur in the right ventricle of 
hearts perfused with L-cysteine. Since this does not appear to have occurred, it 
suggests an alternative CSE independent source of H2S. Interestingly perfusion with 
PAG during ischaemia-reperfusion did not effect the basal levels of H2S, suggesting a 
CSE independent source because even if the CSE enzymes in the right ventricle 
remained unaffected by ischaemia-reperfusion, the presence of PAG would prevent 
them supplying additional H2S. Therefore it appears a CSE independent source of H2S 
must be present.
5.7.4.6 Reasoning fo r elevated H2S levels during ischaemia-reperfusion despite 
impaired CSE function
Interestingly the significantly elevated H2S concentrations observed in left ventricle 
samples from Krebs-Henseleit buffer perfused hearts subjected to ischaemia and 
ischaemia-reperfusion were not observed to the same degree in hearts subjected to 
the same perfusion protocol but with the addition of L-cysteine perfusion for the 
duration of ischaemia and first 10 minutes of reperfusion. There was a modest, but 
not statistically significant, increase in the concentration of H2S measured in the left 
ventricle of L-cysteine perfused hearts and their time matched Krebs-Henseleit buffer 
perfused controls. The reasoning behind the lack of significantly increased H2S 
production in the L-cysteine perfused hearts is difficult to explain, since they only 
differ by the addition of the L-cysteine to the Krebs-Henseleit buffer solution. A 
simple explanation is that the baseline control group of the L-cysteine perfused hearts 
contained a higher concentration of H2S than the Krebs-Henseleit buffer perfused
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hearts to start with and had a relatively large error and therefore the small increases 
observed during ischaemia-reperfusion are not statistically significant.
The observation that there was no further increase in the H2S concentration in the L- 
cysteine perfused hearts during ischaemia-reperfusion, compared to the time 
matched control, suggests that stimulating the CSE enzyme with substrate and co­
factor produces no additional H2S, and an alternative source of H2S may exist to 
provide the elevated basal H2S levels observed in the left ventricle. Therefore the 
myocardium may utilise an alternative non-enzymatic source of H2S during ischaemia- 
reperfusion. This seems feasible because during ischaemia-reperfusion enzymes are 
likely to become impaired due to factors such as lack of ATP, toxic metabolic 
accumulation, and free radical generation. Therefore it appears that there may be a 
more robust source of H2S production to maintain basal levels which may even act in a 
possible attempt to elevate levels to induce endogenous cardioprotection.
5.7.4.7 The potential role o f a non-enzymatic source o f H2S production
A non-enymatic source of H2S also exists where elemental sulphur is reduced using 
reducing equivalents obtained from the oxidation of glucose (Searcy et a i, 1998). All 
of the essential components of this pathway are present in vivo including the supply of 
sulphur. This may therefore be an alternative source of H2S production when the 
enzymes are not viable such as during ischaemia and reperfusion. This source of H2S 
may also have been contributing to the basal H2S levels observed in these 
experiments. A specific inhibitor of this pathway would enable its role to be further 
investigated.
5.7.4.8 Efficiency of the H2S production assay may be a limiting factor
This assay is also of a similar nature to the stimulated H2S production assay and as a 
result may suffer from the same issues regarding efficiency. Again, however this is not 
of great importance, since relative changes are of interest.
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5.7.4.9 Further studies
It would have been interesting to measure the tissue concentration of H2S in the right 
ventricle and see how they related to the enzyme activity. Unfortunately this assay 
required reasonably large quantities of tissues, thus preventing the right ventricle 
being used. A possible option would be to miniaturise the assay, but this may result in 
a loss of sensitivity. Further studies could be performed with the left ventricle and 
other specific inhibitors of H2S synthesising enzymes to gain a further understanding 
of the other (non)enzymatic sources of H2S.
In addition, measurement of the exogenously stimulated enzyme derived H2S and 
tissue concentrations of H2S, could have been measured using an H2S probe. These 
are known to exist for use in environmental monitoring of H2S. This would have 
replaced the need to trap the gas on filter paper and removal several stages from the 
labour intensive assay. However, it appears that the probes available would not be 
sensitive enough for the detection of the relativity low concentrations of H2S 
generated. Interestingly a paper by Doeller et al. (2005) describes the use of a novel 
polargraphic probe H2S sensor with a high signal to noise ratio and signal specificity to 
H2S. It is highly sensitive and can detect H2S concentrations as low as 10 nM and can 
also be used to measure the consumption of H2S by mammalian tissues. It will be 
interesting to see if this gains acceptance for future H2S measurement studies.
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5 .8  Conclusion
The findings from these studies suggest that left and right ventricle tissue samples 
obtained form the rat myocardium are able to synthesise H2S when the enzymes are 
stimulated with the substrate L-cysteine and co-factor pyridoxal-5-phosphate, which 
can be collected and measured. It is also possible to release and measure the 
concentration of H2S contained within the tissue. The results from this study show 
that H2S concentrations were elevated in hearts that underwent ischaemia- 
reperfusion; suggesting that endogenous H2S levels may be elevated in an attempt to 
protect the myocardium from ischaemia-reperfusion injury. However, the ability of 
the left ventricle to synthesise H2S after ischaemia-reperfusion was impaired, whilst 
the right ventricle remained unaffected, suggesting a role of the right ventricle to 
supply H2S to the left ventricle. A robust non-enzymatic H2S source may also exist 
which contributes to the basal level observed in the heart and may even supply H2S 
during ischaemia-reperfusion. Therefore there appears to be a complex interplay 
between various enzymatic and non-enzymatic sources of H2S in the myocardium, 
only some of which this study has explored. These may act to serve as a protective 
mechanism to ensure that H2S is always present at a basal level in the myocardium 
and may compensate for reduced enzyme activity during ischaemia-reperfusion. The 
findings from this study also act to verify the PCR and Western blotting results, 
reported in Chapter 3, that CSE and potentially CBS H2S synthesising enzymes are 
present in the rat myocardium.
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Chapter 6 Investigation into the role of H2S in activation of the 
Reperfusion Salvage Kinase (RISK) pathway, as a potential 
mechanism of cardioprotection
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6.1 Introduction
Studies reported in earlier chapters of this thesis gradually build upon the existing 
knowledge of H2S as a physiological gaseous mediator and attempt to expand the 
knowledge of its existence and role within in the myocardium. In particular it has 
been confirmed that the myocardium possesses the ability to enzymatically generate 
H2S, and that stimulated H2S production was cardioprotective. However, the 
mechanism of the cardioprotective action of H2S has yet to receive attention. The 
series of experiments conducted in this chapter aimed to decipher the 
cardioprotective mechanism of action of NaHS. In addition thiol containing 
compounds with more structural complexity than NaHS were investigated which may 
give a greater insight into the mechanism of action of NaHS.
6.1.1 H2S as a potential activator o f the RISK pathway
The RISK pathway has already been comprehensively described in Chapter 1. 
However a brief overview of the RISK pathway in context of the potential activation by 
NaHS and subsequent cardioprotection will now be discussed. It has been shown that 
a number of factors activate the RISK pathway to cause cardioprotection (Hausenloy 
et a i, 2007). These mediators act through a variety of mechanisms including G-protein 
coupled receptors, growth factor receptors and naturetic peptide receptors 
(Hausenloy et a i, 2007). It has also been shown that volatile anaesthetics can act via 
non-receptor mediated pathways (Chiari et al., 2005). This vast variety of activators 
and mechanisms suggests that there is great potential for many undiscovered 
activators of the RISK pathway, particularly through a non-receptor mediated 
mechanism, to induce cardioprotection. Indeed there is much evidence to support the 
assumption that H2S may induce cardioprotection via action of the RISK pathway. This 
is based on the observations that H2S limits infarct size when hearts are perfused 
during ischaemia and early reperfusion and its mechanism of cardioprotection is KAt p  
channel dependent (Johansen et a i, 2006), which is an important component of the 
RISK pathway (Gross et al., 1999; Gross et a i, 2003). In addition H2S and NO are 
known to interact (Li et a i, 2005; Mok et a i, 2004; Zhao et a i, 2002), and since NO is a 
fundamental mediator of the RISK pathway (Dimmeler et a i, 1999), it suggests that
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H2S may have a role in mediating its actions. Taking these findings together with the 
potential to activate the RISK pathway through a non-receptor mediated fashion, since 
no pharmacological target of H2S had been discovered, a series of experiments were 
proposed to investigate whether H2S activates the RISK pathway to induce 
cardioprotection.
6.1.2 MESNA
The H2S donor NaHS has been selected for use throughout the studies involving H2S 
generation in this thesis. This is because there are very few alternatives and is widely 
used by many other research groups making it possible to directly compare results 
between investigators (Bian et al., 2006; Elrod et al., 2007; Hu et al., 2008; Ji et al., 
2008; Johansen et al., 2006; Pan et al., 2006; Sivarajah et al., 2006; Sodha et al., 2008; 
Zhang et al., 2007; Zhu et al., 2007). It is also the simplest thiol containing compound 
other than H2S gas. Since thiols are known to act as free radical scavengers, it is 
conceivable that the thiol component of NaHS may acts to induce cardioprotection, as 
opposed to the generation of H2S gas. To investigate this concept further a more 
complex thiol containing compound, 2-mercaptoethane sulphonate sodium (MESNA), 
was also selected, enabling the cardioprotective effect of two potential H2S donors, 
but structurally different thiols, to be compared (see figure 6.1 for structure of 
MESNA). Prior to conducting these studies there was to be no other published work 
investigating the potential cardioprotective effects of MESNA.
Figure 6.1 Structure o f MESNA with the thiol group highlighted. The structure o f 
MESNA is fa r more complex than that o f NaHS.
MESNA is primarily used in chemotherapy regimens for the prevention of 
haemorrhagic cystitis induced by the oxazaphosphorines cyclophosphamide and
O
Na+
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ifosfamide (Dechant et a i, 1991). Aside from MESNA's urothelial protective ability, it 
has also been shown to protect the intestinal mucosa by reducing the toxicity of 
cisplatin (Allan et a i, 1986) and ifosfamide (Ypsilantis et a i, 2004) or reducing 
intestinal inflammation in experimental colitis (Shusterman et a i, 2003). Other 
published studies have investiagted the protective effects of MESNA in ischaemia- 
reperfusion in the liver, kidney, and intestine (Ypsilantis et a i, 2006). MESNA's thiol 
group is thought to be responsible for its antioxidant property which enables it to act 
as a free radical scavenger and thus limiting the damage associated with ischaemia- 
reperfusion when oxidant or ROS levels are significantly increased (Gressier et a i, 
1994). MESNA is also a small molecule which enables it to concentrate in the kidneys 
and therefore increase its ability as an anti-oxidant free radical scavenger (Gressier et 
a i, 1994).
6.2 Aim
The aim of this series of experiments was to investigate if H2S activated the 
reperfusion injury salvage kinase (RISK) pathway, as a potential mechanism of 
cardioprotection. The cardioprotective action of the structurally dissimilar and more 
complex thiol-containing compound MESNA was also investigated as an alternative to 
NaHS in relation to activation of the RISK pathway.
6.3 Hypotheses
1. H2S protection against ischaemia-reperfusion injury in the isolated rat perfused 
Langendorff heart by activation of the RISK pathway
2. The thiol-containing compound MESNA will induce cardioprotection via 
activation of the RISK pathway
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6.4 Objectives
These hypotheses were tested through the following experimental objectives:
1. To determine when H2S exerts its protective action, by perfusing hearts with 
Krebs-Henseleit buffer containing the H2S donor NaHS at three different time 
points: pre-ischaemically with wash-out (pharmacological preconditioning); 
during ischaemia; and at reperfusion.
2. To investigate if H2S activates the RISK pathway by the use of pharmacological 
inhibitors.
3. To determine if MESNA is cardioprotection using two different treatment 
protocols: pharmacological preconditioning with wash-out, and at
reperfusion.
4. To investigate if MESNA activates the RISK pathway by the use of 
pharmacological inhibitors.
6.5 Methods
6.5.2 Source of compounds used
The H2S donor NaHS was purchased from Acros Organics, UK. The PI3K inhibitor 
(LY294002), the Akt ihibitor (Akti VIII), and the thiol containing compound 2- 
mercaptoethane sulphonate sodium (MESNA), were all obtained purchased from 
Sigma-Aldrich, UK. LY294002 and Akti VIII were dissolved in DMSO, and required 
vehicle controls (DMSO 0.05%), whilst NaHS and MESNA were dissolved in Krebs- 
Henseleit buffer and therefore required no vehicle controls.
6.5.2 Preparation of Langendorff perfused isolated rat hearts
6.5.2.1 Setup o f isolated heart perfusion
Rat isolated hearts were used to investigate the role of NaHS and MESNA in 
cardioprotection. The hearts were Langendorff perfused using the methods described 
in Chapter 2, section 2.2. All hearts received an initial 10 minute stabilisation period 
following cannulation, to establish sinus rhythm. The hearts were then randomly 
assigned to one of the groups within each study described below:
6.5.3 NaHS perfusion protocols
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6.5.3.1 Study 1: Perfusion o f hearts with NaHS during early reperfusion 
Treatment protocols for this study are illustrated in Figure 6.2.
Group 1 -  Control: After an initial 20 minutes of stabilisation, hearts were subjected 
to 35 minutes regional ischaemia, and a 120 minute reperfusion period. For the 
duration of the experiment hearts were perfused with Krebs-Henseleit buffer.
Groups 2 to 4 -  NaHS 1, 10 or 50 pM early reperfusion: After 20 minutes of
stabilisation, and 30 minutes of ischaemia hearts were perfused with Krebs-Henseleit 
buffer containing NaHS 1 pM (group 2), 10 pM (group 3) or 50 pM (group 4) for the 
remaining 5 minutes of regional ischaemia until the first 10 minutes of reperfusion.
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Figure 6.2 Summary o f the perfusion protocol fo r  Study 1: Pefusion o f hearts with 
NaHS at early reperfusion. For the fina l 5 minutes o f regional ischaemia and the initial 
10 minutes o f reperfusion, the treatment hearts were perfused with NaHS 1-50 pM) 
and then switched back to Krebs-Henseleit buffer fo r  the duration o f the reperfusion 
period.
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6.53.2 Study 2: Perfusion o f hearts with NaHS during early ischaemia 
Treatment protocols for this study are illustrated in Figure 6.3.
Group 1 -  Control: After an initial 20 minutes of stabilisation, hearts were subjected 
to 35 minutes regional ischaemia, and a 120 minute reperfusion period. For the 
duration of the experiment hearts were perfused with Krebs-Henseleit buffer.
Groups 2 to 3 -  NaHS 1, or 10 pM early ischaemia: After 10 minutes of stabilisation, 
hearts were perfused with Krebs-Henseleit buffer containing NaHS 1 pM (group 2) or 
10 pM (group 3) for the remaining 10 minutes of stabilisation and the first 10 minutes 
of regional ischaemia until the first 10 minutes of regional ischaemia.
Group 4 -  NaHS 1 pM duration of ischaemia and early reperfusion: As per group 2 
except that hearts were perfused with Krebs-Henseleit buffer containing 1 pM NaHS 
for the duration of regional ischaemia until the first 10 minutes of reperfusion.
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Figure 6.3 Summary o f the perfusion protocol fo r Study 2: Perfusion o f hearts with 
NaHS during ischaemia. For the fina l 5 minutes o f stabilisation and the initial 10 
minutes o f regional ischaemia, the treatment hearts were perfused with NaHS 1-10 
pM) and then switched back to Krebs-Henseleit buffer fo r the duration o f the 
reperfusion period. Group 4 hearts which were perfused with NaHS (1 pM) after 10 
minutes o f stabilisation and fo r the duration o f ischaemia and until the initial 10 
minutes o f reperfusion.
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6.53.3 Study 3: Pharmacological preconditioning o f hearts with NaHS 
Treatment protocols for this study are illustrated in Figure 6.4.
Group 1 -  Control: After an initial 20 minutes of stabilisation, hearts were subjected 
to 35 minutes regional ischaemia, and a 120 minute reperfusion period. For the 
duration of the experiment hearts were perfused with Krebs-Henseleit buffer.
Group 2 -  1 x 5 '  NaHS 50 pM: After 10 minutes of stabilisation, hearts were perfused 
with Krebs-Henseleit buffer containing NaHS 50 pM for 5 minutes before retunring to 
Krebs-Henseleit buffer perfusion for the remaining 5 minutes of stabilisation and 
duration of experiment.
Group 3 -  Global ischaemic preconditioning: After 10 minutes of stabilisation, total 
flow to the hearts was stopped for 5 minutes and hearts were submerged in a heart 
jacket containing warmed Krebs-Henseleit buffer to maintain temperature. After 5 
minutes the hearts were reperfused for 5 minutes before inducing regional ischaemia.
Group 4 - 2 x 5 ' NaHS 50 pM: After 10 minutes of stabilisation, hearts were perfused 
with Krebs-Henseleit buffer containing NaHS 50 pM for 5 minutes, then perfused with 
Krebs-Henseleit buffer for 5 minutes. This cycle of 5 minutes NaHS followed by 5 
minutes Krebs-Henseleit buffer was repeated again prior to inducing regional 
ischaemia.
Group 5 - 2 x 5 '  global ischaemia: After 10 minutes of stabilisation, total flow to the 
hearts was stopped for 5 minutes and hearts were submerged in a heart jacket 
containing warmed Krebs-Henseleit buffer to maintain temperature. After 5 minutes 
the hearts were reperfused for 5 minutes. This cycle of 5 minutes regional ischaemia 
followed by 5 minutes repefusion was repeated again prior to inducning regional 
ischaemia.
Group 6 - 3 x 3 ' NaHS 50 pM: After 10 minutes of stabilisation, hearts were perfused 
with Krebs-Henseleit buffer containing NaHS 50 pM for 3 minutes, then perfused with 
Krebs-Henseleit buffer for 5 minutes. This cycle of 3 minutes NaHS followed by 5
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minutes Krebs-Henseleit buffer was repeated twice prior to inducing regional 
ischaemia.
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Figure 6.4 Summary o f the perfusion protocol fo r Study 3: Pharmacological 
preconditioning of hearts with NaHS. Hearts were pharmacologically preconditioned 
with NaHS using various protocols. Time matched ischaemic preconditioning controls 
were also performed.
Once it had been established that preconditioning with NaHS 50 pM was the most 
effective method of inducing cardioprotection in isolated rat hearts, a second series of 
experiments were performed using inhibitors of the RISK pathway in order to 
determine whether the cardioprotection observed with NaHS was via activation of the 
RISK pathway.
6.5.3.4 Study 4: Effect o f PI3K and Akt inhibition on NaHS preconditioning 
Treatment protocols for this study are illustrated in Figure 6.5.
Group 1 -  Control: After an initial 20 minutes of stabilisation, hearts were subjected 
to 35 minutes regional ischaemia, and a 120 minute reperfusion period. For the 
duration of the experiment hearts were perfused with Krebs-Henseleit buffer. To 
confirm that the DMSO vehicle used for the inhibitors had no effect on the hearts, 
hearts (n=3) were perfused with Krebs-Henseleit buffer containing DMSO (0.05%) for 
the remaining 5 minutes of ischaemia and initial 10 minutes of reperfusion.
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Group 2 -  NaHS 50 pM: After 15 minutes of stabilisation, hearts were perfused with 
Krebs-Henseleit buffer containing NaHS 50 pM for the remaining 5 minutes of 
stabilisation and the first 10 minutes of regional ischaemia
Group 3 -  NaHS 50 pM + LY294002 10 pM: As per group 2, with the addition that 
hearts were perfused with Krebs-Henseleit buffer containing LY294002 10 pM for the 
final 5 minutes of regional ischaemia and first 10 minutes of reperfusion.
Group 4 -  LY294002 10 pM: For the final 5 minutes of regional ischaemia and first 10 
minutes of reperfusion hearts were perfused with Krebs-Henseleit buffer containing 
LY294002 10 pM.
Group 5 -  NaHS 50 pM + Akti VIII 2 pM: As per group 2, with the addition that hearts 
were perfused with Krebs-Henseleit buffer containing Akti VIII 2 pM for the final 5 
minutes of regional ischaemia and first 10 minutes of reperfusion.
Group 6 -  Akti VIII 2 pM: As per group 4, except hearts were perfused with Krebs- 
Henseleit buffer containing Akti VIII 2 pM.
Group 1 -  Control (DMSO 0.05% n=3)
Group 2 -  NaHS (50 pM) precon.
Group 3 -  NaHS precon. + LY294002 at reper.
Group 4 -  LY294002 (10 pM) at reper.
Group 5 -  NaHS precon. + Akti VIII at reper.
Group 6 -  Akti VIII (2 pM) at reper.
Figure 6.5 Summary o f the perfusion protocol fo r Study 4: Effect o f inhibition o f PI3K 
on NaHS preconditioning. After 10 minutes o f stabilisation hearts were preconditioned 
with NaHS fo r  5 minutes and then back to Krebs-Henseleit buffer fo r the fina l 5 
minutes o f stabilisation. After NaHS preconditioning, hearts were perfused with the 
PI3K inhibitor; LY294002, or Akt inhibitor, Akti VIII, at early reperfusion.
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6.5.4 MESNA perfusion protocols
6.5.4.1 Study 5: Pharmacological pre- and postconditioning o f hearts with MESNA 
Treatment protocols for this study are illustrated in Figure 6.6.
Group 1 -  Control: After an initial 20 minutes of stabilisation, hearts were subjected 
to 35 minutes regional ischaemia, and a 120 minute reperfusion period. For the 
duration of the experiment hearts were perfused with Krebs-Henseleit buffer.
Group 2 -  50 pM MESNA preconditioning: After 15 minutes of stabilisation, hearts 
were perfused with Krebs-Henseleit buffer containing MESNA 50 pM for the remaining 
5 minutes of stabilisation and the first 10 minutes of regional ischaemia.
Group 3 - 5 0  pM MESNA at early reperfusion: After 20 minutes of stabilisation, and 
30 minutes of regional ischaemia hearts were perfused with Krebs-Henseleit buffer 
containing MESNA 50 pM for the remaining 5 minutes of regional ischaemia until the 
first 10 minutes of reperfusion.
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Group 2 -  MESNA (50 pM) precon.
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Figure 6.6 Summary o f the perfusion protocol fo r  Study 5: Pharmacological pre- and 
postconditioning o f hearts with MESNA. Hearts were either preconditioned with 
MESNA fo r  5 minutes during the stabilisation period or postconditioned with MENSA 
fo r  the fina l 5 minutes o f regional ischaemia and firs t 10 minutes o f reperfusion.
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6.5.4.2 Study 6: Effect o f PI3K inhibition on cardioprotection induced by MESNA at 
early reperfusion
Treatment protocols for this study are illustrated in Figure 6.7.
Group 1 -  Control: After an initial 20 minutes of stabilisation, hearts were subjected 
to 35 minutes regional ischaemia, and a 120 minute reperfusion period. For the 
duration of the experiment hearts were perfused with Krebs-Henseleit buffer. To 
confirm that the DMSO vehicle used for the inhibitor had no effect on the hearts, 
hearts (n=4) were perfused with Krebs-Henseleit buffer containing DMSO (0.05%) for 
the remaining 5 minutes of ischaemia and initial 10 minutes of reperfusion.
Group 2 -  50 pM MESNA at early reperfusion: After 20 minutes of stabilisation, and 
30 minutes of regional ischaemia hearts were perfused with Krebs-Henseleit buffer 
containing MESNA 50 pM for the remaining 5 minutes of regional ischaemia until the 
first 10 minutes of reperfusion.
Group 3 -  MESNA at early reperfusion + LY294002: As per group 2, except that hearrts 
were perfused with Krebs-Henseleit buffer containing MESNA 50 pM and LY294002 50 
pM.
Group 4 -  LY294002 10 pM: As per group 2, except hearts were perfused with Krebs- 
Henseleit buffer containing LY294002 lOpM.
-2 0 ’ -1 0 ’ 0 ’ 3 0 ’ 35 ’ 4 5 ’ 155 ’
i i i i i i  ii i i  i i i  ii i i  i i i___________
20’ stabilisation ic H I i IM i M I tblAnmVJ 120’ reperfusion----------- 1-----------1 i i i
Group 1 -  Control (Inc. DMSO n=4) j
*” ] 7.........  i i i  i
Group 2 -  MESNA (50 pM) early reper. * ......................     f l H H H .............................. jy............... i............ i......................................... 1i i i  i i i  i
Group 3 -  MESNA + LY294002 at early reper.
Group 4 -  LY294002 (10 pM) at early reper. :____________________________________________ ]______ I ..............................i
I - - ............i............ v
a .
i ..........................JL.................... I ...............................................J------1----- i.................................. j
Figure 6.7 Summary o f the perfusion protocol fo r  Study 6: Effect o f PI3K inhibition on 
cardioprotection induced by MESNA at early reperfusion. For the fina l 5 minutes o f 
ischaemia and in itia l 10 minutes o f reperfusion, hearts were perfused with Krebs- 
Henseleit buffer containing MESNA. Hearts were also perfused with MESNA and the 
PI3linase inhibitor LY294002 at using the same protocol.
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6.6 Results
6.6.1 Exclusion criteria
In total 168 rat hearts were used for the experiments performed in these studies. Of 
these 168 hearts, 17 were excluded on technical grounds. Data from 151 rat hearts are 
presented in this chapter.
6.6.2 NaHS perfusion data
6.6.2.1 Study 1: Perfusion o f hearts with NaHS a t early reperfusion 
Perfusing the rat heart with NaHS (1-50 pM) at early reperfusion had no significant 
effect at reducing the infarct size (37.7 ± 4.6%, 29.2 ±  3 .8% and 35.7 ±  7.7% vs. 39.6 ± 
3.3% for 1 pM, 10 pM, 50 pM and control respectively). There was a slight tendency 
of the 10 pM concentration to reduce the infarct size (29.2 ±  3.8% vs. 39.6 ±  3.3% for 
10 pM NaHS and control respectively), but this was not significant (as shown in figure 
6.8).
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Figure 6.8 Comparison o f infarct to risk ratios (%) fo r  concentration ranging studies 
with the H2S donor NaHS (1-50 pM) at early reperfusion. NaHS had no significant 
effect at reducing infarct size at any o f the concentrations tested. One-way ANOVA 
was used to test fo r  significance differences between all groups. Each value shown is 
the mean ±SEM from  6-13 individual heartss.
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6.6.2.2 Study 2: Perfusion o f hearts with NaHS during early ischaemia 
Perfusing the rat heart with NaHS (1-10 pM) during early ischaemia had no significant 
effect at reducing the infarct size (36.9 ±  4.7% and 30.3 ± 2.6% vs.39.6 ±  3.3% for 1 
pM, 10 pM and control respectively). There was a slight tendency of the 10 pM 
concentration to reduce the infarct size (30.3 ±  2.6% vs 39.6 ± 3.3% for 10 pM NaHS 
and control respectively), as was seen with NaHS at reperfusion, but this was not 
significant. Perfusing hearts with NaHS 1 pM for the duration of ischaemia and early 
repefusion, produced no reduction in infarct size compared to control (33.4 ± 3.5% vs.
39.6 ± 3.3%) (data summarised in figure 6.9).
45
Figure 6.9 Comparison o f infarct to risk ratios (%>,) fo r  concentration ranging studies 
with the H2S donor NaHS ( 1 - 1 0  pM) at early ischaemia and also perfusion with NaHS 
(1 pM) fo r  the duration o f ischaemia and early reperfusion. NaHS produced no 
significant effect a t reducing infarct size at any o f the concentrations tested. One-way 
ANOVA was used to test fo r  significance differences between all groups. Each value 
shown is the mean ±SEM from 4-13 individual hearts.
6.6.2.3 Coronary flow  and contractility data fo r  studies 1 and 2
Baseline cardiodynamic data (heart rate, coronary flow rate, developed pressure and 
rate pressure product for the hearts in studies 1 and 2 are summarised in figure 6.10. 
The rate pressure product and coronary flow rate of the hearts throughout the two 
experiments is presented in figure 6.11. There were no significant effects of any of the 
compounds tested on the measured parameters. Regional ischaemia caused a
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reduction in rate pressure product and coronary flow rate in all treatment groups as 
expected (as shown in figure 6.11). Run-down of the hearts is demonstrated by a 
reduction in rate pressure product in all treatment groups as expected (as shown in 
figure 6.11).
1 6 1
Treatment group n CFRml/min
HR
BPM LVDP mmHg
RPP
mmHg/min xIO3
RV and LV vol. 
cm3
Risk zone vol. 
cm3
Control 15 17.7 ±0.9 296 ±16 112.3 ±7.5 32.6 ±2.1 0.84 ± 0.02 0.40 ±0.03
NaHS 1 pM early isch. 4 15.8 ±0.7 198 ±26 86.6 ±7.3 26.3 ± 3.6 0.94 ± 0.09 0.45 ±0.05
NaHS 10 pM early isch. 4 17.9 ±1.0 311 ±19 109.7 ±7.9 34.4 ±3.4 0.63 ±0.04 0.36 ± 0.02
NaHS 50 pM isch. and 
early reper 9 17.2 ±1.2 248 ±16 106.1 ±7.0 26.1 ±1.8 0.84 ± 0.02 0.39 ±0.02
NaHS 1 pM early reper. 6 16.2 ±2.2 297 ±17 96.8 ±10.6 28.1 ±2.0 0.76 ±0.03 0.37 ± 0.03
NaHS 10 pM early reper. 8 18.0 ±1.2 300 ±35 108.9 ±2.9 32.8 ±4.3 0.85 ±0.02 0.46 ± 0.04
NaHS 50 pM early reper. 6 19.5 ±14 332 ±14 94.2 ±4.2 31.4 ±2.0 0.82 ± 0.02 0.44 ±0.03
Figure 6.10 Baseline cardiodynamic data fo r hearts used in the NaHS early ischaemia and early reperfusion perfusion studies. Abbreviations: 
LV = left ventricle, RV = right ventricle, CFR = coronary flow  rat, HR = heart rate, LVDP = left ventricular pressure, RPP = rate pressure product 
(HRxLVDP).
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Figure 6.11 Rate pressure product (RPP) (A) and coronary flow  rate (CFR) (B) fo r  
hearts used in the NaHS early ischaemia and early reperfusion perfusion studies. 
Stab.=stabilisation period (20 mins), lsch.=Regional ischaemia (35 mins), Reperfusion 
(120 mins). Each value shown is the mean from 4-15 individual hearts. SEM error 
bars have been removed fo r clarity.
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6.6.2.4 Study 3: Pharmacological preconditioning o f hearts with NaHS 
A single preconditioning stimulus of NaHS (50 pM) prior to a prolonged ischaemia- 
reperfusion episode induced a very significant reduction in the infarct size compared 
to control (27.7 ± 2.1% vs. 39.6 ±  3.3%, **p<0.01). This was comparable to the single 
5 minute episode of global ischaemic preconditioning (Glsch.) (28.6 ± 2.6%) which 
acted as a positive control. Hearts perfused with a dual preconditioning stimulus (2 x 
5 minutes) of NaHS (50 pM) did not induce cardioprotection and produced an 
increase in infarct size in comparison to control (45.8 ± 3.3% vs. 39.6 ± 3.3%) 
although this was not significant. This was in contrast to the two episodes of 5 
minute global ischaemia which caused a significant reduction in infarct size in 
comparison to control (26.1 ± 3.3% vs. 39.6 ±  3.3%, *p<0.05). Increasing the 
preconditioning stimulus of NaHS to three, 3 minute bursts of NaHS, caused no 
significant reduction in infarct size in comparison to control (33.3 ± 1.1% vs. 38.0 ± 
3.5%) (data summarised in figure 6.12).
*
Figure 6.12 Comparison o f infarct to risk ratios (%,), between various NaHS and 
global ischaemia preconditioning protocols. A single NaHS preconditioning stimulus 
induced significant cardioprotection in comparison to multiple which caused no 
protective effect. Both global ischaemic protocols also significantly reduced infarct 
size. One-way ANOVA was used to test fo r significance differences between all 
groups, *<p<0.05, **p<0.01. Each value shown is the mean ±  SEM from 4-15 
individual hearts.
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6.6.2.5 Coronary flow  and contractility data fo r  studies 3
Baseline cardiodynamic data (heart rate, coronary flow rate, developed pressure and 
rate pressure product for the hearts in study 3 are summarised in figure 6.13. The 
rate pressure product and coronary flow rate of the hearts throughout the 
experiments is presented in figure 6.14. There were no significant effects of any of 
the compounds tested on the measured parameters. Regional ischaemia caused a 
reduction in rate pressure product and coronary flow rate in all treatment groups as 
expected (as shown in figure 6.14). Run-down of the hearts is demonstrated by a 
reduction in rate pressure product in all treatment groups as expected (as shown in 
figure 6.14).
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Treatment group n
CFR
ml/min
HR
BPM
LVDP
mmHg
RPP 
mmHg/min xIO3
RV and LV vol.
cm3
Risk zone vol. 
cm3
Control 15 17.7 ±0.9 296 ±16 112.3 ±7.5 32.6 ±2.1 0.84 ± 0.02 0.40 ± 0.03
1 x 5‘ 50 pM NaHS precon. 15 19.9 ±1.1 277 ± 11 156.0 ±21.6 30.7 ± 1.7 0.81 ± 0.03 0.40 ± 0.02
1x5' Glsch. precon. 14 18.0 ±0.8 269 ±13 106.0 ±5.8 27.9 ±1.4 0.79 ± 0.01 0.42 ± 0.02
2 x 5' 50 pM NaHS precon. 4 19.7 ±0.6 308 ± 24 113.4 ±14.6 33.7 ± 2.0 0.76 ± 0.02 0.42 ± 0.03
2x5' Glsch. precon. 6 17.8 ±0.8 272 ± 19 131.7 ±15.4 33.6 ± 3.6 0.84 ± 0.03 0.41 ± 0.02
3x5' 100 pM NaHS precon. 7 19.5 ± 1.0 259 ±16 106.3 ±8.2 27.8 ± 3.2 0.91 ± 0.03 0.47 ± 0.04
Figure 6.13 Baseline cardiodynamic data fo r hearts preconditioned with NaHS. Abbreviations: LV = left ventricle, RV = right ventricle, CFR = 
coronary flow  rat, HR = heart rate, LVDP = left ventricular pressure, RPP = rate pressure product (HR x LVDP).
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Figure 6.14 Rate pressure product (RPP) (A) and coronary flow  rate (CFR) (B) fo r  
hearts preconditioned with NaHS. Stab.=stabilisation period (20 mins), 
lsch.=Regional ischaemia (35 mins), Reperfusion (120 mins). Each value shown is the 
mean from  6-15 individual hearts. SEM error bars have been removed fo r clarity.
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6.6.2.6 Study 4: Effect o f inhibition o f PI3K on NaHS preconditioning 
The protective effect of preconditioning with NaHS was attenuated in the presence 
of the PI3K inhibitor (LY294002) (34.3 ± 3.1% vs. 27.7 ± 2.1%, **p<0.05). LY294002 
alone increased the infarct size above control (47.9 ± 3.6% vs. 39.2 ±  3.0%), although 
not significantly (data summarised in figure 6.15).
Figure 6.15 Comparison o f infarct to risk ratio (%,) fo r NaHS preconditioned hearts in 
the presence and absence o f the PI3K inhibitor LY294002 10 pM.. LY294002 
significantly attenuated the cardioprotective effect o f NaHS preconditioning, and 
alone significantly increased infarct size. **p<0.01, one-way ANOVA was used to test 
fo r significance differences between all groups. Each value shown is the mean ±SEM 
from  5-18 individual hearts.
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6.6.2.7 Study 5: Effect o fA kt inhibition on NaHS preconditioning 
The protective effect of preconditioning with NaHS was attenuated in the presence 
of the Akt inhibitor (Akti VIII) (36.6 ±  5.3% vs. 27.7 ±  2.1% for NaHS + Akti VIII and 
NaHS respectively). Akti VIII alone increased the damaged to the myocardium above 
the control (45.3 ± 5.7% vs. 39.2 ±  3.0% for Akti VIII and Control respectively), 
although not significant (as shown in figure 6.16).
60 n
Figure 6.16 Comparison o f infarct to risk ratio (%,) fo r  NaHS preconditioned hearts in 
the presence and absence o f the Akt inhibitor Akti VIII 2 pM. Akti VIII significantly 
attenuated the cardioprotective effect o f NaHS preconditioning, and alone 
significantly increased infarct size. *p<0.05, one-way ANOVA was used to test fo r 
significance differences between all groups. Each value shown is the mean ±  SEM 
from  5-18 individual hearts.
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6.6.2.8 Coronary flow  and contractility data fo r  studies 4 and 5 
Baseline cardiodynamic data (heart rate, coronary flow rate, developed pressure and 
rate pressure product for the hearts in studies 4 and 5 are summarised in figure 6.17. 
The rate pressure product and coronary flow rate of the hearts throughout the two 
experiments is presented in figure 6.18. There were no significant effects of any of 
the compounds tested on the measured parameters. Regional ischaemia caused a 
reduction in rate pressure product and coronary flow rate in all treatment groups as 
expected (as shown in figure 6.18). Run-down of the hearts is demonstrated by a 
reduction in rate pressure product in all treatment groups as expected (as shown in 
figure 6.18).
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Treatment group n CFRml/min
HR
BPM
LVDP
mmHg
RPP 
mmHg/min xIO3
RV and LV vol. 
cm3
Risk zone vol. 
cm3
Control (inc. DMSO n=3) 18 17.3 ±0.8 297 ±18 107.7 ±7.0 31.8 ±2.5 0.85 ± 0.02 0.39 ±0.03
1 x 5’ 50 pM NaHS precon. 15 19.9 ±1.1 277 ±11 156.0 ±21.6 30.7 ±1.7 0.81 ±0.03 ,0.40 ±0.02
NaHS + LY294002 5 18.6 ±1.2 286 ±9 124.0 ±7.0 35.6 ± 2.6 0.93 ± 0.02 0.49 ± 0.03
LY294002 5 14.0 ±1.9 283 ± 21 89.2 ±11.3 24.7 ± 2.8 0.79 ± 0.01 0.42 ±0.02
NaHS + Akti VIII 5 19.1 ±2.8 288 ± 2.8 117.5 ±9.5 35.2 ±2.5 0.87 ± 0.04 0.48 ±0.01
Akti VIII 5 21.1 ±2.2 262 ± 23 93.4 ± 4.8 24.5 ± 2.7 0.89 ± 0.02 0.43 ± 0.02
Figure 6.17 Baseline cardiodynamic data fo r hearts preconditioned with NaHS in the presence and absence o f a PI3K and Akt inhibitor. 
Abbreviations: LV = left ventricle, RV = right ventricle, CFR = coronary flow  rat, HR = heart rate, LVDP = left ventricular pressure, RPP = rate 
pressure product (HR xL VDP).
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Figure 6.18 Rate pressure product (RPP) (A) and coronary flow  rate (CFR) (B) fo r  
hearts preconditioned with NaHS in the presence and absence o f a PI3K and Akt 
inhibitor. Stab.=stabilisation period (20 mins), lsch.=Regional ischaemia (35 mins), 
Reperfusion (120 mins). Each value shown is the mean from 5-18 individual hearts. 
SEM error bars have been removed fo r clarity.
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6.6.3 MESNA data
6.6.3.1 Study 6: Pharmacological pre- and postconditioning o f hearts with MESNA 
Pharmacological preconditioning with MESNA 50 pM produced cardioprotection 
with a significant reduction in infarct size compared to control (27.1 ± 2.1% vs. 39.2 ± 
3.4%, *p<0.05). A similar cardioprotective effect was seen with MESNA 
postconditioning compared to control (26.1 ± 3.5% vs. 39.2 ± 3.4%, p<0.05) (data 
summarised in figure 6.19).
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Figure 6.19 Comparison o f infarct to risk ratio (%) fo r MESNA preconditioned and 
postconditioned hearts. Both pre- and postconditioned hearts produced a significant 
reduction in infarct size. *p<0.05, one-way ANOVA was used to test fo r significance 
differences between all groups. Each value shown is the mean ±  SEM from 6-12 
individual hearts.
6.6.3.2 Study 7: The effect o f a PI3K inhibitor on the cardioprotective effect o f 
MESNA at early reperfusion
The cardioprotective effect of MESNA at early reperfusion was attenuated in the 
presence of the PI3K inhibitor LY294002 10 pM (26.1 ± 3.5% vs. 40.6 ± 2.5%, 
*p<0.05). LY294002 alone also produced an increase in infarct size compared to 
control although this was not significant (48.6 ± 2.6 vs. 39.2 ± 3.4%) (data 
summarised in figure 6.20).
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Figure 6.20 Comparison o f infarct to risk ratio (%,) fo r MESNA postconditioned 
hearts in the presence and absence o f the PI3K inhibitor LY294002. LY294002
significantly attenuated the cardioprotective effect o f MESNA postconditioning. 
*p<0.05, one-way ANOVA was used to test fo r  significance differences between all 
groups. Each value shown is the mean ±SEM from 7-12 individual hearts.
6.6.3.3 Coronary flow  and contractility data fo r  studies 6 and 7 
Baseline cardiodynamic data (heart rate, coronary flow rate, developed pressure and 
rate pressure product for the hearts in studies 6 and 7 are summarised in figure 6.21. 
The rate pressure product and coronary flow rate of the hearts throughout the two 
experiments is presented in figure 6.22. There were no significant effects of any of 
the compounds tested on the measured parameters. Regional ischaemia caused a 
reduction in rate pressure product and coronary flow rate in all treatment groups as 
expected (as shown in figure 6.22). Run-down of the hearts is demonstrated by a 
reduction in rate pressure product in all treatment groups as expected (as shown in 
figure 6.22).
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Treatm ent group n CFR
m l/m in
HR
BPM
LVDP
m m Hg
RPP  
m m Hg/m in x IO 3
RV and LV vol. 
cm 3
Risk zone vol. 
cm 3
Control 12 17.7 ±0.9 276 ±19 108.5 ±9.4 30.1 ±3.3 0.94 ± 0.04 0.46 ±0.05
MESNA 50 pM precon. 6 18.7 ±1.1 242 ±8 116.4 ±6.0 28.1 ±1.6 0.94 ±0.04 0.43 ± 0.03
MESNA 50 pM postcon. 6 20.6 ± 2.0 252 ±22 134.4 ±9.0 32.9 ±1.2 0.90 ± 0.02 0.43 ±0.02
MESNA postcon. + 
LY294002 7 19.0 ±1.2 264 ±15 166.2 ±8.8 30.7 ±2.6 1.05 ±0.05 0.57 ±0.06
LY294002 10 pM 7 16.0 ±1.8 261 ±20 111.8 ± 17.5 27.5 ±2.9 0.83 ± 0.03 0.44 ±0.02
Figure 6.21 Baseline cardiodynamic data fo r hearts used in the MESNA perfusion studies. Abbreviations: LV = left ventricle, RV = right ventricle, 
CFR = coronary flow  rat, HR = heart rate, LVDP = left ventricular pressure, RPP = rate pressure product (HR x LVDP).
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Figure 6.22 Rate pressure product (RPP) (A) and coronary flow  rate (CFR) (B)for hearts 
used in the MESNA perfusion studies. Stab.=stabilisation period (20 mins), 
lsch.=Regional ischaemia (35 mins), Reperfusion (120 mins). Each value shown is the 
mean from  7-12 individual hearts. SEM error bars have been removed fo r clarity.
Reperfusion
2.0x10*
—■ -  Control 
—a— MESNA precon.
MESNA postcon. 
- © -  MESNA + LY294002 
LY294002
176
Chapter 6 RISK pathway activation by NaHS and MESNA
6.7 Discussion
The findings of these studies can be summarised briefly as follows:
1. Pharmacological preconditioning with NaHS was the only effective 
pharmacological protocol to induce cardioprotection in the Langendorff 
perfused isolated rat heart.
2. The infarct limiting effect of NaHS preconditioning was attenuated in the 
presence of the PI3K inhibitor LY294002 and the Akt inhibitor Akti VIII, 
suggesting a potential for NaHS to activate the RISK pathway to induce 
cardioprotection.
3. Pharmacological pre- and postconditioning with MESNA induced 
cardioprotection in isolated rat hearts.
4. The cardioprotective effect o f MESNA postconditioning was abolished in the 
presence of LY294002, suggesting MESNA may activate the RISK pathway to 
induce cardioprotection.
6.7.1 Perfusion o f hearts w ith NaHS
Perfusion o f hearts with NaHS during early reperfusion does not induce 
cardioprotection
Initially in this study, hearts were perfused with NaHS either at early reperfusion, or 
during the early part of ischaemia. This approach was taken since it has previously 
been reported that isolated rat hearts perfused with NaHS (1 pM) during ischaemia 
plus early reperfusion were found to be protected (Johansen et ai., 2006). However, it 
was not clear at what point H2S was required to induce protection.
The results obtained in this study suggest that perfusing the heart with H2S specifically 
at early reperfusion is not cardioprotective at the concentrations tested (1 -  50 pM 
NaHS). It appears that the 10 pM NaHS may show some tendency towards 
cardioprotection, but this is not a significant finding. Interestingly, the 50 pM NaHS 
does not offer any further protection and matches the control infarct size. This 
highlights the fine homeostatic regulation of H2S in the body, since it is reported that 
only a two-fold concentration above physiological concentrations is in fact toxic
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(Warenycia et al., 1989). Taken in this context, it is possible that there is a 
concentration of NaHS that lies between 10 and 50 pM that offers protection.
There are several published studies that contradict the findings of the studies 
presented in this chapter and show a cardioprotective role of H2S at reperfusion. Ji et 
al. (Ji et al., 2008) showed that four, 15 second perfusions with NaHS (1 pM) with 15 
seconds of normal buffer in between at reperfusion, produced a marked 
concentration-dependent reduction in infarct size. Pharmacological postconditioning 
with NaHS improved cardiodynamics, and produced a reduction in infarct size in 
isolated rat hearts. These protective effects were abolished in the presence of a PI3K 
inhibitor or a PKC inhibitor (Yong et al., 2008a), suggesting that H2S stimulates PI3K 
and PKC signalling. Possible explanations for the differences observed between the 
studies presented in this chapter and published data, could be due to the severity of 
acidosis occuring during ischaemia-reperfusion effecting the dissociation of NaHS and 
subsequent availability of H2S, and also variation in the susceptibility of some of the 
rat the hearts to myocardial damage effecting the amount of infarct size limitation 
achieved.
eNOS activity has been shown to be stimulated in hearts perfused continually with 
NaHS at reperfusion (Yong et al., 2008a), suggesting that H2S may up-regulate the 
production of NO, a central component of the RISK pathway in eliciting 
cardioprotection. Yong et al. (2008a) have shown that ischaemic postconditioning (6 
episodes of 10 second ischaemia at the onset of reperfusion) stimulated the 
production of endogenous H2S during the early period of reperfusion in isolated 
perfused rat hearts. In the presence of PAG, a selective CSE inhibitor, there was an 
attenuation of the improved contractile function and also a reduction in PKC and PKG 
phosphorylation.
In an in vivo mouse model Elrod et al. (2007) demonstrated the ability to induce 
cardioprotection with NaHS (50 pg/kg) at reperfusion. They concluded that the 
cardioprotective effect of NaHS was through the preservation of mitochondrial 
functions. These findings suggest that after H2S activates PI3K and Akt, it induces
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cardioprotection via activation of the downstream components of the RISK pathway, 
preventing the opening of the mPTP. They also showed that transgenic mice with 
increased expression of CSE in the myocardium demonstrated the ability to produce 
twice as much H2S as wild type mice. A 47% reduction in infarct size, compared to 
wild type control, has also been observed in in vivo hearts subjected to 45 minute left 
coronary artery occlusion and 72 hours of reperfusion (Elrod et al., 2007). These 
findings suggest that upregulated endogenous H2S production is cardioprotective and 
support the findings of Silvarajah et al. (2006) who demonstrated that inhibition of 
CSE caused increased myocardial damage in a rat model of ischaemia-reperfusion.
Perfusion o f hearts with NaHS during early ischaemia did not induce cardioprotection
Hearts perfused with NaHS during the initial stages of ischaemia also showed no 
protection against ischaemia-reperfusion injury at the concentrations tested (1-10 pM 
NaHS). There was also a slight reduction in infarct size with 10 pM NaHS, as was seen 
with 10 pM NaHS at reperfusion, although this was not significant. A higher 
concentration of NaHS was not tested, since there was evidence that NaHS 50 pM was 
shown to offer no protection when hearts were perfused at reperfusion implying 
cytotoxic effects. Surprisingly, hearts perfused with NaHS 1 pM for the duration of 
ischaemia and early reperfusion showed no cardioprotection. There was not even a 
tendency towards a protective effect. These findings are in marked contrast to a pilot 
study performed in our lab prior to the start of my PhD, whereby perfusing isolated rat 
hearts for the duration of 35 minutes regional ischaemia and early reperfusion caused 
a significant reduction in infarct size compared to control (Johansen et al., 2006). 
These findings do however support those of Bilksoen et al. (2008) who reported no 
significant reduction in infarct size in isolated rate hearts perfused with NaHS 40 pM 
for the duration of ischaemia and reperfusion. They accounted the lack of 
cardioprotection to two outlying infarct values, but experience of working with NaHS 
in out lab would suggest that this was simply the varying nature of the results 
obtained with NaHS. Additional contradictory data was generated in the study 
presented in this chapter with the H2S donor NaHS. These are outlined in detail later 
in this discussion along with possible reasoning.
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A single 5 minute NaHS preconditioning stimulus induced cardioprotection
A single 5 minute perfusion of NaHS with 5 minutes washout, prior to a 35 minute 
regional ischaemic episode, induced a significant reduction in the infarct size 
compared with control. This pharmacological preconditioning protocol also produced 
a similar reduction in infarct compared to its time matched control which received 5 
minutes global ischaemia preconditioning. However, increasing the number of NaHS 
preconditioning stimuli to two episodes of 5 minutes, and three episodes of 3 minutes 
did not produce cardioprotection, unlike the time matched global ischaemia controls. 
As a result of these findings the single 5 minute NaHS preconditioning perfusion 
protocol was selected for the inhibitor studies. This cardioprotective effect was of a 5 
minute NaHS preconditioning perfusion was abolished in the presence of either the 
PI3K inhibitor, LY294002, or an Akt inhibitor, Akti VIII, at reperfusion. These findings 
suggest that H2S may act via these initial upstream components of the RISK pathway 
to induce cardioprotection at reperfusion.
Interestingly a paper published by Hu et al. (2008) showed that preconditioning with 
NaHS (100 pM) for 3, 3 minute cycles prior to a prolonged ischaemic episode induced 
significant myocardial protection. This was contradictory with the findings from the 
data presented in this chapter which showed no cardioprotection using this protocol. 
However, in keeping with the findings presented in this chapter of the involvement of 
PI3K and Akt in NaHS' cardioprotection, the authors demonstrated that the protective 
effect of NaHS (three time 3 minute episodes NaHS 100 pM) was abolished in the 
presence of LY294002 (15 pM) during both preconditioning and ischaemia. 
Preconditioning with NaHS has also been shown to increase the phosphorylation 
levels of Akt, suggesting that NaHS triggered cardiac protection via the PI3K/Akt 
upstream components of the RISK pathway (Hu et al., 2008).
PKC has also been implicated in the cytoprotective signalling cascade activated by H2S. 
Preconditioning with NaHS activated PKC a, £, and 5 isoforms (Pan et al., 2008). In the 
presence of glibenclamide translocation of the e and 8 isoforms to the membrane 
fraction was abolished, suggesting an involvement of the K At p  channel in their
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activation. NaHS preconditioning also significantly accelerated the decay of 
electrically and caffeine induced intracellular calcium transients, which was reversed 
in the presence of the selective PKC inhibitor cherlerythrine. These findings suggest 
that preconditioning with NaHS activates PKC in cardiomyocytes resulting in 
accelerated clearance of intracellular calcium by stimulating the sodium/calcium 
exchanger and sarcoplasmic reticulum calcium ATP-ase mechanisms (Pan et al., 2008).
Oxidative stress may explain the lack o f cardioprotection seen with NaHS at early 
ischaemia and early reperfusion
The lack of protection seen with NaHS at early reperfusion and early ischaemia in the 
isolated rat heart, may be explained by large amount of oxidative stress already 
occurring in the heart as a result of free radical accumulation during this period 
(Goldhaber et al., 1992). Oxidative stress occurs as a result of an imbalance between 
oxidant and antioxidant defence systems, resulting in cell damage (Cesselli et al.,
2001). Since it is known that H2S has a toxic profile, the free radical characteristic of 
the compound may be exacerbated during periods of iscaheamia-reperfusion, as 
opposed to providing a protective action. H2S appears to have a very narrow 
therapeutic index for protection. Endogenous levels are tightly regulated, since there 
is only a 2-fold difference between a physiological and a toxic level (Warenycia et al., 
1989). H2S may therefore be protective when given as a preconditioning stimulus as a 
result controlling the exposure level of the gas to cells, since a single 5 minute 
exposure followed by washout is all that the cells were exposed to. As a result there is 
the reduced probability that the gas will accumulate and cause detrimental effects. In 
addition, during the basal perfusion period the heart is not undergoing high levels of 
oxidative stress and H2S may therefore be able to act to pharmacologically 
precondition since cells are in a more receptive state than they are during ischaemia- 
reperfusion. ATP is also present to drive active processes enabling the RISK pathway 
to  be primed. Increasing the number of NaHS preconditioning stimuli produced no 
further increase in cardioprotection. In fact two, 5 minute NaHS preconditioning 
stimuli increased the infarct size above control, although not statistically significant. 
This again highlights to fine balance between the cardioprotective and deleterious 
effect of H2S.
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Another possible explanation for the lack o f protective efficacy seen with H2S during 
ischaemia and reperfusion, particularly with the lower concentrations tested (1 and 10 
pM), is that such a low concentration of derived H2S was present. Indeed, Johansen et 
al. (2006) showed that over a 55 minute perfusion with NaHS (1 pM) during the 
duration of ischaemia and start of reperfusion, cardiac protection was induced. Since 
H2S is such a volatile compound that is readily broken down, the 15 minute perfusions 
performed within this study were perhaps simply not long enough at the 
concentrations tested to induce protection. H2S may accumulate within the heart and 
only when a certain threshold concentration is reached does protection occur. 
Increasing the concentration of NaHS to 50 pM showed no protective effect. 
Johansen et al. (2006) also showed that increasing the concentration of NaHS from 1 
pM to lOpM over ischaemia and early reperfusion, showed no protection and was 
associated with cytoxic, metabolic or other non-specific effects. This illustrates the 
very balance between the gas' protective and deleterious effect.
It has also been shown that direct administration of NaHS (50 pg/kg) to the heart at 
reperfusion in an in vivo mouse model also caused substantial protection to the 
myocardium shown by a reduction in infarct size (Elrod et al., 2007). However, since 
this was an in vivo model, there may have been other endogenous factors present that 
influenced the tissue availability of the free gas, making it difficult to compare the 
findings to the ex vivo model used in this study.
6.7.1.1 Difficulties o f working with the H2S donor NaHS
Other groups investigating the actions of H2S have commented on the difficulty of 
working with such an unstable compound (Li et al., 2008a; Zhao et al., 2002) and the 
need for additional chemical tools to assist in understanding the complex biological 
roles o f H2S in the body. The major difficulties of working with NaHS as an H2S donor 
lie within determination of the final concentration of H2S, the storage of the 
compound both as a solid and in solution, and also the apparent lack of awareness of 
some of the users when publishing in the literature as to whether the concentration 
that they refer to is of H2S or the parent compound NaHS.
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The pH of the internal environment of the heart may have effected the dissociation of 
the NaHS to  form H2S. When NaHS dissociates in water it forms Na+ and HS\ The HS' 
then associates with H+ to form H2S. In solution at pH 7.4 and 37 °C, approximately 
18.5% of H2S exists in the undissociated form H2S and the remainder exists as HS‘ 
which is at equilibrium with H2S (Dombkowski et al., 2004). During ischaemia it is 
known that intraceullular acidosis occurs as a result of accumulation of metabolic 
waste products (Kaski et al., 1998). This may effect the final concentration of H2S 
which is present by altering the dissociation constant of NaHS predicted by the 
Henderson Hasselbach equation. The extracellular pH may not be to different as a 
result o f the buffering action of the Krebs-Henseleit buffer.
The stability of H2S in solution has also been investigated (Zhao et al., 2002). It 
appears that the stability of H2S in solution depends on the starting concentration of 
H2S. A Im M  solution of pure bubbled H2S gas has been shown to drop by 15% in 30 
minutes. The graph in figure 6.23 demonstrates that at lower starting concentrations 
of H2S, there is less decline in the concentration remaining in solution. This provides 
confidence that suggesting that in the concentrations tested the H2S should have been 
relatively stable during the short perfusion periods of up to 15 minute. This is 
assuming that H2S derived from NaHS acts in the same manner in solution as the pure 
bubbled gas.
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Figure 6.23 Stability o f H2S solution in Krebs-Henseleit buffer solution. H2S 
concentrations in the Krebs-Henseleit buffer were measured immediately after they 
were made and 30 minutes afterwards. The amount o f remaining H2S is expressed as 
a percentage o f the initial measured concentration. Graph from  Zhao et al. (2002).
6.7.1.2 Alternative H2S donor compounds
Another potentially viable option to NaHS is to bubble pure H2S gas into solution. 
Whilst this ensures that only H2S is present in solution, it does not enable the final 
concentration of the solution to be easily measured. There are H2S probes widely 
used for environmental detection of H2S, but these do not appear to be sensitive 
enough to detect the concentrations within the desired detection range. Other 
compounds have been synthesised such as S-diclofenac, which is a non-steroidal anti­
inflammatory drug (NSAID) with a sulphur group attached. It has been shown that it is 
possible to  induce marked cardioprotection in global low-flow ischaemia in the 
isolated rabbit heart using the H2S donor compound, S-diclofenac, when compared it 
the parent compound diclofenac (Rossoni et al., 2008). As yet there appear to be no 
studies conducted in the isolated rat heart using regional ishaemia, but it would be 
interesting to see the effectiveness of this H2S donor and whether it is a viable 
alternative to NaHS. Another H2S donor compound called Lawesson's compound has 
also recently emerged into the literature (Li et al., 2008a). Lawesson's compound is a 
thionation reagent which as yet does not appear to have been used in ischaemia-
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reperfusion experiments, but may have promising potential as an alternative to NaHS 
in the future.
6.7.1.3 Further studies with NaHS
It would be interesting to investigate the effects of blocking further downstream 
components of the RISK pathway, in particular investigating the potential interaction 
o f H2S with NO synthesis component o f the RISK pathway. It has been reported that 
there is an interaction between NO and H2S, since the production of both gases can be 
increased by pro-inflammatory mediators o f haemorrhagic shock (Mok et ai., 2004) 
and bacterial lipopolysaccharide (Li etal., 2005). H2S has been shown to both enhance 
and attenuate the relaxant effect o f NO in the rat aorta, whilst NO has been shown to 
enhance the release of H2S. These contradictory findings may it difficult to define the 
interaction of the gases. More recently it has been shown that NO and peroxynitrite 
react with H2S to form a novel nitrosothiol, which has been proposed to regulate the 
physiological effects of NO and H2S (Whiteman et ai., 2006). Experiments giving an NO 
synthase inhibitor, such as L-NAME at reperfusion, in H2S preconditioned Langendorff 
perfused isolated rat hearts, would be useful to assist in the understanding of the 
interaction of the two : gases. Western blotting studies to compare the 
phosphorylation state of eNOS in H2S preconditioned and control hearts would also be 
beneficial.
In aortic tissue H2S may directly interact with the K At p  channels to cause 
hyperpolarisation and relaxation (Zhao et al., 2001a). This suggests that H2S has the 
potential to  act directly on the K At p  component of the RISK pathway and may mediate 
protection by activating components downstream of the ion channel. Alternatively 
after activation of PI3K and Akt by H2S, alternative pathways may be activated that 
induce cardioprotection. For example Pim-1, a proto-oncogenic serine-threonine 
kinase (Wang et al., 2001), has been shown to regulate cardiomyocyte survival 
downstream of Akt by regulating cell survival and proliferation (Muraski et al., 2007). 
The role o f Pim-1 in cardioprtotection is still an emerging field. It is also known that 
the PI3K inhibitor LY29002, binds to and inhibits Pim-1 (Jacobs et al., 2005), suggesting
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that previous studies with LY294002 may require reinterpretation in the context of Akt 
depenendent Pim-1 signalling (Muraski etal., 2007).
Ideally a protective therapeutic intervention after a cardiovascular event would occur 
at reperfusion, since it is not possible to predict when a heart attack may occur. In 
this series of experiments H2S did not induce cardioprotection at reperfusion, but the 
ability to pharmacologically precondition the heart suggests that there is still a 
potential therapeutic role. For example in situations such as episodes of unstable 
angina or prior to cardiac interventions such as angioplasty, when it is known that the 
heart is going to be at risk of a scheduled ischaemic period, administration of H2S to 
prime the RISK pathway and reduce the subsequent damage to the heart may be 
possible. H2S as a cardioprotective agent is still an emerging field and with the 
appearance of improved pharmacological tools, in particular H2S donors, knowledge of 
the field should improve more rapidly.
6.7.2 Perfusion of hearts with MESNA
MESNA induces cardioprotection as a preconditioning stimulus and at early 
reperfusion
The results from MESNA perfused hearts show that cardioprotection can be induced 
when hearts were either pharmacologically preconditioned with MESNA, or perfused 
with MESNA at early reperfusion with MESNA, with both protocols producing a 
significant reduction in infarct size compared to control.
MESNA at early reperfusion involves activation o f PI3K
It was decided that the postconditioning effect of MESNA would be investigated in 
relation to the RISK pathway as opposed to pharmacological preconditioning with 
MESNA. This was because it was thought that reperfusion was the most clinically 
relevant therapeutic intervention period, due to unpredictable nature of the onset of 
myocardial infarction. In the presence of the selective PI3K inhibitor LY294002, the 
cardioprotective effect of MESNA was attenuated. This finding suggests that, at least
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in .part, MESNA may act to induce cardioprotection via activation of PI3K and 
subsequently activate the downstream components of the RISK pathway.
MESNA offers a more robust cardioprotection than NaHS
What was perhaps the most interesting observation when working with MESNA was 
the robustness of the cardioprotection elicited compared to NaHS. The 
cardioprotective effects of MESNA were investigated due to the difficulties of 
obtaining robust cardioprotection with NaHS and the distinct absence of alternative 
H2S donors. MESNA is not strictly an H2S donating compound, but it is a thiol (-SH) 
containing compound, meaning that it has the potential to act as a free radcial 
scavenger and thus induce cardioprotection from ischaemia-reperfusion injury 
(Gressier et al., 1994). On first observation of the mean infarct size values obtained 
with NaHS (27.7 ± 2.1%) and MESNA preconditioning (27.1 ± 2.1%) it would appear 
that both compounds produce the same level of cardioprotection. However, when 
the sample size of each of the groups is taken into account NaHS n=15 vs. MESNA n=6, 
it suggests that preconditioning the hearts with MESNA produced more robust 
cardioprotection since the SEM from a sample size of 6 is the same as that obtained 
from a sample size of 15. This implies that there was less spread of data around the 
mean and therefore a more consistent level of cardioprotection was obtained.
The cardiprotective actions o f MESNA appear to be novel findings 
The findings of this study appear to be first report of cardioprotection with MESNA in 
the ischaemic rat heart. This may be attributed to the fact the MESNA is primarily 
used in chemotherapy regimens for the prevention of hemorrhagic cystitis induced by 
the oxazaphosphorines cyclophoshamide and ifosfamide (Dechant et al., 1991). Aside 
from MESNA's uroprotective ability, it has also been shown to protect the intestinal 
mucosa by reducing the toxicity of cisplatin (Allan et ai., 1986) and isofamide 
(Ypsilantis et al., 2004) or reducing intestinal inflammation in experimental colitis 
(Shusterman et al., 2003). Other published studies appear to be involved with 
investigating the protective effects of MESNA in ischaemia-reperfusion in the liver, 
kidney, and intestine (Ypsilantis et al., 2006). MESNA's thiol group is thought to be
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responsible for its antioxidant property which enables it to act as a free radcial 
scavenger and thus limiting the damage associated with ischaemia-reperfusion when 
antioxidant levels are significantly increased (Gressier et al., 1994). MESNA is also a 
small molecule which enables it to concentrate in the kidneys and therefore increase 
its ability as an anti-oxidant free radical scavenger (Gressier et a!., 1994). The ability of 
MESNA to accumulate may also exist in the heart, resulting in increased effectiveness 
of the compound and also lower concentrations required to produce effective 
cardioprotection whilst minimising the side effects or interacts with other drugs.
Not all thiols induce cardioprotection
Interestingly a study performed using the potential antioxidant drugs taurine, which 
contains a thiol group, was only shown to be of moderate effect at increasing external 
heart work after neutrophil-dependent reperfusion injury in an isolated guinea pig 
working heart model subjected to 15 minutes global ischaemia (Raschke et al., 1995). 
A possible explanation for the lack of efficacy of this compound may be due to its size 
or charge, resulting in an inability to access the intracellular environment where its 
protective action was required. The potential explanations for the modest ability of 
taurine to induce cardioprotection may also apply to NaHS. Indeed NaHS may not 
have been acting as an H2S donor, but in fact as an antioxidant to scavenge free 
radicals generated by ischaemia-reperfuion. Despite being the simplest structural 
form of a thiol and therefore the smallest molecule size, it is often described as a 
highly reactive thiol. Therefore it may have never reacted at the optimum intracellular 
site of action as a result o f reacting with other species before it reached there, or 
never reaching there because it became too large a molecule as a result of reacting 
with other species.
6.7.2.1 Further studies with MESNA
Had time permitted it would have been interesting to investigate the effect of 
inhibiting other downstream components of the RISK pathway such as Akt, soluble 
guanylate cyclase, and PKG after hearts were either pre- or postconditioned w|th 
MESNA. This would have given a greater insight into whether MESNA acts via
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activation of the RISK pathway or is simply a free radical scavenger to induce 
cardioprotection.
Another series of experiments that could be undertaken to further decipher the 
mechanism of action of MESNA would be to use an analogue compound with the thiol 
(-SH) group replaced by an unreactive alcohol group (-OH), such as Sodium 2- 
hydroxyethanesulphanate Langendorff isolated perfused rat hearts could be 
perfused with the alternative compound and the effect on infarct size observed. If 
indeed MESNA's cardioprotective action is dependent on the thiol group, perhaps to 
act as a free radical scavenger, then removal of the group should result in the loss of 
cardioprotection.
6 .8  Conclusion
The findings of these studies suggest that preconditioning the myocardium with the 
simple thiol containing compound NaHS induces protection against a subsequent 
ischaemia-reperfusion episode, with a mechanism that appears to involve activation 
of the P13Kinase and Akt components o f the RISK pathway at reperfusion. The more 
complex thiol containing compound MESNA has also been shown to induce 
cardioprotection in a manner similar to that of NaHS, but with the addition of being 
also been cardioprotective when given at early reperfusion. MESNA produced a far 
more robust and consistent cardioprotection than NaHS. These two attributes of the 
MESNA compound are far more desirable and would enable it to be a more effective 
cardioprotective strategy given the volatile and unpredictable nature of the 
occurrence of myocardial infarction. What still remains unanswered though is exactly 
how these two thiols are producing the cardioprotection. An analogue of MESNA with 
the thiol group replaced with an inert moiety such as an alcohol group, would provide
V. )
a far better insight into whether it is the derivation of H2S gas that is producing the 
cardioprotection or the highly reactive thiol group acting as a free radical scavenger to 
lim it infarct. The current findings do at least demonstrate further strong evidence to 
support H2S as a cardioprotective mediator, even without a true understanding of the 
exact cardioprotective role of these compounds.
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7.1 Principal findings:
The principal, findings of the work presented in this thesis can be briefly summarised 
as follows:
1. Rat myocardium has the potential to express CSE and CBS protein, due to the 
confirmed detection of mRNA for both of these enzymes. It has not been 
possible to conclude with confidence if CSE and CBS protein is expressed in 
the rat myocardium, but it appears highly likely.
2. It is possible to exogenously stimulate the CSE enzyme, with its substrate L- 
cysteine, to produce H2S gas which limits infarct size during regional 
ischaemia-reperfusion.
3. Basal H2S levels have been shown to be up-regulated during ischaemia- 
reperfusion, consistent with an endogenous protective role within the 
myocardium
4. Simple and complex thiol containing compounds have been shown to be 
cardioprotective during regional ischaemia-reperfusion, with a mechanism 
that involves PI3K and Akt activation, implicating recruitment of downstream 
kinases within the RISK pathway.
7.2 Context and outlook
The outcomes of the all the studies conducted provide further characterisation of 
the roles and mechanisms of action of H2S in the myocardium. They build upon 
previous findings, providing further evidence to support the role of H2S as a highly 
effective endogenous and exogenous cardioprotective agent. Perhaps one of the 
most significant technical issues is the difficulty o f working with NgHS, as an H2S 
donor, due to the inability to consistently replicate both within my own data and 
previously published work. From a clinical aspect the finding that the administration 
of NaHS at reperfusion did not show cardioprotection is disappointing due to 
reperfusion being the first opportunity for medical intervention after AMI. However, 
other published studies have shown that NaHS is cardioprotective at reperfusion,
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suggesting that the lack of cardioprotection may be due to the difficulties of working 
with NaHS. Interestingly other researchers are experiencing similar problems with 
NaHS and seeking alternative more robust compounds (Li et a!., 2008b; Zhao et al.,
2002). There is also increasing interest in trying to discover a compound that 
behaves more physiologically like H2S, with a low dissociation rate (Li et al., 2008b). 
The use of such tools would certainly improve not only the consistency of results, but 
also provide a more physiologically relevant compound to work with. The finding 
that MESNA was cardioprotective at reperfusion is of greater clinical relevance for 
the treatment of AMI, but great ambiguity surrounds which structural component of 
H2S donors/thiol containing compounds produces cardioprotection. Further 
pharmacological characterisation is clearly needed and would greatly aid future 
mechanistic studies.
The limited success of the Western blotting studies, attributed to the poor selectivity 
of the antibodies, also highlights a need for better experimental tools to advance 
progress. More specific antibodies would also enable techniques such as 
immunohistochemistry to be performed, which would provide greater information 
about the distribution of the enzymes within organs and may assist with the 
discovery of a pharmacological target. However, a large amount of experimental 
evidence was obtained to support the existence of the H2S synthesising enzymes 
within the myocardium from the pharmacological and biochemical studies. The data 
presented in chapter 4 demonstrate that exogenous stimulation of H2S production 
resulted in cardioprotection, at least in part in a CSE dependent manner since the 
effect was attenuated by PAG. Furthermore, the data presented in chapter 5 
demonstrated that tissue H2S levels could be assayed and quantified, and were 
shown to be up-regulated during ischaemia-reperfusion. In addition measurement 
of the maximal H2S synthesising capacity by exogenous stimulation showed that it 
was possible to generate H2S within the myocardium. Ischaemia-reperfusion was 
also shown to reduce the ability of the left ventricle to generate H2S, but evidence 
suggests that the right ventricle may increase production in a compensatory attempt 
to lim it infarct size. These studies also highlighted that H2S may also be generated
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from an alternative enzyme to CSE, such as CBS or even a non-enzymatic source, 
since H2S levels have been shown to increase after pharmacological inhibition of the 
CSE enzyme.: Taken together these findings imply that H2S acts as an endogenous 
cardioprotective agent and a feasible target for manipulation to protect the heart 
during ischaemia-reperfusion.
7.3 Proposed cardioprotection mechanism of action of thiol containing 
compounds
The ambiguity surrounding the cardioprotective mechanism of action of the thiol 
containing compounds, NaHS and MESNA, gives rise to two possible mechanistic 
explanations (summarised if figure 7.1). The first is based on the observation from 
this study that both compounds appear to signal through PI3K and Akt components 
of the RISK pathway, since pharmacological inhibition attenuated cardioprotection. 
It then follows that downstream components o f the RISK pathway such as eNOS, 
soluble gyanulate cyclase, and PKG are activated, ultimately resulting in inhibition of 
the mPTP and cardioprotection. This cardioprotective mechanism of action could be 
tested using Western blotting studies to measure the levels of phosphorylation of 
key components of the RISK pathway in the presence and absence of thiol 
stimulation. In particular investigating the phosphorylation of eNOS may provide 
further understanding of the interaction of H2S and NO.
A perhaps less obvious, but equally valid proposed mechanism of action of NaHS and 
MESNA is that due to the highly reactive nature of thiols, they act as extremely 
effective free radical scavengers. This could occur in two ways. The first is to act 
independently of the RISK pathway, and instead reacting directly with free radicals 
and preventing them from causing damage to the myocardium through oxidative 
stress. Alternatively, and perhaps more in keeping with the observed findings, the 
thiol containing compounds may act as free radical scavengers and prevent ROS 
activation o f Rho-kinase. Inhibition of Rho-kinase results in un-moderated activation 
of the RISK pathway, because Rho-kinase acts as an endogenous regulatory 
mechanism of the RISK pathway, possibly by phosphorylating phosphatase and
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tensin homolog (PTEN). PI3K and Akt are therefore still required to enable the 
downstream components of the RISK pathway to be activated, hence why their 
inhibition attenuated cardioprotection. However, NaHS and MESNA act indirectly to 
activate the RISK pathway by inhibiting Rho-kinase and thus enabling the RISK 
pathway can become fully activated to induce cardioprotection. This proposed 
mechanism could be investigated using Western blotting techniques to measure the 
phosphorylation of Rho-kinase in the presence and absence of thiol containing 
compounds to determine if free radical scavenging prevents ROS induced activation 
of Rho-kinase. If in indeed this was the mechanism of action by which the thiols act, 
it may explain why MESNA provides more robust cardioprotection than NaHS. 
Perhaps the highly reactive nature of NaHS readily results in the formation of H2S 
and thus renders it less effective as a ROS scavenging thiol. Indeed, MESNA is known 
for its stability and ability to accumulate in tissues, suggesting it may act as a more 
robust thiol containing compound and is therefore more effective as a free radical 
scavenger.
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Figure 7.1 Summary o f the three potential mechanism by which thiol containing/H2S donor compounds may induce cardioprotection. 1. Direct activation 
of the RISK pathway occurs via an unknown target. 2. Free radical scavenging prevents activation of Rho-kinase via ROS, allowing unregulated activation 
of the RISK pathway. 3. Free radical scavenging produces cardioprotection by preventing oxidative stress damages independent o f the RISK pathway.
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7.4 Limitations of the thesis and scope for further studies
As with any scientific study, time is one of the main limiting factors and there is scope 
for further work. All of the studies conducted here are complimentary to each other 
and show a logical order of progression with each building upon previous findings. 
During the discussion to each chapter suggestions for further experiments have been 
proposed to complement the data already obtained. However, going beyond the 
obvious additional experiments and broadening the scope of this thesis are several 
other studies that would be of great interest and importance for characterising the 
cardioprotective role of H2S in the myocardium.
Electophysiology could be used to investigate the effect of H2S on ion channels and 
electrical currents generated within isolated cardiac myocytes. There appears to be a 
distinct lack of knowledge of the mechanism of action of H2S both as a 
cardioprotective agent and a vasodilator. Understanding more about how it 
influences ion channels and electrical currents within cells may assist in identifying 
other therapeutic interventions to influence its effect and may even provide 
information about a possible pharmacological target of H2S. There is limited evidence 
in the literature that H2S mediates its effect through opening of the KAt p  channel. This 
could be investigated further by patch clamping isolated cardiac myocytes and 
measuring the change in voltage when an H2S donor was placed into the cell bathing 
media. A specific KAt p  channel blocker could be used and the effect on membrane 
potential observed. Another experiment could be conducted that exogenously 
stimulates the production of H2S using the synthesising enzymes substrate L-cysteine 
and the effect on membrane potential measured. The synthesis of H2S could be 
confirmed by the use of specific inhibitors to the enzymes. These experiments could 
be undertaken with relative ease and would provide much needed information about 
the effects of H2S in the cell and how it mediates its cardioprotective effects.
Further studies investigating the downstream effectors of the RISK pathway would 
provide extremely important information about the mechanism of action of H2S in 
cardioprotection. Whilst the results of the Langendorff isolated rat heart perfusion
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studies have shown that PI3K and Akt appear to be involved in cardioprotection, these 
kinases are a common feature of many other signalling pathways and therefore it 
cannot be assumed that the remainder of the RISK pathway components are 
activated. The use of specific inhibitors to eNOS, soluble guanylate cyclase, PKG and 
the Katp channel given at the time of reperfusion either after preconditioning the 
hearts with an H2S donor or giving an H2S donor at reperfusion with the inhibitors 
could be investigated to decipher their involvement.
Identifying exactly how H2S is generated in the myocardium is also of great 
importance. In the literature it is heavily reported that CSE is the key enzyme to 
produce H2S in the myocardium, but as mentioned previously these findings lack 
convincing experimental evidence. There now arises the question that perhaps 
alternative enzymatic and non-enzymatic sources of H2S may exist in the myocardium 
that act in a compensatory manner to protect the heart if the primary source is 
impaired. Perhaps the employment of a non-enzymatic source occurs during 
ischaemia when ATP levels are limited. Understanding how these H2S sources interact 
and contribute to maintaining or elevating H2S levels would provide a greater 
understanding of the protective mechanism of H2S and the regulation of its 
production.
The limitations of the experimental techniques adopted have been highlighted and 
discussed at the end of each experimental chapter. Overall, the major limitation of 
the work presented in this thesis is the use of the rat as a species of choice to model 
potential therapeutic intervention in humans. However, rats are relativity cheap to 
buy, are abundantly available, and the Langendorff perfusion technique provides a 
robust model to investigate ischaemia-reperfusion. Also, the homology of CSE and 
CBS protein between rat and human has been shown to be very strong at 85.6 % (Ishii 
et al., 2004) and 90 % (Kraus et al., 1993) respectively, which enables the results from 
the enzyme characterisation in the rat to be confidently translated into the human. 
Moreover, the majority of published studies use the rat heart to model ischaemia- 
reperfusion, enabling results to be compared to those previous obtained. The dog is
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also known to be a suitable model of ischaemia-reperfusion, having a similar 
physiology to the human. However, working with dogs would be far more expensive 
than rats, since everything is on a far larger scale. This would mean that greater 
amounts of drugs and reagents would be required, as well as more expensive 
purchasing and housing costs.
The main limitation with any pharmacological study is the specificity of the 
compounds used. Careful consideration to specificity was given when selecting the 
inhibitors and the experimental concentrated used was based on approximately ten 
times the IC50 concentration, to ensure that they produced specific inhibition of the 
desired target. Where possible the most potent, selective and stable compounds 
were selected for a target. For example wortmanin is traditionally used for the 
inhibition of PI3K but it is known to be of limited selectivity and poor stability. Instead 
LY294002 was selected because it is more potent, specific, and stable. Ideally, at least 
two different compounds should have been used for each target, but this has serious 
cost and time implications. A more modern approach to pharmacological studies is to 
use silenced RNA (SiRNA) gene knock down mice models to ensure that the target of 
interest is specifically inhibited. Alternatively transgenic overexpression of a gene of 
interest can also be used in functional genomic studies. Both of these techniques 
have been shown to be very successful and the increased emergence of the use of the 
mouse heart for Langendorff studies has received increasing interest. However, 
knock-out breeding can be a slow process and the mouse is less physiologically 
relevant to the human than the rat.
7.5 Concluding remarks
The research conducted and presented in this thesis aimed to further the 
understanding of the roles and mechanisms of action of H2S in the myocardium and its 
involvement in ischaemia-reperfusion. On balance I feel that the results obtained 
have provided a significant advancement in understanding the involvement of H2S in 
cardioprotection during ischaemia-reperfusion. It has also raised many questions such 
as the exact mechanism of action of H2S donor/thiol containing compounds and
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highlighted the need for more robust H2S donors, which would be a major 
contributing factor to accelerate the understanding of H2S in ischaemia-reperfusion 
further.
The scope for H2S as an endogenous mediator stems beyond that of cardioprotection 
and the range of body systems and cell types is continually expanding. As H2S appears 
to be characteristic of NO it may possess multiple mechanisms and sites of action. 
Identification of these will assist in revealing the physiological significance and 
potential for medical exploitation of this surprisingly complex gaseous mediator. The 
interaction of NO and H2S also suggests a potential role for H2S in erectile dysfunction 
which could lead to the discovery of additional therapeutic targets beyond the already 
successfully exploited PDE5 inhibitors. In addition H2S production could also be 
targeted therapeutically to control hypertension. The ability to readily detect and 
measure H2S the endogenous levels of H2S in patients exhibiting various risk factors 
for progressive coronary artery disease may assist in identifying the role of H2S in both 
disease progression and in cardioprotection. In this respect H2S could act as a 
biomarker enabling the severity of coronary artery disease progression to be 
determined in patients and perhaps controlling it whilst in its infancy. Furthermore, 
understanding whether an imbalance in H2S production is a causal factor or a 
consequence of coronary disease could be central for targeting the key metabolic 
pathways of H2S production as a potential therapeutic strategy to inhibit coronary 
artery disease progression. With the emergence of improved pharmacological tools 
and the increased interest in H2S, the next few years should provide a greater 
understanding of the physiological role of H2S.
Current findings from World Heath Organisation predict that as far as 2030, 
cardiovascular disease will remain the leading cause of mortality in the world 
(Mathers et al., 2006), there is a need for more effective solutions to protect patients 
suffering from acute myocardial infarction. Due to the unpredictable nature of the 
onset of acute myocardial infarction, clinical therapies should ideally be aimed at the 
time of reperfusion when flow is restored to the heart and minimise reperfusion
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injury. The recent discovery of the RISK pathway, and its expanding components and 
activators, provides the basis for a greater understanding of the cardioprotective 
mechanisms that occur at reperfusion and various algorithms that can be used to 
prime this pathway, therefore suggesting a novel target for cardioprotection. The 
increased interest in H2S over the past decade has led to its discovery in the 
myocardium and also revealed the potential cardioprotective effect of exogenous H2S, 
suggesting a potential endogenous mediator of cardioprotection. However, there is 
only a weak characterisation of the enzymes that synthesise H2S in the myocardium 
and the effect of ischaemia-reperfusion on their ability to function. As yet a 
pharmacological target for H2S has not been identified or a specific mechanism of 
action determined.
Major points of focus:
The aim of the studies described in this thesis was to characterise H2S synthesis in the 
myocardium and elucidate potential cardioprotective roles of H2S during ischaemia- 
reperfusion.
The general hypothesis underpinning this work was that H2S synthesising enzymes 
exist in the myocardium and the resulting H2S provides cardioprotection against 
ischaemia-reperfusion.
The specific questions addressed are:
1. Does the rat myocardium contain H2S synthesising enzymes and is there a 
predominant isoform?
2. What effect does ischaemia-reperfusion have on the ability of the rat 
myocardium to synthesise H2S?
3. Does exogenous or endogenously stimulated H2S protect the rat myocardium 
against regional ischaemia-repefusion injury?
4. Does H2S activate the RISK pathway to induce cardioprotection in the rat 
myocardium?
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The approach to these scientific questions involved using a variety of experimental 
techniques and rat myocardium. The techniques undertaken included PCR and 
Western blotting to identify the presence of the mRNA and protein for the H2S 
synthesising enzymes in rat myocardium (Chapter 3). Cloning of the H2S synthesising 
enzymes and transfection into cell lines, to validate the specificity of a custom 
synthesised antibody to CSE used for Western blotting studies. Isolated perfused rat 
hearts were used to investigate the effect of regional ischaemia-reperfusion and 
observe the effects of exogenous and endogenously stimulated H2S on infarct size 
limitation (Chapter 4). The isolated perfused hearts were also used to decipher the 
mechanism of cardioprotection elicited by H2S by use of pharmacological tools to 
inhibit components of the RISK pathway (Chapter 6). Biochemical assays were also 
performed to measure the tissue concentrations of H2S and also determine the 
maximal H2S synthesising capacity of exogenously stimulated enzyme and observe the 
effect of ischaemia and reperfusion (Chapter 5).
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A ppend ix  1: CSE cloning and transfection  m ethods  
G en era tio n  o f a CSE expression vector
In an attempt to validate the protein expression studies of the CSE enzyme in rat 
tissues, a series of experiments were performed to construct a CSE expression vector 
for use in transient transfection analyses. The CSE construct was kindly generated by 
Dr. Steve Allen (RVC). The full length open reading frame (ORF) of the mouse CSE gene 
was generated by splicing together two Image clones (from Geneservice Ltd., 
Cambridge, UK) that overlapped an EcoRl site present in the sequence. Specifically 
the full length ORF was generated by digesting both clones with EcoRl and gel 
purifying the fragment from each digest that contained the CSE ORF. These fragments 
consisted of the 3' ORF inserted into the plasmid pExpressl and the 5' ORF from the 
internal EcoRl to an EcoRl in the multi cloning site immediately upstream of the start 
ATG. These two fragments were then ligated to generate the full length ORF. The 
resulting expression vector was subjected to restriction enzyme digest to confirm the 
correct orientation of the 5' portion of the CSE gene and a maxi-prep plasmid 
preparation was performed to generate sufficient plasmid for transfection studies.
Transient expression o f CSE in ra t GH3 som ato lac to troph  cells
The GH3 cell line was chosen as a heterologous expression model in which to examine 
the expression of CSE, due to its availability and the fact that GH3 cells are of rat 
origin. Briefly, 0 to 2.5 pg/well of CSE plasmid was transfected in to GH3 cells plated 
at a density of 106cells/well. Total protein extracts were produced 48 h post 
transfection, and these cell lysates were subjected to Western blotting for CSE, as 
described in section 3.6.
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Appendix 2: Summary of H2S production assay validation studies
The H2S production assay was adapted from methods published in the literature 
(Stipanuk et o i, 1982) to enable the production of H2S to be measured in cardiac and 
liver tissue. Liver was used to establish the assay because it is a rich source of both 
the H2S producing enzymes CSE and CBS, and because the tissue was in abundant 
supply. Initially, substrate concentrations were taken from the literature and initially 
L-cysteine 2 mM and P-5'-P 0.05 mM were tested. The H2S yield was found to be very 
low and difficult to accurately detect using the spectrophotometer (as shown in figure 
1). The majority of more recently published papers used higher concentrations of 
substrate and enzyme. L-cysteine 10 mM and P-5'-P 2 mM was tested and found to 
give higher absorbance values, indicating a higher yield of H2S (as shown in figure 1). 
A 10% tissue homogenate was also found to be sufficient for the assay and meant less 
tissue could be used and the tissue was more easily re-suspended and pipetted 
without causing tip blockage as found with higher concentrations of tissue (20 and 
40% w/v). The thickness of filter paper onto which the gas was absorbed was also 
investigated. Thick filter paper (0.34 mm) was found to be more effective at 
absorbing the H2S gas produced than thinner paper (0.1 mm) (as shown in figure 1).
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2.5-i
2.0-
Figure 1 Preliminary absorbance results from  the H2S production assay, comparing the 
effects o f low and high concentrations o f L-cysteine (2 mM vs. 10 mM) and Pyridoxal- 
S'-phopshate (50 pM vs. 2 mM), and the effect o f thin (0.34mm) and thick filte r paper 
(0.1 mm). Abs= absorbance value. Each value shown is the mean ±  SEM from 2 
separate experiments.
Initially problems were encountered with variability of results between experiments. 
This was especially the case with the NaHS standard curve, despite using the same 
aliquots on the same day, variation and reduction in absorbance levels occurred. 
NaHS, the H2S, donor was found to be unstable when stored in the freezer at -20 °C; 
as a result fresh results were prepared on each day of experiment. Fresh stocks of 
NaHS were also prepared prior to performing a second experiment on the same day. 
The effect of storing NaHS samples in the freezer is shown in figure 2, where the same 
stocks produced up to a 3 fold decrease in absorbance when used 3 days later, 
suggesting instability of the H2S donor particularly at the higher concentrations where 
stored at -20 °C.
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Figure 2 Comparison o f the standard curves to freshly prepared and frozen (3 days, - 
20 °C/) stocks o f NaHS. Abs= absorbance value. (n=l).
A reduction  in the  absorbance values produced by the  NaHS was observed between 
experim ents. Solid NaHS had started to  absorb m oisture  and is hygroscopic and 
the re fo re  when a fixed am oun t was weighed o u t to  prepare the  stocks it did not 
conta in as much NaHS as was calculated fo r  a dry stock o f the  com pound. The solid 
stock o f NaHS was replaced and fa r g rea te r absorbance values w ere  produced at all 
the  NaHS concentra tions (as shown in figu re  3). As a resu lt o f these find ings the  solid 
NaHS stock is be replaced m ore regularly since th is  com pound appears susceptible to  
absorbing m oisture  fro m  the  air.
0 100 200 300 400 500 600
NaHS conc. (pM)
Figure 3 Comparison o f the standard curves to NaHS with freshly prepared samples 
from  a new solid stock o f NaHS vs. a freshly prepared samples from  an old solid stock 
o f NaHS. Abs= absorbance value. (n=l).
1 .0-1
New stock 
Old stock
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Temperature was also found to be a significant parameter resulting in variability in the 
results between experiments for the tissue samples tested. A more thermostatically 
stable water bath was used and was also covered to create a more even temperature 
distribution over the reaction flasks. When tissue samples were tested in duplicate, 
there was very little variation between the samples.
After addressing each of these variables individually and investigating ways of 
improving them, a H2S production assay was established that enables both 
myocardium and liver tissue H2S production rates to be accurately and reproducibly 
measured.
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Appendix 3: Preparation of assay solutions
PCR reagents (Chapter 3)
A PCR "master mix" was prepared per sample
Buffer (lOx) 2 pi
dNTP's 1 pL
Taq polymerase 0.5 pi
Forward primer 1 pi
Reverse primer 1 pi
"Q" solution 4 pi
DEPC treated H20 5.5 pi
Total volume per sample 15 pi
Loading dye
Bromophenol blue 
Xylene cyenol 
Sterile glycerol 
lOx TBE 
d.H20
lOx TBE stock solution
Tris 30.3 g
Boric acid 15.5 g
EDTA (disodium) 1.9 g
Dissolve in 500 ml d.H20 pH 8.0
1.6% agarose gel
Agarose 8 g
lOx TBE d.H20 50 ml
10 mg 
10 mg 
1.2 ml 
0.8 ml 
2.0 ml
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The solution was then heated in the microwave for 3 minutes in order to dissolve and 
aliquoted into 50 ml tubes. When the gels were required, a 50 ml aliquot was melted 
in the microwave for 90 seconds and once dissolved 5 pi of ethidium bromide 10 
mg/ml was added and mixed into the melted gel. The gel was cast in a mould and 
allowed to set for at least 20 minutes prior to using.
Western blotting reagents (Chapter 3)
Lysis buffer for protein extraction (250 ml)
20 mM Tris-HCI: pH 7.6
10 mM EDTA: pH  8.0 0.93 g
0.25% Triton X-100 625 pi
100 mM NaCI 1.46 g
10 mM KCI 0.19 g
3 mM M g C l2 .6 H 20  0.15 g
Make up 250 mM Tris-HCI, pH 7.6 with 1 M HCI 
Make up 250 mM EDTA, pH 8.0 with 1 M NaOH 
Add 10 ml EDTA (10 ml DETA in 250 ml = 10 mM)
Add 20 ml Tris-HCI (20 ml Tris-HCI in 250 ml = 20 mM)
200 pi aliquots were prepared and 10 pi of protease inhibitor cocktail (Sigma-Aldrich,
UK) was added to each
Aliquots were stored at -20 °C until required
4% stacking gel (makes 2 mini gels)
d.H20 3.4 ml
30% protogel 850 pi
1.5 M Tris-HCI pH 6.8 630 pi
50 pi SDS 50 pi
10% AMPS (0.2 g/2ml) 50 pi
TEMED 5 pi
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10% resolving gel
d.H20 6.9 ml
30% protogel 4.0 ml
1.5M Tris-HCI pH 8.4 3.8 ml
10% SDS 150 pi
AMPS (0.2g/2ml) 150 pi
TEMED 9 pi
Running buffer (lOx) (1L)
0.25 M Tris-base 30.3 g
1.92 M Glycine 144 g
1% (w/v) SDS 10g
Make up to lx  solution using d.H20 and pH to 8.8
Transfer buffer (1L)
2.5 mM Tris Base 
0.2 M Glycine 
20% MeOH 
d.H20 to make 1 L 
pH 8.5 in d.H20
TBS (xlO) (1L)
0.2 M Tris base 24.2 g
1.37 M NaCI 80 g
pH 7.6 with HCI
TBST
Dilute lOx TBS 1:10 in d.H20 
Add 0.1% Tween (1 ml per 1 L)
3.03 g 
14.4 g 
200 ml
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CSE protein purification using protein G HP purification column (Chapter 3)
Binding buffer
20 mM sodium-phosphate, pH 7.0
Elution buffer
0.1 M glycine-HC I, pH 2.7
Eluted fractions were neutralised in 1 M Tris-HCI, pH 7.0 
Langendorff isolated perfused heart experiments (Chapters 4 ,5 ,6)
0.5% Evans blue solution
0.5 g of Evans Blue powder in 100ml of d.H20
1% triphenyltetrazolium solution
1 g of chloride salt in 100 ml of phosphate buffered saline
H2S production assay reagents (Chapter 5)
Sodium phosphate buffer (pH 7.4)
100 mM stocks of NaH2P04 and Na2HP04 were prepared in d.H20
They were combined 2 parts NaH2P04 and 8 parts Na2HP04 to produce a pH 7.4 buffer
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